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Summary 
 
This report describes in detail the research conducted by the ‘Prescribing Research 
Group’, supported by NES funding. Members of the group are listed on the front 
cover. Since inception date, this group has been highly active in the field of 
pharmacy prescribing research with: 
 
• 11 papers in peer-reviewed pharmacy and non-pharmacy journals 
• Over 20 research abstracts presented at national and international research 
conferences 
• Members invited to give key note presentations relating to pharmacist 
prescribing at leading conferences 
• Influence of findings on undergraduate and postgraduate pharmacy education 
and training at RGU and wider afield 
• Attraction of research monies to further explore areas of pharmacist 
prescribing 
 
Each paper published since our last report (March 2007) is provided, highlighting key 
findings and future research direction.  
 
Aim 
The overarching aim of the research presented in this report was to explore and 
evaluate pharmacist prescribing from the perspectives of: 
 
• Patients consulting a pharmacist prescriber 
• Pharmacists as students and potential students on prescribing programmes 
• Pharmacist prescribers 
• Doctors (as independent prescribers and designated medical practitioners) 
• Members of the general public 
 
Methods 
Mixed methods employing quantitative/qualitative designs have been used as 
appropriate to the specific research questions under investigation in each study. Key 
methodological approaches have involved the use of: 
 
• Cross-sectional questionnaires 
• Focus groups and one-to-one interviews 
• Non-participant observation of prescribing practice using video recorded 
consultations 
• Informal ‘consensus methods’ 
• Development and validation of novel approaches in this field (e.g. assessing 
pharmacist prescribers’ consultation skills) 
 
As far as possible, we have taken every step to triangulate research findings, 
maximize validity and reliability and minimize inherent biases (including our own). All 
work was conducted in accordance with best practice in Research Governance and 
received all necessary Ethical and NHS Research and Development approvals.  
 
 
 LL
Key Findings 
In essence, and acknowledging limitations including sub-optimal response rates, 
small sample sizes and geographical foci, we have demonstrated that: 
 
• Prescribing pharmacists perceived better patient management to be the key 
benefit of pharmacist prescribing with inadequate funding the main limitation. 
These data were collected several years ago (2005); we are now revisiting 
this area investigating changes and drivers for change 
  
• Almost all pharmacist prescriber students highly valued the period of learning 
in practice (PLP) of their training programme. However, there was an 
expressed need to enhance the information provided to students and their 
designated medical practitioners (DMPs) about the PLP. This has been 
actioned utilising the Virtual Learning Environment at RGU. Planning the PLP 
in partnership with the DMP and academia was perceived to be crucial for 
optimal learning 
 
• Although pharmacists throughout GB were aware of pharmacist prescribing, 
they had little awareness of educational and training requirements and few 
had plans to undertake such programmes. In addition, they expressed the 
view that their practice settings required attention to ensure readiness in 
terms of IT and administrative support 
 
• Patients who have experienced a pharmacist prescribing service were highly 
satisfied and had positive attitudes to pharmacist prescribing consultations. 
However, given the choice, most patients would still elect to see their doctor 
 
• Pharmacist prescribers, doctors and patients experiencing pharmacist 
prescribing services were supportive of developments in supplementary 
prescribing, although some doctors raised concerns around pharmacist 
independent prescribing 
 
• Members of the Scottish general public were aware of the concept of non-
medical prescribing; with a higher proportion more comfortable with 
prescribing by pharmacists and nurses rather than other healthcare 
professional 
 
• In collaboration with a wide spectrum of colleagues, we have developed and 
validated PharmaCAT (‘Pharmacist Consultation Assessment Tool’), based on 
a validated tool used extensively by the Royal College of General Practitioners 
during GP training. Further research and developments in this field are being 
undertaken in collaboration with NHS Education for Scotland 
 
• In research recently completed, we conducted a GB-wide study of patients’ 
views of their experiences of pharmacist prescribing services. Very 
disappointingly, uptake from pharmacist prescribers was extremely poor, with 
only 92 across GB participating. It was noteworthy that almost one third of 
pharmacist respondents had never prescribed. Although limited, patient 
responses clearly indicated the value patients placed on the services 
 
  
Conclusions 
Literature focusing on UK based pharmacist prescribing structures and processes 
continues to emerge. The work of our Prescribing Research Group is recognised and 
highly valued by policy makers, academics and practitioners nevertheless robust 
conclusions cannot always be drawn, due primarily to the methodological limitations 
described above. 
 
We now need to produce robust evidence in terms of patient outcomes beyond 
patient and practitioner views i.e. a need for clinical, economic and humanistic foci. 
These elements are embraced within our plans for future research as described 
within the report. However, we also need to explore novel methodologies to enhance 
pharmacist prescriber participation in research. 
 
Further Research Direction  
Funding from NES continues until January 2012.  
 
Strategic Aims 
• To maintain our focus on all aspects of pharmacist prescribing implementation 
with increased emphasis on patient outcomes 
 
• To maintain our Prescribing Research Group at the forefront of pharmacist 
prescribing related research 
 
Our plans for research to January 2012 are as follows: 
 
1. Preparation and submission of full paper manuscripts to the International Journal 
of Pharmacy Practice, relating to outputs 7 and 9 listed below.  
 
2. Qualitative research focusing on the translation and adaptation from pharmacist 
supplementary to pharmacist independent prescribing. This research will be 
conducted with a purposive selection of pharmacist prescribers in various settings 
and practising within Scotland in key clinical conditions. 
 
3. Repeat our 2005/2006 national survey of pharmacists’ planned activities in 
relation to pharmacist prescribing training. As before, this will be a GB wide cross 
sectional survey of 10% of pharmacists. We are keen to investigate any changes 
in pharmacists’ plans to undertake prescribing training and attitudes towards 
pharmacist prescribing. 
 
4. Explore issues relating to registered pharmacist prescribers who have yet to use 
their prescribing skills and to compare these to those experienced by registered 
nurse prescribers who are not yet prescribing. Identifying, characterising and 
understanding these issues is the first key step in formulating potential solutions.  
 
In addition, we are planning submission of grant applications to conduct research in 
the areas of: 
 
• pharmacist prescribing consultation skills, with emphasis on the value of 
assessors’ feedback in developing prescribing practice 
 
• pharmacist prescriber management of patients with chronic obstructive 
pulmonary disease, focusing on impact on clinical outcomes.

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Benefits and challenges of prescribing training and 
implementation: perceptions and early experiences 
of RPSGB prescribers 
Johnson George, Dorothy McCaig, Christine M Bond, 
IT Scott Cunningham, H Lesley Diack and Derek C Stewart 
Abstract 
Objective To investigate the challenges experienced by pharmacists in delivering supplementary
prescribing (SP) services, to explore their perceptions of benefits of SP and to obtain feedback on
both SP training and implementation. 
Method A postal questionnaire focusing on prescribing training, early experiences of prescribing
and general demographics was sent in September to November 2005 to all SP pharmacists (n = 488)
in Great Britain after excluding a pilot sample (n = 30). The biggest benefits and challenges of SP,
and reasons for not practising SP, were identified. Responses to a general open question were con-
tent analysed for major themes. 
Key findings A total of 401 responses (82.2%) was received; 195 (48.6%) had started practising SP
of which 154 (79%) had written at least one prescription. This paper focuses primarily on perceived
benefits and challenges to the implementation of SP, and the responses to the open question. Bet-
ter patient management (n = 58; 29.7%) was identified as the main benefit of SP and inadequate
funding (n = 27; 13.8%) as the biggest challenge in delivering SP service. The main reasons for not
commencing SP were: no organisational recognition of SP (n = 37; 18%); lack of funding (n = 33;
16%); non-availability of prescription pads (n = 22; 10.7%), and change of jobs (n = 18; 8.7%). The
comments to the open question (n = 145; 36.2%) were regarding: SP training; perceived benefits of
SP; and barriers to SP. Respondents highlighted the need for greater emphasis on clinical skills
development as part of the SP course. 
Conclusion Despite optimism among SP pharmacists, the need for support in terms of infrastruc-
ture and integration into the healthcare team has been identified. Our findings also inform the
need for modifications in the structure, content and delivery of the prescribing course for pharma-
cists. Greater publicity of pharmacists’ roles in medication management, support from the medical
profession and healthcare organisations, and high standards by early practitioners are warranted
for the success of SP by pharmacists. 
In Great Britain, the skills and competencies of non-medical health professionals are
increasingly being used to improve patient access to medicines and to reduce doctors’ work-
load.1–5 The final Crown Report in March 1999 proposed that non-medical health profes-
sionals should be permitted to take on additional prescribing responsibilities. The report
defined two new types of prescribers: the independent prescriber and the dependent pre-
scriber.3 The Health and Social Care Act 2001 (Section 63) allowed for the introduction of
dependent prescribing (implemented into practice as supplementary prescribing) status for
non-medical health professionals, including pharmacists.2 
Supplementary prescribing (SP) is defined as ‘a voluntary partnership between an independ-
ent prescriber (a doctor or dentist) and a supplementary prescriber to implement an agreed
patient-specific clinical management plan (CMP) with the patient’s agreement’.3 Within this
framework there are no legal restrictions on the clinical conditions that may be treated or drugs
that can be prescribed by supplementary prescribers. Pharmacists with at least two years’
experience as a pharmacist can undertake SP after training at a higher education institution
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(200 h at the degree/masters level over 25 days) and completing a
‘period of learning in practice’ (PLP) (supervised training under a
designated medical practitioner for a minimum of 12 days) in
accordance with the curriculum and assessment methods specified
by the Royal Pharmaceutical Society of Great Britain (RPSGB).6,7
Pharmacists working in various practice settings across
Great Britain have been practising SP since March 2004.8
Published research on pharmacist prescribing is limited to the
views of pharmacists from various practice settings and anec-
dotal experiences of the SP course and the implementation of
SP.9–14 No national study has been published reporting the
experiences of pharmacists relating to their SP course and
implementation of SP. Such a study is critical to optimise
future training programmes for pharmacist prescribing.
Understanding perceived challenges to and benefits of SP
implementation could inform policy makers, organisations
considering implementation of SP service and pharmacists
planning to undertake prescribing training. 
Aims 
The aims of this study were to investigate the challenges
experienced by pharmacists in Great Britain in delivering SP
services, to explore their perceptions of benefits of SP and to
obtain feedback on both SP training and implementation. 
Subjects were all supplementary prescribers registered with
the RPSGB (n = 518). A self-completion questionnaire was
developed. Four experts in non-medical prescribing reviewed
the questionnaire for face and content validity. The question-
naire was pilot tested in 30 pharmacists randomly selected
from the RPSGB list of SP pharmacists. Based on the pilot
sample’s responses (n = 17; 56.7%), the open questions on
benefits and challenges were organised into themes which
were presented as tick list options. The final questionnaire
had four sections. These were pertaining to: SP training (10
items), activities as prescriber (4 items), first CMP (13 items),
and demographics (5 items). Pharmacists who had started
practising SP were asked to identify all the benefits and chal-
lenges of SP from the provided tick lists, based on their expe-
riences. They were also asked to identify the main benefit and
challenge. An open question seeking general comments on
SP training and/or processes was also included. The final
questionnaire was mailed to the remainder of the sample
(n= 488) in June 2005. The questionnaire did not collect any
personal information that could identify the respondent.
Non-respondents (identified using a unique code printed on
the questionnaire; only the first author had the key linking the
codes and the names of the study subjects) were sent up to
three reminders at 2-weekly intervals. 
Data were managed and analysed using SPSS version 13.0
(SPSS Inc). Content analysis of the open questions was
undertaken independently by two authors to identify major
themes, and results compared to ensure reliability.15 All
emerging themes and illustrative quotes, including any disa-
greements, were discussed and finalised by the research team.
This study was approved by the ethical review panel of the
School of Pharmacy at The Robert Gordon University. Gram-
pian Research Ethics Committee advised that this study did
not require formal review by an NHS ethics committee. 
A total of 401 responses (82.2%) was received. The char-
acteristics of the respondents are given in Table 1. The
questionnaire contained a wider range of items regarding
Methods 
Results 
Table 1 Characteristics of the respondents (n = 401) 
Because some data are missing, some characteristics do not add up to
401. 
Characteristic n (%) 
Sex  
male 131 (32.7)
female 270 (67.3)
Age (years)  
25–34 124 (30.9)
35–44 173 (43.1)
45–54 94 (23.4)
>54 10 (2.5)
Years since registration as pharmacist  
<6 13 (3.2)
6–10 97 (24.2)
11–15 83 (20.7)
16–20 85 (21.2)
>20 123 (30.7)
Main practice setting  
community pharmacy 80 (20.0)
primary care medical practice 119 (29.7)
hospital pharmacy 160 (39.9)
other 41 (10.2)
Postgraduate qualifications  
yes 314 (78.3)
no 78 (19.5)
Institution offering prescribing course  
English school 262 (65.3)
Scottish school 110 (27.4)
Welsh school 27 (6.7)
Time since completion of prescribing training (months)  
<4 3 (0.7)
4–6 23 (5.7)
7–9 51 (12.7)
10–12 85 (21.2)
>12 229 (57.1)
Post-course training  
yes 209 (52.1)
no 180 (44.9)
Conditions focused on during period of learning in practice  
cardiovascular 143 (35.7)
respiratory 31 (7.7)
endocrine 22 (5.5)
CNS 23 (5.7)
multiple conditions 82 (20.4)
other (malignant diseases; infections; musculoskeletal; 
obstetrics, gynaecology and urinary tract; eye; 
skin; etc) 
94 (23.4)
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SP training and implementation, but this paper focuses on
perceived benefits and challenges to the implementation of
SP and the responses to the open question on SP training
and/or processes. The other findings have been reported
elsewhere.16 Of the respondents, 195 (48.6%) had started
practising SP, of which 154 (79%) had written at least one
prescription. The perceived benefits and challenges of pre-
scribing in the views of those who had practised SP are
given in Table 2. Inadequate funding was identified as the
single biggest challenge (27 (13.8%)), and better patient
management (58 (29.7%)) was identified as the single big-
gest benefit of SP. The main reasons given for not com-
mencing SP by those who had not started practising were:
no organisational recognition of SP (n = 37, 18%); lack of
funding (n = 33, 16%); non-availability of prescription
pads (n = 22, 10.7%); and change of jobs (n = 18, 8.7%).
Graduates from 20 different higher education institutions
offering the SP course responded to the questionnaire, and
their perceptions about the SP course were diverse. 
Of the respondents, 145 (36.2%) gave comments to the
open question seeking general comments on SP training
and/or implementation. The characteristics of these respond-
ents are summarised in Table 3. The open comments varied in
volume, with word counts between 4 and 156; the majority of
open comments had between 40 and 50 words. Brief descrip-
tions of the themes generated from these comments along
with illustrative quotes are given below: 
SP training 
The comments on SP course reflected the diversity in the struc-
ture, content and delivery of courses offered in Great Britain. 
Course content and delivery 
The generic nature of the SP course, topics covered and over-
laps with other postgraduate courses already completed, and
tight deadlines were criticised by respondents across all prac-
tice settings. 
There is an enormous amount of work to fit into 6 months espe-
cially when you are working full time and/or have (other) family
commitments. (respondent 228; hospital pharmacist; 11–15 years’
experience; postgraduate; not started SP) 
Too much time was wasted on irrelevant topics like the molec-
ular basis for drug action. (respondent 56; community pharma-
cist; >20 years’ experience; no postgraduate qualifications;
started SP) 
Some, especially those working in hospitals, felt that their SP
course was more community pharmacy/primary care oriented
and the therapeutic modules were of little relevance to their
clinical practice. However, some believed that it was the
pharmacist’s responsibility to acquire specialised skills dur-
ing their PLP. 
The course at [school X] is very much orientated towards pharma-
cists working in primary care and retail. There was very little that
we, as hospital pharmacists, could use from it and there was minimal
support. (respondent 228; hospital pharmacist; 11–15 years’ experi-
ence; postgraduate; not started SP) 
I would have appreciated more detailed therapeutics included
in the course, but this was assumed to be covered in the time
spent with the independent prescriber. (respondent 59; primary
care pharmacist; >20 years’ experience; postgraduate; started
SP) 
The respondents highlighted the importance of clinical skills
development, especially in physical examination and consul-
tation, as part of the SP course. They felt that they could have
had more training in practical aspects of prescribing, such as
physical examination, as part of the SP course. 
I feel it is important to include physical examination skills other
than blood pressure monitoring and some other basic ones. (respond-
ent 240; prescribing adviser; 11–15 years’ experience; postgraduate;
started SP) 
The training process was a big learning curve especially the
counselling and consultation skills which enhance my knowledge
and improved the way in which I interact with patients. (respondent
383; hospital pharmacist; >20 years’ experience; postgraduate;
started SP) 
The responses indicated that some had completed a SP course
with nurses, while others had undertaken a course only for
pharmacists. The idea of a combined course for nurses and
pharmacists was considered inappropriate by some respond-
ents from primary care, though a few others recognised the
Table 2 Perceived benefits and challenges according to pharmacists practising SP (n = 195) 
Responses add up to more than 195 as many respondents identified more than one benefit and/or challenge.
Perceived benefits n (%) Challenges experienced n (%) 
Better patient management 139 (71.3) Inadequate funding 71 (36.4)
Job satisfaction 137 (70.3) Inadequate IT support 54 (27.7)
Patient satisfaction 
Increased self-confidence 
Greater independence 
Better recognition of pharmacy role by other health professionals 
Others (e.g. time saving) 
109 (55.9)
79 (40.5)
75 (38.5)
75 (38.5)
19 (9.7)
Difficulties in referral process/identification of 
suitable patients 
53 (27.2)
Poor recognition of pharmacy role by other health 
professionals 
51 (26.2)
Inadequate administrative support 45 (23.1)
Others (e.g. CMP-related, lack of space/facilities, 
shortage of staff) 
50 (25.6)
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benefits. Some thought there should be separate courses even
for pharmacists, based on their work experience and practice
setting, again highlighting the varying needs of pharmacists
which cannot be fulfilled by a single course. 
Training nurses and pharmacists together may be politically correct
but does not work, as the professions have very different background
and training needs. (respondent 257; primary care pharmacist; 16–20
years’ experience; no postgraduate qualification; not started SP) 
Training was appalling – primary care and senior hospital pharma-
cists in group together with completely different learning needs.
Course based on nurse prescribers course; our knowledge and learning
requirements [are] totally different to nurses. (respondent 148; primary
care pharmacist; >20 years’ experience; postgraduate; started SP) 
I did a joint course with nurses, which I found very beneficial [to
pharmacists and nurses] we had different strengths to our practice
which we all learnt from. (respondent 288; primary care pharmacist;
6–10 years’ experience; no postgraduate qualification; not started SP) 
Period of learning in practice 
The majority of the participants, irrespective of their practice
setting, appreciated the support they had received from their
designated medical practitioners (DMPs) during the PLP.
They regarded this experience to be more useful in develop-
ing their clinical skills than the SP course. 
I felt that the course itself was not wholly satisfactory. I am confi-
dent in my competence but believe I can give most credit to my GP
[general practitioner] mentor, who was very supportive throughout.
(respondent 176; prescribing adviser; 11–15 years’ experience; no
postgraduate qualifications; not started SP) 
I learnt the most useful information from working alongside my
mentor. I did not find the study days as useful as I hoped they would
be. (respondent 376; hospital pharmacist; 6–10 years’ experience;
postgraduate; started SP) 
Although I found the university section useful, I learnt so much
sitting in with the GP/nurse. I feel this experience with the GP has
helped me a lot, even in working in the shops. (respondent 88; com-
munity/primary care pharmacist; 6–10 years’ experience; postgradu-
ate; not started SP) 
Some respondents from primary care settings recommended
that more time should be spent on PLP and that it should be
made more diverse to increase the opportunities for learning. 
It was a real rush with time being spent with my mentor in all his
clinics to make sure we completed the hours rather than when it was
relevant. (respondent 9; prescribing advisor; 16–20 years’ experi-
ence; no postgraduate qualifications; started SP) 
The need for greater communication and support during PLP
with input from qualified SP pharmacists was highlighted by
some respondents working in primary care. 
Need more guidance of areas to look at during period of learning
in practice. This could be achieved through a network of practising
pharmacists linking in to those going through the course, relating
their experiences of what may have helped them prepare better.
(respondent 5; primary care pharmacist; 6–10 years’ experience;
postgraduate; started SP) 
Need more forums to share ideas, CMP templates, clinic set-ups
which work etc. (respondent 11; primary care pharmacist; 11–15
years’ experience; postgraduate; not started SP) 
I think GPs who have had a positive experience of working with
pharmacist prescribers should be encouraged to discuss this with
other GPs to encourage them to become mentors as this is a huge
stumbling block to future students. (respondent 129; primary care
pharmacist; 16–20 years’ experience; postgraduate; started SP) 
Many SP courses placed emphasis on reflective practice and used
the National Prescribing Centre Competencies for Pharmacist SP
Table 3 Characteristics of the respondents to the open question
(n = 145) 
Because some data are missing, some characteristics do not add up to 145. 
Characteristic n (%) 
Sex  
male 36 (24.8)
female 109 (75.2)
Age (years)  
25–34 36 (24.8)
35–44 64 (44.1)
45–54 41 (28.3)
>54 4 (2.8)
Years since registration as pharmacist  
<6 3 (2.1)
6–10 33 (22.8)
11–15 26 (17.9)
16–20 31 (21.4)
>20 52 (35.9)
Main practice setting  
community pharmacy 24 (16.6)
primary care medical practice 50 (34.5)
hospital pharmacy 50 (34.5)
other 21 (14.5)
Postgraduate qualifications  
yes 115 (79.3)
no 30 (20.7)
Institution offering prescribing course  
English school 97 (66.9)
Scottish school 37 (25.5)
Welsh school 11 (7.6)
Time since completion of prescribing training (months)  
<4 1 (0.7)
4–6 10 (6.9)
7–9 16 (11.0)
10–12 27 (18.6)
>12 91 (62.8)
Post-course training  
yes 85 (58.6)
no 58 (40.0)
Conditions focused on during period of learning in practice  
cardiovascular 52 (35.9)
respiratory 10 (6.9)
endocrine 9 (6.2)
CNS 6 (4.1)
multiple conditions 35 (24.1)
other (malignant diseases; infections; 
musculoskeletal; obstetrics, gynaecology and 
urinary tract; eye; skin; etc) 
33 (22.8)
IJPP 15(1).book  Page 26  Monday, February 12, 2007  12:52 PM
5
March 2007, The International Journal of Pharmacy Practice
to aid learning during the PLP. This focus received both pos-
itive and negative comments. Pharmacists from hospital and
primary care settings had concerns about the inequality
between supplementary prescribers in their skills. 
[The course] relies too heavily on trainee defining their own level
of competence. This may lead to inequality between supplementary
prescribers. [There] should be a recognised standard one should
attain. (respondent 61; hospital pharmacist; >20 years’ experience;
postgraduate; started SP) 
My training involved a great deal of reflective practice which
was very demanding but I can really appreciate its benefit now. I
use the techniques in my consultations and clinics. (respondent
186; primary care pharmacist; 6–10 years’ experience; postgradu-
ate; started SP) 
I feel that the 83 competencies prescribed by the [National Prescrib-
ing Centre are] excessive and unnecessary. (respondent 178; primary
care pharmacist; >20 years’ experience; postgraduate; started SP) 
Teething problems 
Being a new course, participants from hospital and primary
care settings highlighted the ‘teething problems’ in their pre-
scribing course. Though some believed that these problems
had since been rectified, others emphasised the need to use
feedback from practising SP pharmacists in revising the SP
curriculum. 
I was in the very first group to undergo the SP course at [school
Y] . . . I felt a bit of a ‘guinea pig’ on occasions. I understand the
course has been refined and developed since this first cohort and sub-
sequent students have benefited from the ‘teething troubles’ of the
first course. (respondent 33; hospital pharmacist; >20 years’ experi-
ence; postgraduate; not started SP) 
The new course at [School Z] is apparently better and has more
structure. Bit of a shambles when I did it as a lot of the other pharma-
cist agreed. (respondent 95; primary care pharmacist; 11–15 years’
experience; postgraduate; started SP) 
Society and the universities need to review the SP curriculum
based on the experiences and reflection of practising supplementary
prescribers. (respondent 131; hospital pharmacist: >20 years’ experi-
ence; postgraduate; started SP) 
Continuing professional development (CPD) 
The need for inclusion of SP in continuing pharmacy educa-
tion programmes and more opportunities for ongoing training
for supplementary prescribers have been stressed by some of
the respondents. 
There should be special training days for supplementary prescrib-
ers within each area to update their knowledge and other training
needs. (respondent 334; community pharmacist; 16–20 years’
experience; postgraduate; not started SP) 
I require to develop consultation, examination and monitoring
skills, especially if I am involved in areas such as congestive heart
failure. Nurses manage it. Not pleased with the support from the
RPSGB. Recent [Centre for Pharmacy Postgraduate Education]
workshops have not included SP. (respondent 127; primary care
pharmacist; 16–20 years’ experience; postgraduate; not started SP) 
I have learnt a lot more about my chosen topic through personal
CPD since I have completed the course. (respondent 59; primary
care pharmacist; >20 years’ experience; postgraduate; started SP) 
Perceived benefits of SP 
Respondents from all practice settings thought that SP offered
better therapeutic management and resulted in greater patient
satisfaction. Job satisfaction, increased self-confidence,
greater independence, better recognition and time savings
were regarded as the main benefits of SP to the prescribers.
However, for some practitioners, especially for those working
in hospital settings and primary care, SP has only been a
minor extension of their existing role. 
Patients [are] generally very appreciative of the service as I have
more time with them and they do not feel inhibited by the time con-
straints of a GP appointment and ask more questions which I believe
leads to better management. (respondent 2; primary care pharma-
cist; >20 years’ experience; postgraduate; started SP) 
I derive huge personal satisfaction from being a supplementary
prescriber and have developed my role in new therapeutic areas at
the request of the GPs with whom I work. It has helped me develop
better working relationships with the GPs and nurses in the practice.
(respondent 129; primary care pharmacist; 16–20 years’ experience;
postgraduate; started SP) 
I believe supplementary prescribing allied to repeat dispensing by
pharmacists is the single biggest weapon available to the NHS to
combat long-term illness. (respondent 80; community pharmacist;
11–15 years’ experience; no postgraduate qualifications; started SP) 
Supplementary prescribing has little changed my practice – it has
legalised what I did anyway. (respondent 109; hospital pharmacist;
6–10 years’ experience; postgraduate; started SP) 
Barriers to SP 
Funding issues 
Inadequate funding was mentioned by respondents as a major
limitation for undergoing training and for setting up prescrib-
ing services, especially by community pharmacists. Even with
funding, competition from nurse supplementary prescribers
could reduce the opportunities for pharmacist prescribers. 
For community pharmacists, it is difficult to practice as: first you
have to pay for your locum; then after qualification, primary care
does not support or subsidise you working; [the] GP does not want to
pay you and there are not many PCTs who have protocols for SP
pharmacists to practice. (respondent 333; community pharmacist;
>20 years’ experience; postgraduate; not started SP) 
I did supplementary prescribing for approximately 5 months, but
now the (Consultation and Negotiation Partnerships) don’t want to
spend ‘limited’ funding on pharmacist since nurses can do an almost
similar job at a much reduced rate! (respondent 220; community
pharmacist; 16–20 years’ experience; postgraduate; practised SP) 
Delay in getting prescription booklets 
Delay in getting prescription booklets after qualification as a
supplementary prescriber, and inability to print prescriptions
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were frustrations for many respondents, especially for those
working in primary care and community pharmacies. 
Process once qualified is too complex. Practice computer systems
not ready for scripts/CMP. (respondent 225; community pharmacist;
11–15 years’ experience; no postgraduate qualification; not started SP) 
I have spent 4 years persuading GPs to use the computer for
scripts and then I have to write my own with no computer aids.
(respondent 57; primary care pharmacist; >20 years’ experience;
postgraduate; started SP) 
Lack of recognition 
Lack of awareness of the pharmacist’s role in medication
management, especially as a prescriber, by health profession-
als and the public, and lack of organisational recognition
were barriers to initiating prescribing services for many
respondents, irrespective of their practice setting. Networking
and publicity were regarded as the key by those who have
been successful in initiating the services. 
I would like to be able to use my SP in my job but find it very diffi-
cult to get GPs on board. (respondent 367; community pharmacist; <6
years’ experience; no postgraduate qualification; not started SP) 
[It was] difficult to implement as I was first to qualify as a SP in
my trust. No one knew what it was about. But now that I am actually
prescribing, other healthcare professionals think it’s a great asset to
enhance patient care. (respondent 219; hospital pharmacist; >20
years’ experience; postgraduate; started SP) 
Patients do not understand the role at all; nor do most GPs! We
need far more publicity. The best thing for me was the networking.
I have made many new friends/contacts which have really helped
in my role as prescribing advisor. (respondent 9; prescribing
advisor; 16–20 years’ experience; no postgraduate qualification;
started SP) 
Restrictions due to CMP 
Respondents from all practice settings mentioned many prac-
tical difficulties caused by CMPs, despite appreciating its
importance. CMPs were considered restrictive as they were
time consuming to complete and unsuitable in getting agree-
ment from the independent prescriber, especially when
patients have multiple medical conditions. Independent pre-
scribing rights for pharmacists, generic CMPs and alternative
methods of getting approval from the independent prescriber
were recommended as solutions to overcome these barriers. 
CMPs are useful to ensure patients have a documented therapeutic
plan for medicines use but they’re time consuming to prepare and
can be restrictive if new conditions appear and aren’t added. I would
value independent prescribing for minor, transient conditions in my
patients. (respondent 141; hospital/nursing home pharmacist; 16–20
years’ experience; postgraduate; started SP) 
[I] have developed an approach which uses an overall care plan for an
individual that specifies the CMPs for that person under it and the care
that the independent prescriber will deliver. (respondent 147; primary
care pharmacist; >20 years’ experience; postgraduate; practised SP) 
I find it a lot easier to use the GP’s prescription pad when writing
prescriptions and getting him to sign it and therefore did not have to
develop individual CMPs! (respondent 247; community pharmacist;
11–15 years’ experience; postgraduate; started SP)
In this first national survey of all SP pharmacists in Great Britain,
SP has been perceived by pharmacists across all practice settings
to be highly beneficial for both patients and the pharmacists. The
study also gave us an insight of the issues surrounding SP train-
ing and implementation. Modifications in the content, delivery
and assessment of the SP course for pharmacists, based on feed-
back from practising SP pharmacists and more CPD opportuni-
ties for practising SP, were recommended by some of the
respondents. The need for greater publicity of pharmacists’ role
in medication management and support from the medical profes-
sion and healthcare organisations in implementing SP services
were recognised by the study participants as key factors for the
success of SP by pharmacists. 
This was the first major study of experiences of SP phar-
macists in Great Britain. Our findings could inform current
and prospective pharmacist prescribers, policy makers, pro-
viders of the prescribing course and organisations considering
implementation of prescribing services by pharmacists in
Great Britain and overseas. Our study has a few limitations.
The response rate for the survey was high, but only just over
one-third of the respondents answered the general open ques-
tion. The study was exploratory in nature, and the method of
data generation did not allow further exploration of the
themes or issues identified. However, those who gave open
comments were similar to those who did not in terms of
demographics. Despite differences in the views of practition-
ers from different practice settings, there were minimal differ-
ences in the views of respondents from the same setting,
supporting the reliability of our findings. There is a need for
more in-depth qualitative investigation of our findings. In
addition, more practice-based research for establishing the
safety and value of SP by pharmacists in terms of clinical out-
comes and patient satisfaction is warranted, to win the confid-
ence of other health professionals and the general public. 
Respondents thought that SP would lead to better patient
management, job satisfaction for pharmacists and greater
patient satisfaction, These are similar to those reported by
early nurse prescribers in Great Britain.17–20 SP pharmacists
in secondary care thought that SP had made little change in
their day-to-day practice, as it only legitimised some of the
services that they were already providing. Similar views have
been reported elsewhere.9 Financial and logistical challenges
to the implementation of SP were perceived to be more in
primary care and community pharmacy settings. However,
lack of recognition as a prescriber, and practical difficulties in
completing patient-specific CMPs were found to be chal-
lenges across all practice settings. Lack of time, insufficient
staff and lack of awareness among other health professionals
and the general public about the pharmacists’ skills and
attributes are known to be the major obstacles in expanding
pharmacists’ professional role, especially in the community
setting.21 Financial and logistical barriers in the implementa-
tion of prescription monitoring and review services in the
community setting have also been reported earlier.22 Specific
Discussion
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funding and support services directed at SP are essential for phar-
macists to set up clinics and focus on prescribing responsibilities,
especially in those settings where such services are non-exist-
ent. The Scottish Executive has recently made available fund-
ing to allow community pharmacists to set up or continue to
run supplementary prescribing clinics.23 Access to electronic
health records and ability to generate electronic prescriptions
are also critical in ensuring optimal outcomes when prescrib-
ing responsibilities are undertaken by pharmacists.24,25 
The respondents’ views about their SP course reflected the
diversity in the structure, content and delivery of courses
offered in Great Britain. The range of course satisfaction
scores among SP pharmacists from various higher education
institutions (HEIs) complement these findings.16 The
respondents emphasised the importance of training focused
on clinical and consultation skills as part of the SP course.
The need for revisions in the SP curriculum based on feed-
back from practising supplementary prescribers, independent
prescribers and policy makers was also highlighted. Many
respondents acknowledged that the SP course at their HEI
had been adapted since they completed their training. It is
critical that by the end of their SP course all SP pharmacists
achieve competencies in accordance with the framework set
by the National Prescribing Centre.26 
The medical profession has voiced concerns about pharma-
cists’ proficiency in diagnosis, awareness of clinical and
patient details and the likely communication problems when
they take up prescribing responsibilities.27–29 Some universi-
ties in Great Britain have already introduced topics relevant to
prescribing in the undergraduate pharmacy degree course,
whereby students get familiarised with the legal and psycho-
logical aspects of prescribing and auditing, monitoring and
evaluation of prescribing practice.30 Students also work on
case studies to make use of their problem-solving skills and
gain hands-on experience in monitoring outcomes from drug
treatment. To better prepare students for a possible prescribing
role, it is likely that most universities in Great Britain will
include elements of the prescribing curriculum within the
undergraduate pharmacy course. Universities could use the rec-
ommendations for teaching safe and effective prescribing in
medical schools as a guideline to ensure that all pharmacy
graduates are prepared to undertake additional prescribing
responsibilities, with minimal training during the PLP.31 This
is crucial, especially when a majority of the primary and second-
ary care trusts are intending to implement SP by pharmacists.9 
Independent prescribing by pharmacists will commence in
the near future.32,33 Pharmacist independent prescribers will be
able to prescribe any licensed medicine (with the exception of
controlled drugs) for any medical condition (diagnosed or
undiagnosed) within their clinical competence, after successful
completion of an independent prescribing course for pharma-
cists.32,33 The Department of Health is working with RPSGB
and other stakeholders to confirm the education and training
requirements for pharmacist independent prescribers. In the
early phases of independent prescribing, its uptake may be
more likely by those with previous training in SP.11 Clinical
training focusing on disease conditions and drugs, ability to
communicate prescribing actions to GP practice, and gaining
improved patient consultation skills were regarded to be
important prior to implementation of independent prescribing
by community pharmacists.11 The need for CPD was stressed in a
national survey of nurse prescribers in England.19 Opportunities
for supplementary prescribers to further develop clinical and
consultation skills through CPD would ensure ongoing quality
in SP and prepare them to undertake independent prescribing
responsibilities in the future. 
Conclusion 
This study has explored the experiences and perceptions of
early pharmacist supplementary prescribers in Great Britain.
SP has been regarded to be highly beneficial for both patients
and pharmacists. Several logistical and financial barriers hin-
dering the implementation of SP have been identified. Modifi-
cations should be made in the content, delivery and assessment
of the SP course for pharmacists, based on feedback from prac-
tising SP pharmacists. Greater publicity of pharmacists’ role in
medication management, support from the medical profession
and healthcare organisations, and high standards by early prac-
titioners are essential for the success of SP by pharmacists.
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Supplementary prescribing is definedas “a voluntary partnership between
an independent prescriber (ie, physician,
dentist) and a supplementary prescriber to
implement an agreed patient-specific clini-
cal management plan (CMP) with the pa-
tient’s agreement.”1 Training for pharma-
cists to become supplementary prescribers
in Great Britain involves at least 25 days
(200 h) of university tuition at the degree
or master’s level. In addition, there are 12
days of experiential learning under medi-
cal supervision, termed the Period of
Learning in Practice (PLP).2,3 On success-
ful completion of supplementary prescrib-
ing training and registration with the Roy-
al Pharmaceutical Society of Great Britain
(RPSGB) as a prescriber, supplementary
prescribing pharmacists may prescribe for
the full range of medical conditions. How-
ever, they must be practicing within their
professional competence and under the
terms of a patient-specific CMP. Before
supplementary prescribing can begin, it is
obligatory that an agreed paper-based or
electronic CMP relating to a named pa-
tient and that patient’s specific conditions
be in place, to be managed by the supple-
mentary prescriber. Both independent and
supplementary prescribers must formally
agree on the CMP before supplementary
prescribing can begin. The patient’s agree-
ment also needs to be obtained by either the independent
or the supplementary prescriber before supplementary pre-
scribing can proceed. In addition to patient details, the
CMP must include reference to the class or description of
drugs that may be prescribed or administered under the
plan and any restrictions or limitations as to the strength or
dose of any drug that may be prescribed.2
Experiential Learning as Part of Pharmacist Supplementary
Prescribing Training: Feedback from Trainees and Their Mentors
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BACKGROUND: A period of learning in practice (PLP) is an integral part of
supplementary prescribing training for pharmacists in Great Britain. During the
PLP, a designated medical practitioner (DMP) supervises and supports the
trainee to develop competence in prescribing.
OBJECTIVE: To evaluate the views and experiences of supplementary prescribing
pharmacists and DMPs regarding the PLP and identify their perceived support
needs during the PLP.
METHODS: Prepiloted questionnaires were mailed in September 2006 to all
pharmacists who had started their supplementary prescribing training at The
Robert Gordon University, Aberdeen, Scotland (n = 242) and their DMPs (n =
232). Nonrespondents were sent up to 2 reminders. Responses were analyzed
using descriptive and comparative statistics; responses to open questions were
analyzed thematically. 
RESULTS: Responses were received from 186 (76.9%) pharmacists and 144
(62.1%) DMPs. Just over half of the pharmacists agreed/strongly agreed that
they knew what was expected of them and their DMPs during the PLP, but less
than half agreed/strongly agreed that it was important to communicate with
pharmacist colleagues in the prescribing course. One hundred twelve (60.2%)
pharmacists had their consultation skills reviewed by their DMPs during the PLP.
Opportunities for professional development and teamwork were regarded as
major positive experiences by both pharmacists and DMPs. Organizational,
attitudinal, and time barriers were also reported. There was considerable interest
among both pharmacists and DMPs for an Internet-based support network during
the PLP.
CONCLUSIONS: Information on the roles and responsibilities of pharmacists and
DMPs during the PLP should be enhanced. The Internet could be a useful
medium for communication during the PLP. Input from a multidisciplinary team of
healthcare professionals and review of consultation videos could further enhance
the PLP experience.
KEY WORDS: experiential learning, mentors, pharmacists, supplementary prescribing. 
Ann Pharmacother 2007;41:1031-8.
Published Online, 8 May 2007, www.theannals.com, DOI 10.1345/aph.1H650
 
11
Pharmacists from various practice settings in Great
Britain have been practicing supplementary prescribing for
a range of conditions since 2004.4,5 The Robert Gordon
University in Aberdeen, Scotland, is a major provider of
supplementary prescribing training for pharmacists in
Great Britain, with more than one-fifth of RPSGB pre-
scribers completing their supplementary prescribing train-
ing there.4
The main purposes of the PLP are to enable pharmacists
to transfer academic knowledge to practice; acquire and
practice skills, including communication with patients,
caregivers, and other prescribers; develop clinical knowl-
edge and skills necessary for the diagnosis, treatment, and
monitoring of the condition(s) for which they intend to
prescribe; and maintain accurate and timely records of
their prescribing practice.3 The National Prescribing Cen-
tre, which promotes and supports high quality, cost-effec-
tive prescribing and medicines management across the Na-
tional Health Service, has produced a framework of 9
competencies covering 3 main areas—consultation, pre-
scribing effectively, and prescribing in context. The goal is
to ensure quality of care and patient safety when prescrib-
ing responsibilities are undertaken by pharmacists.6,7 The
individual competencies are listed in Table 1. During the
PLP, a supervising physician, known as the designated
medical practitioner (DMP), provides the trainee with su-
pervision, support, and opportunities to devel-
op competence in prescribing practice. The fo-
cus is on one or more therapeutic areas and
concentrates on the group of patients for
whom the pharmacist will prescribe initially.2,3
The PLP is planned by the candidate, in col-
laboration with the DMP, after agreeing on the
clinical area(s) and the competencies relevant
to the individual. Aspects of training can be
delegated as appropriate. The PLP may be ex-
tended beyond the recommended 12 days, if
necessary. Candidates are required to submit a
portfolio to the university, providing evidence
of achievement of relevant competencies.6,7
This portfolio was first developed as a paper-
based tool, but by 2005 had become an online
portfolio. Finally, the DMP must sign a decla-
ration that the pharmacist is suitable for regis-
tration as a prescriber with RPSGB.
Supplementary prescribing training at The
Robert Gordon University is at Scottish mas-
ter’s level, and the modules in the academic
portion of the course are delivered by distance
learning, supplemented by a 5 day residential
period at the university. Various assessment
methods are used, including analysis of case
studies, reports, thematic and reflective prac-
tice essays, and objective structured clinical examinations.
There is no set format for the PLP, and it may be undertak-
en concurrently or subsequent to the university-based
training. All of the relevant competencies must be
achieved; however, the training need not be completed in
12 consecutive days. Trainees and DMPs are provided sep-
arate handbooks that detail their roles and responsibilities,
as well as the required NPC competencies. The DMP’s
handbook also describes the background of the supple-
mentary prescribing course and details of the university-
based training including the aims, learning outcomes, in-
dicative content, and assessment methods. This affords the
DMPs the opportunity to put the PLP into context with the
entire supplementary prescribing course. The DMPs are
also given a point of contact at the university. 
Many supplementary prescribing pharmacists who par-
ticipated in a national survey regarded their PLP experi-
ence as more valuable in developing their clinical skills
than the university training.4,8 Therefore, it is crucial that
the PLP provides an optimal learning experience, leading
to safe and appropriate prescribing. The PLP is an integral
part of prescribing training for pharmacists, yet there had
been no publicized, formal research evaluation of trainee
and DMP needs in relation to the PLP. 
The primary objective of our study was to evaluate the
views and experiences of pharmacist supplementary pre-
n The Annals of Pharmacotherapy    n 2007 June, Volume 41 www.theannals.com
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Table 1. Competencies for Pharmacist 
Supplementary Prescribers6
Competency Area Overarching Competency
Consultation clinical and pharmaceutical knowledge: has up-to-date 
clinical and pharmaceutical knowledge relevant to own
area of practice
establishing options: reviews diagnosis and generates 
treatment options for pt. within the clinical management
plan; always follows up treatment
communicating with pts.: establishes a relationship 
based on trust and mutual respect; sees pts. as part-
ners in the consultation; applies principles of concor-
dance
Prescribing effectively prescribing safely: is aware of own limitations; does not 
compromise pt. safety; justifies prescribing decisions
prescribing professionally: works within professional and 
organizational standards
improving prescribing practice: actively participates in 
review and development of prescribing practice to
improve pt. care
Prescribing in context information in context: knows how to access relevant 
information; can critically appraise and apply information
in practice
the NHS in context: understands and works with local and 
national policies and services that impact wider NHS
prescribing practice; sees how own practice impacts the 
wider NHS
team and individual context: works in partnership with
colleagues for the benefit of pts.; is self aware and
confident in own ability as a prescriber
NHS = National Health Service.
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scribing trainees and DMPs about the PLP as part of phar-
macists’ supplementary prescribing training. The secondary
objective was to explore both the trainees’ and DMPs’ per-
ceived need for additional support during the PLP. 
Methods
Postal questionnaires for supplementary prescribing
pharmacists and DMPs were developed (Appendices I and
II, www.hwbooks.com/pdf/appendices/H6501.pdf and
www.hwbooks.com/pdf/appendices/H6502.pdf), using in-
formation gathered from 2 focus groups with supplemen-
tary prescribing pharmacists (n = 5 and 7) and one-to-one
telephone interviews with DMPs (n = 13), conducted by
the research team.9 Both questionnaires had 2 sections of
open and closed questions that focused on general demo-
graphics (7 items for pharmacists, 6 items for DMPs) and
experiences during the PLP (18 items for pharmacists, 16
items for DMPs). The section on the PLP included items
about the setting, patient groups/therapeutic areas, others
involved in training, and activities relating to consultations.
Details of contact with the university during the PLP, atti-
tudes toward the PLP (5 point Likert scales), positive and
negative experiences, and recommendations to improve
the PLP experience were also sought. The research team,
which had expertise in a range of disciplines within the
fields of pharmacy, psychology, and education, including
e-learning, tested the content validity of the questionnaires.
Piloting of the questionnaires followed, with 20 randomly
selected pharmacist supplementary prescribing trainees
and DMPs each. After minimal changes, the question-
naires were mailed in September 2006 to all pharmacists
who had started their supplementary prescribing training
through the Robert Gordon University before March 2006
(n = 242) and their DMPs (n = 232), excluding the pilot
samples. DMPs were fewer in number than the supple-
mentary prescribing pharmacists because some had retired
or had mentored multiple pharmacists. Nonresponders re-
ceived 2 follow-up reminders at 2 week intervals.
Responses were entered into an SPSS database (version
13.0) and analyzed using descriptive statistics. Responses
to open questions were analyzed for content and classified
into broad themes to facilitate descriptive statistical analy-
sis. The reliability of attitudinal items was tested using split
sample method10; internal consistencies (Cronbach’s α)
were compared after reverse scoring the negatively word-
ed items. Differences in responses to the attitudinal items,
between pharmacists in different sectors of practice, were
explored using the Kruskal–Wallis test, and the Mann–
Whitney U test was used for differences between pharma-
cists and DMPs. A p value less than 0.05 was considered
statistically significant. The study had approval from the
Multi-centre Research Ethics Committee (MREC) for
Scotland.
Results 
Responses were received from 186 of 242 (76.9%)
pharmacists and 144 of 232 (62.1%) DMPs. Respondents’
characteristics are summarized in Table 2. Input from med-
ical and nonmedical professionals, other than DMPs, in-
cluding multiple sources to improve clinical, diagnostic,
consultation, and management skills, was described by 123
(66.1%) pharmacists. Training from a practicing supplemen-
tary prescribing pharmacist during the PLP would be valu-
able, according to 148 (80.0%) pharmacists. However, only
12 (8.3%) DMPs reported discussing the PLP with other
medical practitioners or healthcare professionals.
One hundred twelve (60.2%) pharmacists reported hav-
ing their consultation skills reviewed by their DMPs dur-
ing the PLP, using the following review methods: face to
face (78; 69.6%), consultation videos (17; 15.2%), written
reports (3; 2.7%), tape recordings (2; 1.8%), face to face/
consultation videos (7; 6.3%), and face to face/written re-
ports (4; 3.6%). Pharmacists reported the frequency of re-
viewing of consultations by their DMPs as some consulta-
tions (70; 62.5%), most consultations (26; 23.2%), and ev-
ery consultation (12; 10.7%). DMPs similarly reported a
high level of consultation-skills activity during the PLP.
Eighty-seven (60.4%) reported reviewing pharmacist con-
sultation skills, with methods and frequencies similar to
those reported by the pharmacists.
Responses to the attitudinal items on experiential learn-
ing from supplementary prescribing pharmacists and
DMPs are presented in Table 3. Using a split sample
method, the internal consistencies of the attitudinal items
for community pharmacists (n = 94) and other pharmacists
(n = 92) were 0.64 and 0.61, respectively. DMPs with clin-
ical experience up to 20 years (n = 60) and those with
more than 20 years of clinical experience (n = 84) had in-
ternal consistencies of 0.55 and 0.49, respectively, for the
attitudinal items. 
Just over half of the pharmacists agreed/strongly agreed
that they knew what was expected of themselves and their
DMPs during the PLP, but less than half agreed/strongly
agreed that it was important to communicate with pharma-
cist colleagues in the prescribing course. Some significant
differences were observed between DMP and pharmacist
responses, with DMPs agreeing that they were more aware
of the DMP role than the pharmacists had perceived. Phar-
macists, more than DMPs, agreed that it was easy to com-
municate with the university and their peers during the
PLP. There was considerable support among both pharma-
cists and DMPs for an Internet-based network during the
PLP. No significant differences in responses were observed
for pharmacists working in different sectors of practice. 
Pharmacists and DMPs cited many positive experiences
that occurred during the PLP (Table 4). Both groups recog-
nized opportunities for professional development as well
Pharmacist Supplementary Prescribing Training
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as teamwork. Some challenges and/or negative experi-
ences, mainly time barriers, were also experienced by both
pharmacists and DMPs (Table 4). Pharmacists reported
contacting the university at some time during their PLP to
inquire about deadlines for submitting portfolios or to in-
form the university about delays in submitting portfolios
(10; 5.4%), to clarify the types of clinical experiences ac-
ceptable for PLP (8; 4.3%), for information on completing
portfolios (6; 3.2%), to clarify the responsibilities of the
DMP or discuss DMP-related difficulties (5; 2.7%), and
other queries (administrative, course work related) (3;
1.6%).
Recommendations made by pharmacists to improve the
PLP experience include the following: more opportunities
for information sharing and clearer, more structured infor-
mation on PLP for DMPs and pharmacists (44; 23.7%); al-
lowing trainees to undertake whole or part of supplemen-
tary prescribing training with a supplementary prescribing
pharmacist or a medical practitioner with experience in
mentoring for supplementary prescribing (14; 7.5%);
structural changes in the supplementary prescribing course
or the PLP to suit the experience and knowledge of indi-
viduals (12; 6.5%); remuneration for DMPs and greater
awareness of the benefits of supplementary prescribing (9;
4.8%); and other (organizational support; multiple DMPs,
better preparation for PLP during university training) (3;
1.6%). 
DMPs’ suggestions for improving the PLP experience
included clearer information on the objectives of the PLP
and the role of DMPs (9; 6.3%), remuneration for DMPs
(8; 5.6%), training programs to prepare mentors for under-
taking responsibility for PLP (7; 4.9%), and communica-
tion and feedback between mentors and academia through-
out the PLP (4; 2.8%).
Discussion
This is the first major study of experiences of pharma-
cists during the experiential learning phase of supplemen-
tary prescribing training. Just over half the pharmacists and
just under half the DMPs knew what was expected of them
and their partners at the start of the PLP. For many phar-
macists and DMPs, the PLP provided an opportunity for
professional development and teamwork. Some attitudinal,
organizational, and time barriers during the PLP were
identified. A mechanism to allow pharmacists to maintain
contact with their peers in the supplementary prescribing
course was regarded as helpful by the majority of pharma-
cists and DMPs, although, interestingly, most DMPs did
not recognize the need for any communication with their
medical colleagues mentoring other pharmacists. The In-
ternet was perceived as a useful resource to provide further
information from the university and for communication
among pharmacists and DMPs during the PLP. 
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Table 2. Characteristics of Survey Respondentsa
Pharmacists DMPs 
Characteristic n (%) n (%)
Sex
male 57 (30.6) 109 (75.7)
female 128 (68.8) 34 (23.6)
Age, y
25–34 51 (27.4) 5 (3.5)
35–44 73 (39.2) 53 (36.8)
45–54 53 (28.5) 62 (43.1)
>54 8 (4.3) 23 (16.0)
Experience as a practitioner, y
<6 14 (7.5) 0
6–10 33 (17.7) 3 (2.0)
11–15 39 (21.0) 19 (13.2)
16–20 27 (14.5) 38 (26.4)
>20 73 (39.2) 84 (58.4)
Practice setting
community pharmacy 94 (50.5) NA
primary care medical practice 48 (25.8) 113 (78.5)
secondary care 42 (22.6) 29 (20.1)
tertiary care 0 1 (0.7)
other (eg, academia, hospice, service) 6 (3.2) 1 (0.7)
Patient groups/therapeutic areas of
focus during PLP
cardiovascular 92 (49.5)
respiratory 25 (13.4)
endocrinology 22 (11.8)
mental health 9 (4.8)
substance misuse 8 (4.3)
other (eg, musculoskeletal, 44 (23.7)
oncology, pain, geriatrics)
Training status, pharmacists
registered prescriber 115 (61.8)
practicing supplementary prescriber 53 (28.5)
completed training; not registered 10 (5.4)
experiential learning ongoing 46 (24.7)
experiential learning not started 13 (7.0)
Training status, DMPs, previous 
experience training health 
professionals
yes 124 (86.1)
no 20 (13.9)
Involvement of health professionals
other than DMP in training
nurses (practice, prescriber, specialist) 89 (47.8)
physicians, non-DMP (GPs, 58 (31.2)
consultants, registrars)
pharmacists (clinical, SP, practice) 45 (24.2)
technical staff (phlebotomists, 12 (6.5)
respiratory technicians)
practice managers 7 (3.8)
other (allied health, administrative) 12 (6.5)
Consultation reviews, frequency
none 50 (34.7)
some 45 (31.3)
most 30 (20.8)
every 10 (6.9)
DMP = designated medical practitioner; NA = not applicable; PLP =
period of learning in practice; SP = supplementary prescribing.
aNumber of respondents = 186 pharmacists, 144 DMPs; responses
do not total 186 and 144 for pharmacists and DMPs, respectively, due
to missing data; some respondents were practicing in more than one
setting.
(continued on page 1035)
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Despite provision of detailed information about the PLP
in separate handbooks for pharmacist trainees and DMPs,
many in both groups did not feel fully informed about the
program. Consideration needs to be given to providing
clearer and more structured information to both groups, es-
pecially before the start of the PLP. They should have in-
formation on their roles and responsibilities, and it could
be provided through other media such as the Internet
and/or group meetings. Greater opportunities for commu-
nication among pharmacists, DMPs, and academia are also
warranted. Such needs might be more critical for pharma-
cists who do not have input from a practicing supplemen-
tary prescribing pharmacist during the PLP and for those
DMPs without prior experience in training healthcare pro-
fessionals. 
Many of the negative experiences and challenges during
the PLP were attitudinal and organizational. Outcomes-
based research and high standards by early supplementary
prescribing pharmacists are essential for winning the con-
fidence of medical practitioners and patients and for sus-
taining the role of pharmacists in prescribing. Interprofes-
sional education at an undergraduate level might help to al-
leviate some of the attitudinal barriers toward teamwork
and undertaking of cross-professional responsibilities
among health professionals from different backgrounds.
Remuneration was mentioned by only a few responding
pharmacists as a crucial factor for the future viability of the
PLP. However, financial barriers to training of junior
physicians has been reported11 and should be resolved at
the policy level. 
Our study demonstrated some of the positive effects of
multidisciplinary teamwork on health professionals and
patients. Approximately half of the pharmacist respondents
worked with nurses during their PLP. The willingness of
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Table 2. Characteristics of Survey 
Respondentsa (continued)
Pharmacists DMPs 
Characteristic n (%) n (%)
Consultation reviews, method
face to face 68 (47.2)
consultation videos 6 (4.2)
report and discussion 4 (2.8) 
consultation video/face to face 5 (3.5)
report and discussion/face to face 4 (2.8)
DMP = designated medical practitioner.
aNumber of respondents = 186 pharmacists, 144 DMPs; responses
do not total 186 and 144 for pharmacists and DMPs, respectively, due
to missing data; some respondents were practicing in more than one
setting.
Table 3. Pharmacists’ and DMPs’ Responses to Attitudinal Itemsa
n (%) 
Strongly Strongly
Item Disagree Disagree Neutral Agree Agree p Valueb
Pharmacists: When I started the PLP, I knew what was 10 (5.4) 28 (15.1) 27 (14.5) 88 (47.3) 19 (10.2) 0.395
expected of me
DMPs: When the pharmacist started the PLP, I knew what was 2 (1.4) 28 (19.4) 25 (17.4) 77 (53.5) 5 (3.5)
expected of him/her
Pharmacists: When I started the PLP, I knew what was 7 (3.8) 30 (16.1) 36 (19.4) 84 (45.2) 15 (8.1) 0.882
expected of my DMP
DMPs: When the pharmacist started the PLP, I knew what was 3 (2.1) 30 (20.8) 37 (25.7) 64 (44.4) 4 (2.8)
expected of me
Pharmacists: When I started the PLP, I felt my DMP was fully 24 (12.9) 54 (29.0) 42 (22.6) 39 (21.0) 12 (6.5) <0.001
aware of his/her role
DMPs: When the pharmacist started the PLP, I was fully 5 (3.5) 38 (26.4) 28 (19.4) 61 (42.4) 6 (4.2)
aware of my role
Pharmacists/DMPs: It is/was easy for me to get in touch with 1 (0.5) 5 (2.7) 66 (35.5) 68 (36.6) 26 (14.0) <0.001
the university during the PLP 1 (0.7) 10 (6.9) 96 (66.7) 15 (10.4) 1 (0.7)
Pharmacists: It is/was difficult for me to get in touch with my 14 (7.5) 71 (38.2) 55 (29.6) 22 (11.8) 6 (3.2) <0.001
colleagues in the prescribing course during the PLP
DMPs: It is/was difficult for me to get in touch with other 2 (1.4) 22 (15.3) 78 (54.2) 22 (15.3) 3 (2.1)
medical practitioners mentoring pharmacists
Pharmacists/DMPs: It is/was important to communicate with 6 (3.2) 21 (11.3) 61 (32.8) 64 (34.4) 18 (9.7) <0.001
colleagues in the prescribing course during the PLP 3 (2.1) 44 (30.6) 65 (45.1) 19 (13.2) 2 (1.4)
DMPs: It is/was important for pharmacists to communicate 1 (0.7) 1 (0.7) 24 (16.7) 87 (60.4) 22 (15.3)
with their colleagues in the prescribing course during the PLP
Pharmacists/DMPs: Internet-based network could be/is an 4 (2.2) 11 (5.9) 48 (25.8) 89 (47.8) 20 (10.8) 0.479
efficient way of interacting during the PLP 2 (1.4) 3 (2.1) 34 (23.6) 87 (60.4) 8 (5.6)
DMP = designated medical practitioner; PLP = period of learning in practice.
aPharmacists = 186, DMPs = 144; responses do not total 186 and 144 for pharmacists and DMPs, respectively, due to missing data.
bMann–Whitney U test.
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community pharmacists to work collaboratively with nurs-
es has been reported.12 Learning and practicing in multidis-
ciplinary teams provides opportunities for healthcare pro-
fessionals to learn from each other and should result in bet-
ter patient outcomes. A study exploring the views of
community pharmacists regarding nurse prescribing and
interdisciplinary working in primary care concluded that
increased contact with other health professionals and
greater understanding of roles are necessary to achieve the
potential of teamwork.12 Socialization to an immediate
work group could override professional or hierarchical dif-
ferences among health professionals, and effective inter-
professional working could lead to more effective service
delivery and user outcomes.13 The input that trainees re-
ceived from medical and/or nonmedical professionals dur-
ing their PLP and their positive feedback suggest that a
multidisciplinary training team would be ideal for mentor-
ing pharmacists during their PLP, especially for those
without team working experience prior to their PLP. Com-
munity pharmacists are known to have several challenges
to practicing supplementary prescribing4,8; a PLP provides
an ideal opportunity for them to foster professional rela-
tionships, which is the key for practicing as a prescriber af-
ter qualification.
Nearly two-thirds of pharmacists in our study received
feedback on their consultation skills, but this was largely
face to face; only a minority experienced video-based
feedback. The advantages of video-based feedback training
over conventional teaching in improving interviewing skills
of medical graduates is well documented.14 The ability of
videotaped consultations to identify medical trainees who are
not competent to undertake independent practice has also
been established.15 The RPSGB has recognized the impor-
tance of video feedback training and has included it in recent
guidelines for prescribing training for pharmacists.16 Perhaps
this should become a mandatory element of the PLP. 
Our study has some limitations. First, all participants
were pharmacists who had started prescribing training
through our university only. It is possible that their re-
sponses were biased, especially based on their experiences
during the PLP. Those who had negative experiences
and/or attitudes might not have completed the question-
naires. The extent to which the views and attitudes identified
in this study are held by the entire population of supplemen-
tary prescribing pharmacists and DMPs is unknown. Some
of the supplementary prescribing pharmacists continue as
students at the university, and this may have influenced
their responses. Second, we relied on self-reports, and the
findings were not evaluated objectively. However, the
study was anonymous in nature, and we had responses
from more than three-quarters of pharmacists and two-
thirds of mentors involved in the PLP, including those with
negative experiences. The questionnaire also had several
limitations. For ethical reasons and to maintain anonymity,
we did not attempt to link and compare pharmacists with
their DMPs. Such comparisons would have provided inter-
esting data on different professional perspectives within
the same setting. Although we inquired about pharmacist
and DMP contacts with the university and with other col-
leagues, this issue was not quantified or explored further.
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Table 4. Positive and Negative Experiences During PLPa
Positive, Pharmacists n (%) Positive, DMPs n (%)
Opportunity for developing and testing communication and/or 36 (19.4) Professional development 29 (20.1)
diagnostic skills Greater collaboration with pharmacists 26 (18.1)
Working with medical practitioners/supplementary prescribing 34 (18.3) Professional satisfaction 26 (18.1)
pharmacists/other healthcare professionals Better understanding of pharmacist’s role 11 (7.6)
Building interprofessional relationships 29 (15.6) Benefit to pts. 10 (6.9)
Interaction with pts./achieving pt. outcomes 28 (15.1)
Professional recognition 14 (7.5)
Other (doing consultations, using prescribing software, improving 21 (11.3)
knowledge)
Challenges/Negative, Pharmacists Challenges/ Negative, DMPs
Inadequate information given regarding the PLP 17 (9.1) Time constraints/complexity of paper work 11 (7.6)
Physicians’/other health professionals’ attitudes toward pharmacist 16 (8.6) Poor information regarding mentor’s role 8 (5.6)
prescribing Other (lack of remuneration, concerns regarding
Time barriers for pharmacists to undertake PLP 15 (8.1) pharmacist’s role as prescriber, lack of feedback) 5 (3.5)
Organizational barriers for pharmacists to undertake prescribing 14 (7.5)
Pts.’ perceptions of pharmacist prescribing 10 (5.4)
Lack of available time with DMPs 8 (4.3)
Acquiring diagnostic/consultation skills 6 (3.2)
Other (record keeping, structure of PLP) 4 (2.2)
DMP = designated medical practitioner; PLP = period of learning in practice.
aReported by pharmacists (n = 188) and DMPs (n = 144); not all respondents reported positive/negative experiences; some respondents reported
more than one positive/negative experience.
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Additional information in this area would further inform
the development of a communication network to support
PLP. Despite these limitations, demographics of the phar-
macists who responded to the questionnaire were compa-
rable with the rest of supplementary prescribing pharma-
cists in Great Britain, with the exception of their practice
settings.4 Due to the differences between Scotland and the
rest of Great Britain with regard to pharmacist and general
practitioner contracts, interpretation of the financial barri-
ers reported in our study should be used with caution. Due
to the larger proportion of community pharmacists among
our respondents, compared with the national survey,4 the
reports of positive and negative experiences or challenges
during the PLP might be skewed. The significance of these
factors might have been different for pharmacists from
other practice settings, especially pharmacists who already
work in multidisciplinary teams and/or are involved in dis-
ease management. Further research is needed to evaluate
the efficacy of an Internet-based network of pharmacists
and their mentors for information sharing during the PLP.
Pharmacists in Great Britain have recently been given
rights for independent prescribing,17 defined as, “prescrib-
ing by a practitioner (eg, physician, nurse, pharmacist) re-
sponsible and accountable for the assessment of patients
with undiagnosed or diagnosed conditions and for deci-
sions about the clinical management required, including
prescribing.”18 RPSGB has specified the curriculum for the
training program for pharmacists to undertake independent
prescribing.16 Many higher education institutions in Great
Britain are preparing for independent prescribing training.
Our findings could inform not only pharmacists undertak-
ing the conversion course for practicing supplementary
prescribing pharmacists and those undertaking the new
prescribing course, but also mentors and policy makers. 
Conclusions
The PLP provided an opportunity for professional de-
velopment and team working for many pharmacists and
DMPs. More structured and clearer information on roles
and responsibilities of pharmacists and DMPs during the
PLP are warranted, as are greater opportunities for com-
munication among pharmacists, DMPs, and academia. In-
put from a multidisciplinary team of healthcare profession-
als, including a practicing supplementary prescribing phar-
macist, and review of consultation videos could further
enhance the PLP experience. 
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EXTRACTO
TRASFONDO: Un período de aprendizaje en la práctica (PAP) es parte
integral del adiestramiento de prescripción suplementaria (PS) para
farmacéuticos en Gran Bretaña. Durante el PAP, un profesional médico
designado (PMD) supervisa y ofrece apoyo a la persona que se adiestra
para desarrollar la facultad de prescribir.
OBJETIVO: Evaluar la visión y las experiencias de los farmacéuticos en
PS y de los PMD respecto al PAP e identificar las necesidades de apoyo
percibidas durante el PAP.
MÉTODOS: En septiembre de 2006, se enviaron por correo cuestionarios
prepiloto a todos los farmacéuticos que comenzaron el adiestramiento de
PS en Robert Gordon University, Aberdeen, Escocia (n = 242) y a sus
PMD (n = 232). A los que no respondieron, se les envió hasta 2
recordatorios. Las respuestas se analizaron utilizando estadísticas
descriptivas y comparativas; las respuestas a las preguntas abiertas se
analizaron según el tema. 
RESULTADOS: Se recibieron respuestas de 186/242 (76.9%) farmacéuticos
y 144/232 (62.1%) PMD. Sobre la mitad de los farmacéuticos
estuvieron de acuerdo/muy de acuerdo en que conocían qué se esperaba
de ellos y sus PMD durante el PAP, pero menos de la mitad estuvo de
acuerdo/muy de acuerdo en que era importante comunicarse con colegas
farmacéuticos durante el curso de la prescripción. Ciento doce (60.2%)
farmacéuticos fueron evaluados por sus PMD en cuanto a sus destrezas
de consulta durante el PAP. Las oportunidades de desarrollo profesional
y trabajo en equipo se consideraron como experiencias positivas
principales durante el PAP tanto por el farmacéutico como por el PMD.
También, se informaron barreras organizacionales, actitudinales y
temporales. Hubo un interés considerable entre los farmacéuticos y los
PMD por una red de apoyo en internet para el PAP. 
CONCLUSIONES: Se debe aumentar la información sobre los roles y las
responsabilidades de los farmacéuticos y los PMD durante el PAP. El
internet puede ser un medio de comunicación útil durante el PAP. La
información ofrecida por un equipo interdisciplinario de profesionales
de la salud y la revisión de vídeos sobre consultas pudieran reforzar la
experiencia del PAP. 
Rafaela Mena
RÉSUMÉ
OBJECTIF: Évaluer les opinions et les expériences des pharmaciens
prescripteurs et des praticiens médicaux désignés suite au programme de
Période d’apprentissage dans la pratique (PLP) et identifier leurs
perceptions quant au soutien accordé durant ce programme. 
MÉTHODES: Des questionnaires ont été postés en septembre 2006 à tous
les pharmaciens qui ont débuté le programme d’entraînement à
l’université Robert Gordon d’Aberdeen en Écosse (n = 242) ainsi
qu’aux praticiens médicaux désignés (n = 232). Les non-répondants ont
reçu au moins 2 avis de rappel. Les réponses ont été analysées en
utilisant des statistiques descriptives et comparatives. Les réponses aux
questions ouvertes ont été analysées selon les différents thèmes. 
RÉSULTATS: Le taux de réponse était de 76.9% (186/242) pour les
pharmaciens et de 62.1% (144/232) pour les praticiens médicaux
délégués. Plus de la moitié des pharmaciens ont répondu qu’ils étaient
fortement en accord concernant le fait qu’ils étaient au courant des
attentes durant la PLP mais moins de la moitié étaient fortement en
accord qu’il était important de communiquer avec les autres collègues
pharmaciens durant la période du cours. Chez 112 pharmaciens (60.2%),
les habiletés de consultation ont été évaluées par les praticiens médicaux
délégués. Des possibilités de développement professionnel et de travail
d’équipe ont été présentés comme des expériences positives durant la
PLP tant au niveau des pharmaciens que des praticiens médicaux
délégués. Des barrières organisationnelles, psychologiques et au niveau
du temps ont été rapportées. Un intérêt a été manifesté par les
pharmaciens et les praticiens médicaux délégués quant à la mise en
place d’un support internet. 
CONCLUSIONS: Les rôles et les responsabilités des pharmaciens et des
praticiens médicaux délégués durant le programme de PLP devraient
être améliorés. L’utilisation de l’internet pourrait être un medium utile
pour communiquer durant le cours de PLP. Les commentaires des
membres de l’équipe multidisciplinaire et la révision des consultations
par vidéo pourraient améliorer l’expérience de PLP.
Louise Mallet
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Pharmacist supplementary prescribing training: a study 
of pharmacists’ perceptions and planned participation 
Derek C Stewart, Johnson George, David E Pfleger, Christine M Bond*, 
H Lesley Diack, IT Scott Cunningham and Dorothy J McCaig 
Abstract 
Objective The aim of this research was to investigate in a national sample of pharmacists, who
have not yet applied for a supplementary prescribing (SP) course, their planned participation in
training, and attitudes towards pharmacist SP. 
Setting Great Britain. 
Method A postal questionnaire was sent to 4300 pharmacists (approximately 10% of all Great Brit-
ain registered pharmacists). The questionnaire had five sections: awareness of SP training; percep-
tions of aspects of SP training; actions taken relating to SP training based on ‘stage of change’
model; attitudes towards implementing SP into practice; and demographics. Within demographics,
respondents were asked to denote themselves as innovators, early adopters, early majority, late
majority and laggards, based on receptivity to change. Non-respondents were mailed up to two
reminders. 
Key findings The response rate was 55.1% (2371/4300). Of the 1707 with patient contact but who
had not commenced training, almost all (1668, 97.7%) were aware of pharmacist SP. A minority had
taken any significant SP training action, with most being at the precontemplation/contemplation
stage of change. However, most respondents either strongly agreed/agreed that practising SP
would improve patient care, but strongly disagreed/disagreed that they had sufficient pharma-
cist/technical support. Two-hundred and forty-three (73.0%) of the ‘venturesome’ pharmacists (the
innovators) and 291 (79.5%) of the ‘role models’ (the role models) had either never thought about
training or had not yet explored training options further. Following logistic regression, predictors of
prescribing training actions were: awareness of local networks for SP; receptivity to change; know-
ledge of colleagues who had undertaken or were currently undertaking SP training; postgraduate
qualifications; intrinsic (professional) factors such as professional duty to become a prescriber; and
extrinsic (infrastructure) factors such as sufficient IT support. 
Conclusion We have demonstrated that pharmacists are aware of SP courses and that certain fac-
tors are associated with actions relating to prescribing training. However, the practice setting(s)
require(s) attention to ensure readiness to support such innovations in areas such as IT and adminis-
trative support. These issues have implications for education providers, the NHS and policy makers;
and the extension into independent prescribing. Issues based on receptivity to change and models
of change require further investigation. 
Improving patient access to medicines and making best use of the clinical skills of
non-medical health professionals, particularly pharmacists and nurses, are among the aims
of recent changes in prescribing legislation in Great Britain.1–5 Supplementary prescribing
(SP), one such innovation, has been undertaken by pharmacists working in various practice
settings across Great Britain since March 2000,6 and is a key development for pharmacy
practice. 
Supplementary prescribing (SP) is defined as ‘a voluntary partnership between an inde-
pendent prescriber (a doctor or dentist) and a supplementary prescriber to implement an
agreed patient-specific clinical management plan (CMP) with the patient’s agreement’.7
There are no restrictions on the conditions that may be managed or drugs that can be pre-
scribed. Before SP can begin, it is obligatory for the CMP to be in place (paper-based or
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electronic) relating to a named patient and to that patient’s
specific conditions to be managed by the supplementary pre-
scriber.5 
Background information on pharmacist SP training
courses has been published elsewhere.8,9 Essentially, training
for pharmacists with a minimum of 2 year’s post registration
experience comprises at least 25 days (200 hours equivalent)
of university tuition at the degree/masters level and a period
of learning in practice (PLP) of at least 12 days, under the
supervision of a designated medical practitioner (DMP). Dur-
ing the PLP the DMP will provide the pharmacist with oppor-
tunities to develop competence in prescribing practice. 
It is key to study the awareness and perceptions of the
members of a profession regarding any new developments
within that profession. In addition, there should also be a
focus on the appropriateness, effectiveness and outcomes of
associated training. Findings can then inform further course
development and implementation into practice. This is of
prime importance for SP, given the recent extension to inde-
pendent prescribing. As independent prescribers, defined as
‘practitioners responsible for the assessment of patients with
undiagnosed or diagnosed conditions and for decisions about
the clinical management, including prescribing’, they will be
able to prescribe any licensed medicine (other than controlled
drugs) within their competence.2 Despite these innovations,
few national studies with any emphasis on pharmacist pre-
scribing training have been published to date. 
A survey of pharmacists who would oversee the imple-
mentation of SP in primary (n = 271) and secondary care
(n = 143) in England found that 56% of primary care trusts
and 57% of secondary care trusts were intending to imple-
ment SP by the end of 2005.10 Time commitments and work-
load were perceived to be the major factors that would affect
the recruitment of DMPs. These barriers were perceived to be
greater in primary care than other settings. Factor analysis of
questionnaire data gave three factors describing concerns
relating to pharmacist SP.11 One factor, labelled as ‘limita-
tions of the SP training model’, related specifically to train-
ing. Scores in primary and secondary care indicated that
respondents agreed that there were limitations to the training
model. However, no further information relating to this
aspect was provided by the authors. It should also be borne in
mind that NHS trust strategies relating to the implementation
of pharmacist prescribing may have altered significantly
since the study was conducted. 
All Royal Pharmaceutical Society of Great Britain
(RPSGB)-registered pharmacy prescribers were surveyed in
June 2005 (n = 518) to explore their early experiences of pre-
scribing and perceptions of the prescribing course.8 The
response rate was 82%, with respondents giving a median
‘course satisfaction score’ on a scale of 3–15 (lowest to high-
est) of 10. Content analysis of responses to open questions
provided further insight into views of the training course and
the PLP.12 Findings highlighted the diversity of courses on
offer in Great Britain in terms of content and delivery. Most
participants, irrespective of their practice setting, appreciated
the support received from their DMPs. 
One key limitation of these studies in prescribing initia-
tives by pharmacists is that they have focused either on phar-
macists in a strategic position or on those who have
completed the SP course. To inform further the implementa-
tion of SP and ensure capacity for future supplementary and
independent prescribing delivery, the views of pharmacists
who are yet to apply for a SP course need to be ascertained,
and any factors that could act as drivers or barriers to parti-
cipation need to be identified. This information could be a
reflection of priorities for the provision of prescribing serv-
ices by pharmacists working in various practice settings. The
aim of this research was to investigate in a national sample of
pharmacists, who have not yet applied for an SP course, their
planned participation in SP training and attitudes towards
pharmacist SP. 
A postal questionnaire was developed by eight experienced
pharmacy practitioners and/or researchers. A random sample
of 4500 registered pharmacists was obtained from the
RPSGB, approximately 10% of all registered pharmacists.13
The pilot questionnaire was mailed to a sample of 200 phar-
macists randomly selected from the RPSGB list, along with a
letter describing the aim of the study. Piloting resulted in
minimal changes to the wording and sequencing of some
questions. 
The final questionnaire had five sections of open and
closed questions, which focused on: awareness of SP and
training (10 items); perceptions of aspects of SP training pro-
grammes such as appropriateness of course content, duration,
level of difficulty measured using five-point semantic differ-
entials with an additional response option of ‘unable to rate’
(11 items); actions taken relating to SP training (six items)
based on the ‘stage of change’ model which describes stages
of precontemplation, contemplation, preparation and action;14
five-point Likert scales measuring attitudes towards imple-
menting SP into practice (11 items); and demographics (8
items). The attitudinal statements were adapted from previous
work of the research team investigating community pharmacists’
attitudes towards independent prescribing and the implemen-
tation of pharmacist supplementary prescribing into
practice.8,15 In the demographics section, respondents were
asked to denote themselves as innovators, early adopters,
early majority, late majority and laggards based on receptiv-
ity to change as described by Rogers.16 Although largely
derived from the domains of business and marketing,
receptivity to change is considered appropriate to healthcare
organisation and was included as a measure of how quickly
individuals change their behaviour. Descriptors for each of
these were selected from the literature as being most appro-
priate for a prescribing training context.16 
The questionnaire was mailed to the remainder of the
RPSGB list (4300) in November 2005 along with a covering
letter and a reply-paid envelope. Non-respondents were sent
up to two reminders at four-weekly intervals. Responses from
registered supplementary prescribers or those undertaking the
course were excluded from analysis. 
Data were analysed using SPSS for Windows version 13.0
(SPSS Inc), using descriptive statistics. The items regarding
pharmacists’ attitudes measured on five-point Likert scales
were subjected to principal components analysis (PCA) – a
Methods 
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statistical technique used to reduce a large number of items or
variables to a smaller, more manageable number of compo-
nents (domains).17 Orthogonal (Varimax) rotation was
performed initially to aid in the interpretation of the compo-
nents, and the results were compared to oblique (Promax)
rotation. Total scores were obtained by assigning scores of 1
(strongly disagree) to 5 (strongly agree) to each of the Likert
statement responses. Internal consistencies of the resulting
components were tested using Cronbach’s alpha. Alpha
internal consistencies greater than 0.60 are regarded as desira-
ble for psychometric scales.17 One-way analysis of variance
(ANOVA) was used to compare any differences in scores
between individuals based on receptivity to change for both
components. P values <0.05 were considered statistically
significant. 
Prescribing training actions were summarised into two:
those taking very little action (‘I have never thought about
training as a supplementary prescriber’/‘I have thought about
training but have not yet explored this further’) and the
remainder, taking some action. Factors associated with these
prescribing training actions were identified using
Chi-square/Student’s t test. Variables identified as significant
in univariate analysis (P <0.005 after applying a Bonferroni
correction to reduce the risk of type 1 errors18) were further
analysed in a logistic regression model. 
This study was approved by the Ethical Review Panel
of the School of Pharmacy at The Robert Gordon Univer-
sity. Grampian Research Ethics Committee advised that
this study did not require formal review by an NHS ethics
committee. 
The response rate was 55.1% (2371/4300). Two-hundred and
thirty-five respondents (9.9%) were either non-practising or
about to retire, and were thus excluded from further analysis.
Also excluded from analysis were 305 (12.9%) respondents
with no patient contact (15 missing responses), 63 (2.7%)
registered supplementary prescribers and 46 (1.9%) undertak-
ing SP training at the time of the study. 
Of the remaining 1707 respondents, the majority was
female (1030, 60.3%), had been registered >15 years (853,
50.0%), and worked within community pharmacy (1190,
69.7%). Less than half described themselves as innovators or
early adopters. Details of demographics and characteristics
are given in Table 1. 
Almost all (1668, 97.7%) were aware of SP by pharma-
cists, but fewer (1274, 74.6%) were aware of SP training
courses for pharmacists. Sources of awareness of pharmacist
SP training courses are given in Table 2. Very few were able
to rate their perceptions of aspects of pharmacist SP training
courses such as content, level of difficulty and duration, as
given in Table 3.
Less than half claimed to be aware of the legal require-
ments of CMPs (498, 29.2%), while 780 (45.7%) were not
aware and 382 (22.4%) were unsure. Similar findings were
obtained for restrictions on conditions that could be managed
by a supplementary prescriber (544 aware, 31.9%; 643 not
aware, 38.3%; and 458 unsure, 26.8%) and for restrictions on
drugs that could be prescribed by a supplementary prescriber
(698 aware, 40.9%; 527 not aware, 30.9%; and 430 unsure,
25.2%). 
Only a minority had taken any significant action in terms
of SP training, with most being at the precontemplation/
Results 
Table 1 Respondent demographics and characteristics, n = 1707a 
aPercentages do not total to 100 due to missing responses. 
Characteristic n (%) 
Sex  
Male 673 (39.4) 
Female 1030 (60.3) 
Age in years  
<25 91 (5.3) 
25–34 525 (30.8) 
35–44 422 (24.7) 
45–54 377 (22.1) 
>54 286 (16.8) 
Years since registration as pharmacist  
<6 390 (22.8) 
6–10 245 (14.4) 
11–15 212 (12.4) 
16–20 178 (10.4) 
>20 675 (39.5) 
Main practice setting  
Community pharmacy 1190 (69.7) 
Primary care medical practice 51 (3.0) 
Hospital pharmacy 384 (22.5) 
Other 79 (4.6) 
Postgraduate qualifications  
Yes 518 (30.3) 
No 1189 (69.7) 
Hours with patient contact per week  
<10 240 (14.1) 
10–19 249 (14.6) 
20–29 268 (15.7) 
30–39 495 (29.0) 
>39 439 (25.7) 
Hours of continuing education in last 12 months  
<6 123 (7.2) 
6–10 133 (7.8) 
11–15 133 (7.8) 
16–20 170 (10.0) 
21–25 168 (9.8) 
26–30 257 (15.1) 
>30 703 (41.2) 
Respondent classification based on receptivity to change  
‘Venturesome and willing to take risks in relation to 
new ways of working’ 
333 (19.5) 
‘Serve as a role model for others in relation to new 
ways of working’ 
366 (21.4) 
‘Deliberate for some time before adopting new 
ways of working’ 
775 (45.4) 
‘Caution in relation to new ways of working and tend 
to change once most peers have done so’ 
180 (10.5) 
‘Resist new ways of working’ 13 (0.8) 
Knowledge of colleagues who have completed/undertaking 
supplementary prescribing training 
 
Yes 612 (35.9) 
No 1050 (61.5)
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contemplation stage of change (Table 4). Two-hundred and
forty-three (73.0%) of the ‘venturesome’ pharmacists and 291
(79.5%) of the ‘role models’ had either never thought about
training or had not yet explored training options further.
Six-hundred and forty-five (37.8%) stated that they would be
more likely to undertake prescribing training once the
programme covered both supplementary and independent
prescribing. 
Attitudes towards implementing SP into practice are given
in Table 5. Most strongly agreed or agreed that practising SP
would improve the care of their patients and that SP would
enhance their professional standing, but strongly disagreed or
disagreed that they had sufficient pharmacist and technical
support for SP. When these 11 items were subjected to PCA,
the correlation matrix contained multiple coefficients above
0.3. The Kaiser–Meyer–Olkin measure of sampling adequacy
(0.843) and Bartlett’s test of sphericity (significance < 0.001)
confirmed the factorability of the items. Two components had
eigenvalues exceeding 1.0, for which Varimax rotation was
used. The two-factor solution explained 56.7% of the vari-
ance. The items in the two components pertained to intrinsic
(professional) factors and extrinsic (infrastructure) factors,
respectively (Table 6).
The total scores (mean ± standard deviation (SD)) for these
components were: 21.4 ± 4.50 (minimum possible = 6,
maximum = 36, with a higher score indicating more agree-
ment with the statements) for intrinsic (professional) factors;
and 11.8 ± 3.52 (minimum possible = 5, maximum = 30) for
extrinsic (infrastructure) factors. The alpha internal consisten-
cies of these domains were 0.84 and 0.75 respectively.
Respondents who regarded themselves to be more ‘venture-
some’ had significantly higher scores for both these domains
than those who were more ‘cautious’ (P <0.001). 
In univariate analysis, the following factors were signifi-
cantly associated with prescribing training actions: know-
ledge of colleagues who had undertaken/were undertaking SP
training (P <0.001); awareness of local networks for SP
(P <0.001); practice setting (P <0.001); possession of a post-
graduate qualification (P <0.001); classification based on
receptivity to change (P <0.001); intrinsic (professional) fac-
tors (P <0.001); and extrinsic (infrastructure) factors
(P <0.001). 
In logistic regression, the following factors were retained
as independent predictors of prescribing training actions:
awareness of local networks for SP (more likely to have
taken some action, odds ratio (OR) = 2.994, 95% confidence
interval (CI) 1.705–5.259, P <0.001); classification based
Table 2 Source of awareness of pharmacist SP training course,
n = 1274 
Source of awareness n (%) 
Pharmaceutical Journal 845 (66.3) 
Centre for Pharmacy Postgraduate Education 
(England)/ NHS Education for Scotland 
(Pharmacy)/ Welsh Centre for Postgraduate 
Pharmaceutical Education 
311 (24.4) 
Higher Education Institutions 265 (20.8) 
Health authority/primary care trust/health board 243 (19.1) 
RPSGB 220 (17.3) 
Chemist and Druggist 171 (13.4) 
Conference 82 (6.4) 
Departments of Health (England/ Scotland/ Wales) 81(6.4)
Table 3 Pharmacists’ perceptions of aspects of pharmacist SP training courses, n = 1707 
Aspect of course Description of ‘1’ 1 n (%) 2 n (%) 3 n (%) 4 n (%) 5 n (%) Description of ‘5’ Unable to rate 
Course content Appropriate for 
prescribing 
pharmacists 
124(7.3) 98(5.7) 71(4.2) 31(1.8) 7(0.4) Inappropriate for 
prescribing 
pharmacists 
1244(72.9) 
Level of difficulty Too easy 7 (0.4) 38 (2.2) 173 (10.1) 84 (4.9) 9 (0.5) Too difficult 1258 (73.7) 
Duration Too short 14 (0.8) 47 (2.8) 220 (12.9) 65 (3.8) 29 (1.7) Too long 1196 (70.1) 
Relevance to my practice Highly relevant 129 (7.6) 155 (9.1) 155 (9.1) 105 (6.2) 71 (4.2) Highly irrelevant 954 (55.9) 
Attendance at a higher 
education institution 
Too little 
attendance 
required 
16 (0.9) 56 (3.3) 199 (11.7) 76 (4.5) 43 (2.5) Too much 
attendance 
required 
1182 (69.2) 
Self-study Too little emphasis 
on self-study 
16 (0.9) 44 (2.6) 181 (10.6) 85 (5.0) 30 (1.8) Too much 
emphasis on 
self-study 
1214 (71.1) 
Tutor support Insufficient tutor 
support 
22 (1.3) 70 (4.1) 127 (7.4) 28 (1.6) 7 (0.4) Excessive tutor 
support 
1317 (77.2) 
Course location Accessible 118 (6.9) 99 (5.8) 113 (6.6) 84 (4.9) 53 (3.1) Inaccessible 1105 (64.7) 
Online delivery Too little emphasis 
on online 
delivery 
28 (1.6) 59 (3.5) 101 (5.9) 24 (1.4) 14 (0.8) Too much 
emphasis on 
online delivery 
1346 (78.9) 
Interaction with other 
health professions on 
course 
Too little 
interaction with 
other health 
professions 
31 (1.8) 60 (3.5) 157 (9.2) 53 (3.1) 6 (0.4) Too much 
interaction with 
other health 
professions 
1263 (74.0) 
Period of learning in 
practice 
Difficult to arrange 
doctor support 
129(7.6) 117(6.9) 74(4.3) 42(2.5) 19(1.1) Easy to arrange 
doctor support 
1191(69.8)
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on receptivity to change (venturesome/role model, more
likely to have taken some action, OR = 2.678, 95% CI
1.809–3.966, P <0.001); knowledge of colleagues who had
undertaken/were undertaking SP training (more likely to
have taken some action, OR = 2.429, 95% CI 1.662–3.549,
P <0.001); possession of a postgraduate qualification (more
likely to have taken some action, OR = 1.700, 95% CI
1.144–2.527, P = 0.009); intrinsic (professional) factors
(higher score more likely to have taken some action,
OR = 1.131, 95% CI 1.078–1.188, P < 0.001); and extrinsic
(infrastructure) factors (higher score more likely to have
taken some action, OR = 1.062, 95% CI 1.004–1.122,
P = 0.034). These six variables explained 22% of the
variance. 
This is the first national study of views and attitudes of phar-
macists to prescribing training among those yet to register for
any prescribing course. Although respondents were generally
aware of SP by pharmacists and the pharmacist SP course,
very few were able to rate detailed elements of the course
such as content and duration. Although most had taken very
little action in terms of prescribing training, they demon-
strated positive attitudes in terms of intrinsic (professional)
factors, while indicating issues or challenges to be overcome
relating to extrinsic (infrastructure) factors. Awareness of
local networks, being more venturesome or a role model,
knowledge of colleagues undertaking prescribing training,
possession of postgraduate qualifications, intrinsic (profes-
sional) factors, and extrinsic (infrastructure) factors were
independent predictors of prescribing training action. 
Our study has several strengths. We sampled a consider-
able proportion of the profession and had responses from a
range of pharmacists in terms of age, experience and prac-
tice setting. To our knowledge this is the first study that has
related classification of individuals based on receptivity to
change to pharmacists’ actions. Nevertheless, our study had
some limitations. Almost 10% of our respondents were
inactive members of the RPSGB, and perhaps should have
been excluded. Our findings are limited by the response
rate, which reduces the generalisability of our findings;
there is a possibility of non-respondent bias in that
non-respondents may have had little interest in the topic of
pharmacist prescribing. We were unable to compare the
characteristics of respondents and non-respondents due to
the lack of available information relating to the
non-respondents. However, our respondents are similar in
age and sex to national pharmacist statistics.13 In addition,
Table 4 Pharmacists’ actions (based on the stage model of change) in
terms of SP training, n = 1707a 
aPercentages do not total to 100 due to missing responses. 
Action n (%) 
I have never thought about training as a 
supplementary prescriber
413 (24.2) 
I have thought about training but have not yet 
explored this further 
1028 (60.2) 
I have investigated training options 143 (8.4) 
I now have a plan to undertake training 29 (1.7) 
I have arrangements in place to support my 
training (e.g. locum cover, doctor support 
for the period of learning in practice etc) 
4 (0.2) 
I have applied for a course in supplementary 
prescribing 
11(0.6)
Table 5 Attitudes towards implementing SP into practice, n = 1707 
Item (n) Strongly agree Agree Unsure Disagree Strongly disagree 
Practising as a supplementary prescriber would inprove the care of 
my patients (n=1601)
369 (21.6) 746 (43.7) 357 (20.9) 107 (6.3) 22 (1.3) 
I already have access to all of the patient information I need to 
practise as a supplementary prescriber (n = 1596) 
125 (7.3) 208 (12.2) 398 (23.3) 561 (32.9) 304 (17.8) 
Supplementary prescribing would be a major change to my 
day-to-day practice (n = 1593) 
517 (30.3) 752 (44.1) 230 (13.5) 84 (4.9) 10 (0.6) 
A supplementary prescribing role would enhance my professional 
standing (n = 1597) 
572 (33.5) 718 (42.1) 216 (12.7) 64 (3.7) 27 (1.6) 
I already have sufficient administrative support to implement 
supplementary prescribing (n = 1585) 
36 (2.1) 118 (6.9) 530 (31.0) 583 (34.2) 318 (18.6) 
I already have sufficient IT support to implement supplementary 
prescribing (n = 1586) 
44 (2.6) 196 (11.5) 537 (31.5) 534 (31.3) 274 (16.1) 
Supplementary prescribing would work well in my practice setting 
(n = 1588) 
157 (9.2) 465 (27.2) 657 (38.5) 226 (13.2) 83 (4.9) 
I would be happy to become a supplementary prescriber (n = 1596) 359 (21.0) 597 (35.0) 424 (24.8) 143 (8.4) 73 (4.3) 
I feel confident in my ability to become a supplementary prescriber 
(n = 1595) 
320 (18.7) 584 (34.2) 470 (27.5) 168 (9.8) 53 (3.1) 
I feel it is my professional duty to become a supplementary 
prescriber (n = 1599) 
143 (8.4) 388 (22.7) 463 (27.1) 457 (26.8) 148 (8.7) 
I already have sufficient pharmacist and technical support to 
implement supplementary prescribing (n = 1592) 
51 (3.0) 160 (9.4) 543 (31.8) 584 (34.2) 254(14.9)
Discussion 
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the attitudinal items were developed by the research team
around issues considered relevant by the team, which may
have introduced an element of bias. 
Pharmacists in this study were clearly aware of training
courses, largely from published sources, education providers
and policy makers. However, the lack of awareness of CMPs,
conditions that could be managed and drugs that could be pre-
scribed, together with the lack of detailed knowledge of
aspects of the prescribing course such as content, duration
and difficulty may be reducing the uptake of training. Policy
makers and education providers may wish to revise their mar-
keting and recruitment strategies to ensure that information
provided meets pharmacists’ needs. Of note, almost 40%
stated that they would be more likely to undertake prescribing
training once programmes covered both supplementary and
independent prescribing. This will be tested in the near future
as the curricula for the conversion course from supplementary
to independent prescribing and the full independent prescrib-
ing course have now been published.19 Encouraging pharma-
cists to apply for prescribing training is therefore even more
important to fulfil the profession’s aspirations. A recent sur-
vey of Scottish community pharmacists’ awareness, views
and attitudes of independent prescribing by pharmacists
showed high awareness and perceived competence in select-
ing appropriate drugs for many common conditions.15 Most
respondents expressed an interest in training prior to any ser-
vice development. This is consistent with our finding of inter-
est in independent prescribing training. A further study in
Scotland determined community pharmacists’ involvement
with extended service provision, including the minor ailment
scheme, supplementary and independent prescribing.20 Pre-
scribing was noted as the ninth most popular extended
service. 
It is perhaps not surprising that many pharmacists, even
those who were venturesome or considering themselves as
role models, appeared reluctant to commit to prescribing
training. Prescribing is a very new development for the pro-
fession, with models of practice and adequate administration
just beginning to emerge.8 As part of the national survey, a
number of barriers and challenges to the implementation of
pharmacist SP were cited by many pharmacist supplementary
prescribers in all healthcare settings.12 Once these initial
issues have been resolved, models may be disseminated as
good practice to inform further implementation. Other factors
may also act as stimuli; the new community pharmacy con-
tracts have a clear emphasis on chronic disease management
and medication review,21,22 processes that dovetail very well
with prescribing and may provide further motivation to con-
sider prescribing training. In addition, the minor ailments
schemes allow pharmacists to prescribe certain medicines for
those normally exempt from prescription charges.23 This may
increase pharmacists’ confidence around processes of
prescribing. 
Several factors were found to be independent predictors
of prescribing training action. The positive influence of col-
leagues and peers has been demonstrated in many health
professional groupings,24–29 and has also been shown to be
important to models of change.30 This, combined with the
importance of local SP networks, should be used by policy
makers to consider the setting up of local peer support
groups and engaging leading-edge practitioners with SP
qualifications in encouraging non-SP colleagues to get
involved. 
The fact that different classifications of individuals based
on receptivity to change were evident in this research may
mean that different strategies are required to encourage
uptake of prescribing training.30 PCA of the attitudinal data
revealed two components: intrinsic (professional) factors and
extrinsic (infrastructure) factors. Generally, scores were high
for the intrinsic factors indicating a very positive attitude pro-
fessionally, while the extrinsic scores were much lower.
These findings indicate that although pharmacists are clearly
interested in implementing SP into their practice, the practice
environment is not yet ready for such a development. Phar-
macist, technical, administration and IT support are required
along with access to patient information. These findings con-
cur with other research we have conducted on supplementary
Table 6 Rotated component matrix relating to implementation of sup-
plementary prescribing into practice 
Extraction method, principal component analysis; rotation method: Var-
imax with Kaiser normalisation. Rotation converged in three iterations.
Item Component 
Intrinsic 
(professional) 
factors 
Extrinsic 
(infrastructure) 
factors 
I would be happy to become a 
supplementary prescriber
0.823  
Practising as a supplementary 
prescriber would improve the care 
of my patients 
0.815  
I feel it is my professional duty to 
become a supplementary 
prescriber 
0.765  
A supplementary prescribing role 
would enhance my professional 
standing 
0.744  
Supplementary prescribing would 
work well in my practice setting 
0.650 [0.353] 
I feel confident in my ability to 
become a supplementary 
prescriber 
0.555 [0.324] 
I have sufficient administrative 
support to implement 
supplementary prescribing 
 0.797 
I have sufficient IT support to 
implement supplementary 
prescribing 
 0.797 
I have sufficient pharmacist and 
technical support to implement 
supplementary prescribing 
 0.745 
I already have access to all of the 
patient information I need to 
practise as a supplementary 
prescriber 
 0.688 
Supplementary prescribing would be 
a major change to my day-to-day 
practice 
[0.348] 0.427
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pharmacist prescribing.8 While developments such as the
NHSnet will facilitate access, there are still many aspects to
be carefully considered. 
Further work in this area is required. Qualitative explora-
tion of pharmacists’ attitudes and beliefs may provide some
of the explanations around the lack of prescribing training
action. This would also help to validate and possibly expand
the attitudinal items explored in this research. Explanation
could provide the stimulus for targeted interventions aiming
to increase motivation to participate in prescribing training.
The classification of individuals according to receptivity to
change requires further testing and validation, to determine
the usefulness of this system to predict those more likely to be
leading-edge practitioners and its ability to predict changing
behaviour. It may be worthwhile applying this classification
to those who are already registered pharmacist prescribers.
On a policy and organisational level, we also need to consider
the numbers of pharmacist prescribers required to meet the
needs of patients and the healthcare system. This would then
facilitate targeting training to those areas and individuals of
need. 
In conclusion, this research has demonstrated that pharma-
cists are aware of SP courses from a variety of sources, but
that they lack detailed knowledge of the courses and also of
the legal and professional frameworks of SP. In addition, the
practice setting(s) require close attention to ensure that they
are ready to support such innovations. These issues have
important implications for education providers, the NHS, and
policy makers, and urgent attention is required with the
extension into independent prescribing. Issues based on
receptivity to change and models of change require further
investigation. 
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Abstract Objective To explore the views and experiences
of pharmacists and their mentoring designated medical
practitioners (DMPs) about the ‘period of learning in
practice’ (PLP) as part of supplementary prescribing (SP)
training. Method Two focus groups (n = 5 and 7) of SP
pharmacists were organised in Scotland. The experiences
and views of DMPs (n = 13) were explored using one-to-
one telephone interviews. The focus groups and interviews
were transcribed verbatim and analysed using the frame-
work approach. Main outcome measures Views and
experiences of pharmacists and DMPs about the PLP.
Results Planning the PLP in consultation with the DMP
was found to be crucial for an optimal learning experience.
Pharmacists who did not have a close working relationship
with the medical team had difficulties in identifying a DMP
and organising their PLP. Participants stressed the impor-
tance of focusing on and achieving the core competencies
for prescribers during the PLP. Input from doctors involved
in the training of others, review of consultation videos, and
formal independent assessment including clinical assess-
ment at the end of the PLP might improve the quality of the
PLP. Forums for discussing experiences during the PLP
and gathering information might be valuable. Conclusion
Our findings have implications for prescribing training for
pharmacists in the future. The PLP should focus on core
competencies with input from doctors involved in the
training of others and have a formal assessment of con-
sultation skills. Support for pharmacists in organising the
PLP and forums for discussing experiences during the PLP
would be valuable.
Keywords Competency  Great Britain 
Medical practitioner  Period of learning in practice 
Pharmacists  Scotland  Supplementary prescribing
Impact of findings on practice
• Planning a period of learning in practice (PLP) in
consultation with a mentoring designated medical
practitioner (DMP) is crucial for an optimal learning
experience.
• The input from doctors involved in the training of
others, review of consultation videos, and formal
independent assessment including clinical assessment
at the end of the PLP might improve the quality of the
PLP.
• Forums (especially Internet based) for discussing
experiences during the PLP might be valuable.
Introduction
Supplementary prescribing (SP)—a voluntary partnership
between an independent prescriber (a doctor or dentist) and
a supplementary prescriber to implement an agreed patient-
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specific clinical management plan, with the patient’s
agreement [1]—by pharmacists has recently been intro-
duced in the UK [2, 3]. SP training for pharmacists should
involve at least 25 days (200 h) of university tuition at the
degree/masters level and a ‘period of learning in practice’
(PLP) of at least 12 days [4]. During the PLP, a mentoring
designated medical practitioner (DMP) provides the stu-
dent with supervision, support and opportunities to develop
competence in prescribing practice focusing on one or
more therapeutic areas and concentrating on the group of
patients for whom he/she will initially prescribe [4, 5]. The
PLP may be undertaken at the same time as or after the
university based training. There is no set format for these
12 days and there is no need for these to be consecutive
days of training. Universities offering SP courses provide
pharmacists and DMPs with handbooks describing the
background to the SP course and their respective roles
during the PLP. They are also provided with a point of
contact at the university.
The National Prescribing Centre has produced a com-
petency framework to ensure quality of care and patient
safety when prescribing responsibilities are undertaken by
non-medical health professionals [6]. The 75 competencies
listed in this framework cover three main areas—the con-
sultation, prescribing effectively and prescribing in
context. The DMP and the candidate agree which compe-
tencies are relevant to the individual and the clinical area,
and use this as a basis for planning the PLP. Events are
based around relevant competencies and, for example,
could include: patient consultations, multidisciplinary
meetings, patient review, monitoring and follow-up. The
DMP is responsible for assessing the candidate but can
delegate aspects of training to appropriate personnel. All
relevant competencies must be achieved—if necessary, the
PLP may be extended beyond 12 days. Candidates are
required to submit a portfolio to the university providing
evidence of achievement of relevant competencies. Finally,
the DMP must sign off the pharmacist as suitable for
registration as a supplementary prescriber. Upon successful
completion of SP training and registration with the Royal
Pharmaceutical Society of Great Britain (RPSGB) as a
prescriber, SP pharmacists may prescribe for the full range
of medical conditions, provided that they are within their
professional competence and do so under the terms of a
patient-specific clinical management plan agreed by both
the patient and the independent prescriber(s) [4].
The PLP is an integral part of SP training and it is
crucial that it provides an optimal learning experience
leading to safe and appropriate prescribing by SP phar-
macists. Many SP pharmacists regard their PLP experience
as more useful in developing their clinical skills than the
university component of the training [3, 7]. However, the
need for greater communication and support during the
PLP and standardised methods of assessment have been
stressed by many SP pharmacists [3, 7].
Aim of the study
The aims of this research were to explore the views and
experiences of SP pharmacists and DMPs about the PLP
and to evaluate the extent to which the PLP had prepared
the SP pharmacists to undertake prescribing.
Methods
Focus groups were conducted with the SP pharmacists and
semi-structured telephone interviews were conducted with
the DMPs. The focus groups were moderated by members
of the research team (JG and LD) and a note taker was
present. All the telephone interviews were conducted by
JG. Invitations to participate in a focus group were sent to
75 SP pharmacists trained through The Robert Gordon
University (RGU) before June 2005. RGU has the highest
number of SP completions (n = 85; 21.2% of registered
prescribers; data based on responses to a national survey)
[3]. Pharmacists distant from the two focus group sites
were not invited (n = 10). Twenty-five were unavailable
due to lack of time and other commitments and four did not
respond. For the 21/75 who expressed interest in partici-
pating, the choice of either of the two focus groups at two
central locations in Scotland at different times was offered.
Only 12 were available, but they represented a range of
practice settings, therapeutic areas covered during the PLP
and geographic location. Two 90-min focus groups, com-
prising five and seven participants, were held. Findings
from the national survey of SP pharmacists [3, 7] were used
as stimuli for discussion. The topic guide centred around
PLP activities, pharmacists’ perceptions of the DMP role,
professional relationships, competencies, major experi-
ences, markers of good practice and recommendations to
enhance the PLP.
Focus groups were not feasible for DMPs due to their
geographical distribution and busy work schedules; instead
one-to-one telephone interviews were conducted. Invita-
tions to participate were sent to 140 DMPs who had
mentored pharmacists up to March 2006. The time frame
was larger than used for the SP pharmacists due to initial
poor response rate. Eighty-three DMPs did not respond; 39
could not take part due to lack of time. Of the 18 DMPs
who consented to take part, 13 were selected for interview
(15–20 min) to represent a range of practice settings,
clinical specialities and locations. The interview schedule
was similar to the focus group topic guide but also included
awareness of SP legal frameworks, previous professional
266 Pharm World Sci (2008) 30:265–271
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relationships with the SP pharmacist and usefulness of the
university handbook.
The interview schedule was largely based on the find-
ings of the pharmacist interviews since the aim of the
research was to explore the views of pharmacists and
mentors on the PLP and issues arising for the pharmacists
were likely to also be issues for the mentors. The schedule
did, however, allow for exploration of issues specific to the
mentors.
As saturation of data was thought to have occurred after
interview 13, it was felt that additional interviews were
unlikely to generate new themes and hence no more
interviews took place.
The focus groups and interviews were transcribed ver-
batim and data analysis was based on the framework
approach, a method widely used in applied or policy rel-
evant qualitative research in which the objectives of the
investigation are typically set in advance and shaped by the
study objectives [8]. After familiarisation with the data by
repeated reading of the transcripts (JG), emerging themes
were identified and the data was coded supported by
NVivo1. Two of the authors (JC and DS) independently
verified the themes. Saturation of themes was reached after
two focus groups and 13 telephone interviews.
Ethics permission for this study was granted by the Multi-
centre Research Ethics Committee (MREC) for Scotland. All
participants provided written informed consent.
Results
Twenty-one (28.0%) SP pharmacists and 18 DMPs
(12.9%) were interested in participating in the study, of
which 12 and 13 respectively were included. Of the 18
DMPs who consented to take part, initially 13 were
selected. Characteristics of the pharmacists and DMPs are
summarised in Tables 1 and 2.
The major themes emerging from the data plus sup-
porting quotes are presented below. These are organised
around the PLP organisation and delivery.
Major theme I PLP organisation
Pharmacist selection of the DMP
In the absence of clear guidelines, the main criterion for
choosing a DMP was prior working relationship rather than
earlier mentoring experience or the practice setting:
There wasn’t much guidance given choosing a men-
tor... Because there was a shortage of numbers and it
was all very new, people just ran to the GPs that they
Table 1 Characteristics of pharmacists participated in focus groups
(n = 12)
Characteristic N
Sex of the pharmacist
Male 3
Female 9
Practice setting
Community pharmacy 5
Primary care 4
Secondary care 2
Community pharmacy and primary care 1
Practice setting where PLP was undertaken
Primary care 5
Secondary care 2
Primary and secondary care 5
DMP in-charge of PLP
General practitioner 10
Hospital consultant 2
Therapeutic area focused during PLP
Cardiovascular 6
Respiratory 3
Other (diabetes; geriatrics; rehabilitation) 3
Table 2 Characteristics of medical practitioners interviewed
(n = 13)
Characteristic N
Sex of the DMP
Male 11
Female 2
Practice setting
Primary care 10
Secondary care 1
Tertiary care 2
Clinical speciality/area of interesta
Obstetrics & gynaecology/women’s health 4
Respiratory 4
Cardiovascular 3
Endocrine 3
Psychiatry 2
Other (headache, oncology) 2
Clinical experience in years
\10 years 1
11–20 years 6
21–30 years 6
Experience in training
Medical students 12
Non-medical health professionals 6
a Some DMPs had multiple areas of interest
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knew of and used their relationship. But they may not
necessarily have been the best mentors. (Primary care
pharmacist)
DMPs too preferred pharmacists whom they knew:
I think you need to know where their limitations are
and what their experience is like—rather than just
taking on somebody cold. (Hospital consultant)
Awareness of responsibilities during the PLP
Many pharmacists and DMPs felt that they were not ade-
quately informed by the university about their respective
roles and responsibilities during the PLP:
I went into the period in practice not really knowing
what I was to do... So there’s got to be some kind of
guidance as far as what’s expected. (Community
pharmacist)
I just think that [DMPs] need a bit more guidance
(Primary care pharmacist)
It was always presented to me like a ‘fait-accompli’...
I didn’t really understand even at the end what was
really expected of me. (General practitioner)
DMPs who were regularly involved in training of medical
students were perceived to have better understanding of
mentoring responsibilities, while those without such expe-
rience relied on the SP pharmacist to provide information
on what was required to drive the PLP:
I was reasonably okay with what I was doing. I think
that information would be much more important,
again if you didn’t have a background in some sort of
training. (General practitioner)
It would appear from interviews that DMPs in all settings
would appreciate concise, simplified and structured infor-
mation, perhaps provided in non-paper based mode about
their responsibilities before agreeing to the role of mentor:
It was almost too much information... I think it could
have been simplified from a GPs point of view.
(General practitioner)
I think written information should probably be kept to
a relevant minimum. Really far more important was
the discussion between myself and the pharmacist
prior to taking it on. (Hospital consultant)
Balancing routine work and the PLP
While the PLP was simply an extension of their routine job
for many of those pharmacists working in primary and
secondary care NHS Trusts, planning and organising the
PLP was much more of a challenge for some community
pharmacists:
I found my period in practice quite difficult to define
because really I felt everything I did in my job I was
having to do again in this period in practice (Sec-
ondary care pharmacist)
I went and spoke to the doctor and found that... I
couldn’t go on a number of days that suited the lo-
cums and suited me. So I then had to go and book
other locums... basically you just had to accept that
you were neglecting your business. (Community
pharmacist)
Some DMPs, particularly general practitioners, had diffi-
culty fulfilling their everyday practice commitments during
the PLP. This was not an issue in secondary and tertiary
care settings where pharmacists were already working as a
team with medics on a regular basis:
I had to reduce the number of patients that I saw
while [the pharmacist] was sitting in with me, simply
because you talk about the cases, you go over each
one the sort of learning points so therefore it takes a
lot more time than your normal 10 minute appoint-
ments. (General practitioner)
I guess the 12 days of experience was a continuation
of our normal working patterns. (Hospital consultant)
Major theme II PLP delivery
Need for support during the PLP
Almost all SP pharmacists and DMPs, with the exception of
those regularly involved in training, felt an information ses-
sion on PLP or a network for discussing issues or asking
questions would have been valuable. Recommendations on
services, which could be made available through the support
network were also made. However, it was also clear that the
range of topics requested to be covered was very diverse:
This is a new area. I mean I’m doing it my way but it
would be quite interesting to find out what other
mentors are doing. (General practitioner)
Some sort of way of feedback or a forum type thing
where people can ask more general questions and get
answers would be handy. (General practitioner)
I think it should be like a quite a detailed website
about—what is supplementary prescribing? What’s
the background? What’s the course about? What’s the
period of learning in practice about? Case studies
you’ve gone through, people who you could contact.
(Primary care pharmacist)
268 Pharm World Sci (2008) 30:265–271
123
31
Several indicated that time and not mentoring on a regular
basis might discourage many doctors from contributing to
such networks:
I don’t see myself using an e-network for mentors. I
think quite simply time would prohibit me being a
useful contributor to it and I think it’s unlikely that I
would use it. If I was perhaps regularly mentoring
pharmacists 2 or 3 a year then perhaps it would be
different. (Hospital consultant)
Adequacy of training
Participants (DMPs and SP pharmacists) were of the
opinion that the duration and intensity of the PLP should be
based on the knowledge and experience of the pharmacist.
A longer, more structured, PLP was recommended by some
DMPs, particularly if they did not know the pharmacist
well:
I don’t think that 12 days in practice for someone
who is newly qualified and who has really not had
any hands on experience will be enough. (Commu-
nity/primary care pharmacist)
12 days you know it’s like a commitment, but it’s
still a relatively short period of time to cover...you
know there is a long list of competencies to go
through. (General practitioner)
However, time and lack of remuneration for mentors were
voiced particularly by those in a primary care setting as
barriers for longer training:
I think you’d be lucky to get GPs to do it [for more
than 12 days] without sort of paying them full rate
and that would be prohibitive. (General practitioner)
Nevertheless, length of the PLP was, in some cases, not the
real issue. Rather DMPs had reservations about pharma-
cists’ prescribing authority after qualifying as a
supplementary prescriber.
I think pharmacists aren’t doctors. That’s the bottom
line. I think it’s all very well for pharmacists to
prescribe as per protocols but they’ve not done
medical training... You have to be very careful about
what you are expecting pharmacists to actually be
doing. (General practitioner)
National prescribing centre competencies
The number and nature of competencies, especially inclu-
sion of some competencies any pharmacist would have,
was criticised by many participants from all settings:
I think initially we didn’t know how much work was
involved in those [75] competencies. They really are
quite off putting. (Primary care pharmacist)
I think there were some on there that essentially you
shouldn’t have qualified as a pharmacist unless you
could have ticked those boxes already. (General
practitioner)
Some DMPs recommended cutting down the number of
competencies and focusing on a limited number of core
competencies:
I think it needs to try and both be a bit more limited in
the number but also a bit more specific [about] the
level of competencies that is required. (General
practitioner)
Assessment
Assessment of competencies (and not just the number of
competencies) was a challenge for many DMPs, especially
for those with minimal training experience:
I personally find it always quite hard to make those
sort of assessments and judgements for that matter but
then that may be me rather than anything else—but
because I don’t do it very often. (General practitioner)
Independent and formal assessment at the end of the PLP
was recommended by some DMPs, especially when they
knew the candidate well.
It was quite difficult to do a sort of formal assessment on
someone you know quite well. (General practitioner)
As a mentor I would have preferred a bit more clin-
ically orientated assessment than we had. (Hospital
consultant)
It would be useful to have like sort of structured case
questions... I’m trying to think the equivalent of an
OSCE [objective structured clinical examination] on
paper. (General practitioner)
Review of video-recording of consultations was recognised
to be an important aspect of training and assessment by
both pharmacists and DMPs; however, time and availabil-
ity of equipment were barriers to doing this in some
practice settings both in primary and secondary care:
I didn’t do [videos] with prescribing because again
that was a time issue. (General practitioner)
Experiences during the PLP
All DMPs reported that SP pharmacist training had been a
positive experience for them. Many expressed interest in
Pharm World Sci (2008) 30:265–271 269
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undertaking mentoring for other pharmacists in the future
although at the same time acknowledging that lack of time
and remuneration issues may be potential impediments:
[You] feel that you are working towards something
that’s new and you know that you feel is going to add
to the range of health care that is available... and
working with another professional I think you both
learn a bit more about each other and your profes-
sions which is quite a positive thing. (General
practitioner)
I would do it again if it was somebody within the
building. If it was somebody out with the building I
would really think hard about that in terms of the fact
that I think the time commitment would be much
greater and I don’t think we would get nearly so
much out of it. (General practitioner)
Recommendations to improve the PLP experience
DMPs and SP pharmacists were able to reflect on possible
ways to improve the PLP experience. For example, seeking
advice and/or support from previous SP pharmacist trainees
was viewed as one possible way of adding to the experience:
I got advice from somebody else that had done the
course before I did it. So I had a good idea what was
needed in the twelve days in practice. (Primary care
pharmacist)
I would have liked to seen perhaps a pharmacist
integrated [in the training]. (General practitioner)
Careful planning of the PLP in consultation with the
DMP was seen as crucial:
If you spend more time in planning and don’t rush
into it, then you are more likely to be successful.
(Community pharmacist)
I would want to know before I started what the aims
were and how much teaching you wanted me to do.
(General practitioner)
As was providing more information to DMPs on the
pharmacist’s role in medication management:
It would be a bit more helpful if the GPs could have a
bit more info particularly round about what the
advantages are of having the pharmacist and helping
the pharmacist. (Primary care pharmacist)
Discussion
As a new concept, the PLP has been a learning experience
for both SP pharmacists and DMPs. Planning the PLP in
consultation with the DMP is crucial for an optimal PLP
experience. Pharmacists who do not have a close working
relationship with the medical team might need support for
identifying a DMP and organising the PLP. Participants
stressed the importance of focusing on and achieving the
core competencies for prescribers during the PLP. Input
from doctors involved in the training of others, review of
consultation videos, and formal independent assessment
including clinical assessment at the end of the PLP might
improve the quality of the PLP. Forums for discussing
experiences during the PLP and gathering information
might be valuable to SP pharmacists.
Our findings have implications for prescribing training
for pharmacists in the future. Pharmacists working in pri-
mary care trusts in England thought it would be harder for
them than nurses to recruit DMPs [9]. In our study, iden-
tification of DMP and organising the PLP were not
problems for pharmacists employed by both primary and
secondary care NHS Trusts, but were for community
pharmacists who did not work closely with medical pro-
fessionals on a daily basis. These findings suggest that prior
working relationship with medical professionals is crucial
in organising the PLP.
Remuneration of DMPs’ time might encourage more
doctors to undertake mentorship for pharmacists and
devote specific time towards the PLP. In a study exploring
the experiences of GPs involved in pilot pre-registration
rotations in general practice for house officers, increased
remuneration was mentioned as a key factor for the future
viability of the scheme [10]. The Scottish Executive Health
Department has recently made available funding to allow
community pharmacists to set up or continue to run SP
clinics [11]. Such initiatives might be essential to attract
more pharmacists, especially community pharmacists, to
undertake SP training and practice.
Data from our study suggest that some DMPs had res-
ervations about pharmacists’ prescribing authority due to
their lack of medical training. Concerns among medical
professionals about SP pharmacists’ proficiency in diag-
nosis, awareness of clinical and patient details and the
likely communication problems when they take up pre-
scribing responsibilities have been reported [12, 13]. With
the introduction of inter-professional undergraduate edu-
cation, some of the competencies for health professionals
are becoming cross-disciplinary [14]. These are essential
for SP where the services offered cross professional
boundaries. Independent prescribing (IP) rights for non-
medical health professionals [15] would allow suitably
trained pharmacists to undertake the assessment of patients
with undiagnosed or diagnosed conditions and to make
decisions about the clinical management required, includ-
ing prescribing [16]. It is anticipated that many pharmacists
practising SP will undertake IP in the future [17] after
additional training as recommended by the RPSGB [18].
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Research evidence to establish the value of pharmacists as
prescribers might help to overcome some of the attitudinal
barriers. While an enhanced PLP has obvious educational
value, the ultimate test of the SP pharmacists is how they
perform as prescribers. Further research on structures,
processes and outcomes of pharmacist SP is warranted.
Our study has some limitations. The participants were
purposively selected from SP pharmacists who had completed
their SP training in only one of the accredited institutions in
the UK and their DMPs. The extent to which the views and
attitudes identified in this study are held by the whole popu-
lation of SP pharmacists and DMPs is unknown. Those who
had negative experiences and/or attitudes might not have
participated or divulged their negative views and experiences.
We relied on self-reports and the findings were not evaluated
objectively. The views of pharmacists and DMPs were
mutually supportive although the majority of SP pharmacists
and DMPs participated in the study were not directly linked
and confirm the reliability of our findings. Moreover,
recruitment to the study and the interviews were conducted by
a researcher independent of the SP training programme. Due
to the differences in pharmacy and GP contracts in Scotland
and the rest of the UK, extrapolation of our findings on
reimbursement and time in other practice settings should be
made with caution.
Conclusion
Planning the PLP in consultation with the DMP is crucial
for a good learning experience. The PLP should focus on
achieving the core competencies for prescribers. Input from
doctors involved in the training of others, review of con-
sultation videos, and formal independent assessment might
ensure high standards in SP pharmacists at the completion
of their PLP. Forums for discussing experiences during the
PLP and support in organising the PLP for pharmacists
who do not work with the medical team on a regular basis
might be valuable.
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Abstract Aim The aim of this study was to explore
patients’ perspectives and experiences of pharmacist sup-
plementary prescribing (SP) in Scotland. Method A survey
in primary and secondary care in Scotland. Pharmacist
supplementary prescribers (n = 10) were purposively
selected across Scotland. All pharmacists distributed
questionnaires to 20 consecutive patients as they attended
appointments during October to December 2006.
Reminders were mailed to all 20 patients by each phar-
macist 2 weeks after initial distribution. Main outcome
measures The questionnaire contained items on: attitudes
towards pharmacist SP derived from earlier qualitative
research; consultation satisfaction derived from a validated
scale developed initially for general practitioners, with the
term ‘doctor’ being replaced by ‘pharmacist prescriber’;
and demographics. Closed and Likert scales were used as
response options. Results One pharmacist withdrew. The
patient response rate was 57.2% (103/180). The median
age was 67 years (interquartile range 56.5–73 years), with
53.4% being female. Most (76, 73.8%) consulted with the
pharmacist in a general practice setting. Patients reported
positive consultation experiences with 89.3% agreeing/
strongly agreeing that they were satisfied with the consul-
tation, 78.7% thought the pharmacist told them everything
about their treatment and 72.9% felt the pharmacist was
interested in them as a person. Most patients were positive
in their attitudes, agreeing that they would recommend a
pharmacist prescriber to others and that they had trust in
the pharmacist. However, 65% would prefer to consult a
doctor. Conclusion Most patient respondents were satisfied
with, and had a positive attitude towards, pharmacist pre-
scribing consultations. However, most patients would still
elect to see a doctor given the choice.
Keywords Pharmacist prescribing  Supplementary
prescribing  Patient satisfaction  Patient views 
Scotland
Impact of findings on practice
• This study provides evidence of high levels of patient
satisfaction with the pharmacist consultation particu-
larly concerning medication-related information.
• These findings, in a number of different clinical settings
and disease states, might enhance confidence levels of
pharmacist prescribers involved in patient care.
• Patient perspectives should be explored as a routine
part of clinical practice and research.
Introduction
The prescribing roles and responsibilities of non-medical
health professionals, primarily pharmacists and nurses, are
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being redefined in the UK [1, 2]. Anticipated outcomes are
an improvement in patients’ convenient and safe access to
medicines coupled with a reduction in doctors’ workload.
Supplementary prescribing (SP) is one such initiative.
Supplementary prescribing (SP) is defined as ‘a voluntary
partnership between an independent prescriber (a doctor or
dentist) and a supplementary prescriber to implement an
agreed patient-specific clinical management plan (CMP)
with the patient’s agreement’ [2]. Within this framework
there are no legal restrictions on the clinical conditions that
may be treated or drugs that can be prescribed by supple-
mentary prescribers.
The CMP is the foundation stone of SP. In addition to
patient details, the CMP must include reference to the
class or description of medicines which may be prescribed
or administered under the plan and any restrictions or
limitations as to the strength or dose of any medicine
which may be prescribed. Situations warranting referral
back to the independent prescriber must also be docu-
mented [2].
Since March 2004, pharmacists in the UK have been
practising SP in various settings [3]. An overview of the
historical developments around pharmacist prescribing in
Scotland is summarised in Table 1. In June 2005, a survey
of all pharmacist supplementary prescribers in Great Brit-
ain (n = 518) indicated that almost half the respondents
had written a prescription within 6 months of registration
as a prescriber [3]. The published literature to date focuses
mainly on pharmacists’ perspectives of training and service
implementation [4–7]. As the end users of prescribing
services, it is imperative that patients’ views and experi-
ences are sought. There is a paucity of such studies with
those few published describing favourable comments in
terms of patients’ views and experiences [8, 9]. However,
they are limited in terms of sample size and setting.
Research focusing on patients’ views of nurse prescribing
is similarly limited [10]. Patient involvement and patient
choice in health service planning and delivery are key
elements of National Health Service (NHS) policy [11].
There have recently been conflicting research findings
relating to pharmacists’ roles in medication review, a role
similar to SP. Several studies indicated positive clinical
and patient outcomes but others reported increased hospital
admissions and sub-optimal advice giving [12–17].
Aim of the study
The aim of the study was to explore patients’ perspectives
and experiences of pharmacist SP in Scotland.
Method
Pharmacist supplementary prescribers (n = 10) were pur-
posively selected from a range of Scottish geographical
regions, settings (community pharmacy, general practice
and hospital) and fields of prescribing (respiratory, car-
diovascular, diabetes, oncology and pain). We anticipated
that a sample of ten pharmacist prescribers would allow
inclusion of different care settings and patient groups most
frequently being managed by pharmacists. To participate,
each had to be have been managing at least 20 patients for
the previous 3 months. Information on pharmacist pre-
scribing activities was not readily available and was based
on three sources: data of prescribing activities collected
from a Great Britain wide survey [3]; Scottish prescribing
data; and information from Chief Pharmacists/Directors
of Pharmacy. Nineteen pharmacists were approached
sequentially to recruit the sample of ten.
Table 1 Historical developments around pharmacist prescribing in Scotland
Date Event
1999 Publication of the final report of the Government-led Review of Prescribing, Supply and Administration of Medicines
2001 Section 63 of the Health and Social Care Act enabled the Government to extend prescribing responsibilities to pharmacists
(and nurses initially and then extended to chiropodists/podiatrists, physiotherapists and radiographers in 2005)
2003 Amendments to NHS regulations allowed supplementary prescribing by suitable trained pharmacists (and nurses)
2003 First pharmacist supplementary prescribing courses accredited by the Royal Pharmaceutical Society of Great Britain
2003 First pharmacists recruited onto courses in supplementary prescribing
2004 First pharmacists to complete courses and register as supplementary prescribers
2006 New category of prescriber, pharmacist (and nurse) independent prescriber created
2006 Amendments to NHS regulations to allow independent prescribing by pharmacists (and nurses)
2007 First conversion prescribing course accredited by the Royal Pharmaceutical Society of Great Britain, allowing registered
pharmacist supplementary prescribers to train as independent prescribers
2007 First pharmacist independent prescribing conversion course completions and registration as independent prescribers
2007 First courses for pharmacist prescribing (supplementary and independent)
At the time of the study there were approximately 300 registered pharmacist prescribers in Scotland
Pharm World Sci (2008) 30:892–897 893
123
37
A postal questionnaire was developed and piloted in 20
patients being managed by one of the study pharmacists.
As no changes were made to the questionnaire post pilot,
these pilot data were included in the overall results. The
questionnaire contained items on: attitudes towards phar-
macist SP (12 items) derived from our earlier qualitative
research [18]; consultation satisfaction derived from a
validated scale developed initially for general practitioners
(9 items) [19], with the term ‘doctor’ being replaced by
‘pharmacist prescriber’; and demographics. There were
closed questions and Likert scale response options in the
questionnaire.
Each of the pharmacists distributed questionnaires to
20 consecutive patients, who had been managed by them
for at least 3 months, as they attended appointments in
community or hospital settings during October to
December 2006. There were no exclusion criteria.
Reminders were mailed to all 20 patients by each phar-
macist 2 weeks after initial distribution. Approval was
obtained from the Multi-centre Research Ethics Com-
mittee for Scotland and the relevant Research and
Development Committees in Scotland.
Data were entered into SPSSv13 (SPSS Inc.). Internal
consistencies of the scales were tested using Cronbach’s
alpha. Negatively worded statements were reverse scored.
Alpha internal consistencies greater than 0.60 are regarded
as desirable for psychometric scales [20].
Results
Ten pharmacists were recruited from six geographical
regions in the north, west, south and east of Scotland giving
a variety of pharmacy settings and clinical areas. The
geographical regions have been anonymised to protect the
identity of the pharmacists. The pharmacists (see Table 2
for further details) were mostly female (n = 8) with
between four and 25 years experience as a pharmacist. The
nine who declined involvement were interested but unable
to participate due to reasons of workload and/or still
establishing prescribing systems.
The patient response rate was 57.2% (103/180). The
median age was 67 years (interquartile range 56.5–
73 years), with 53.4% female. Most (76, 73.8%) consulted
with the pharmacist in a general practice setting, 15
(14.6%) in community pharmacy and one seen in both
general practice and community pharmacy (there were 11
missing responses). The pharmacists were managing a
range of medical conditions, most commonly hypertension
(33 patients) and asthma (18 patients).
Patients reported positive experiences and high levels of
satisfaction with the consultations (Table 3): 89.3%
agreed/strongly agreed that they were totally satisfied;
78.7% agreed/strongly agreed that the pharmacist told them
everything about their treatment; 72.9% agreed/strongly
agreed that the pharmacist was interested in them as a
person; 56.3% agreed/strongly agreed that the pharmacist
really knew what they were thinking. Most patients were
positive in their attitudes agreeing that they would rec-
ommend a pharmacist prescriber to others and that they had
trust in the pharmacist (Table 4). However, 13.6% agreed/
strongly agreed that some things about the consultation
could be better; 49.5% disagreed/strongly disagreed that
they would find it difficult to tell the pharmacist prescriber
about some private things; and 65% would prefer to consult
a doctor.
Discussion
Respondents were highly satisfied with the pharmacist
consultations, and the medication-related information pro-
vided. They trusted the pharmacists, were comfortable
during the consultations, and would recommend a phar-
macist prescriber to a friend. However, most respondents
would choose to see a doctor rather than a pharmacist
Table 2 Settings and clinical
areas of the participating
prescribing pharmacists
Pharmacist ten withdrew from
the study
Geographical
region
Prescribing setting Clinical area(s)
Pharmacist 1 1 General practice Respiratory
Pharmacist 2 1 General practice Respiratory
Pharmacist 3 1 General practice/community pharmacy Cardiovascular
Pharmacist 4 2 General practice Cardiovascular
Pharmacist 5 3 General practice/community pharmacy Rheumatology/pain
Pharmacist 6 4 General practice Cardiovascular/
diabetes
Pharmacist 7 4 General practice Cardiovascular
Pharmacist 8 5 Community pharmacy Respiratory
Pharmacist 9 6 Hospital (secondary care) Oncology
894 Pharm World Sci (2008) 30:892–897
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prescriber and some felt that their consultation with the
pharmacist could have been better.
This research has strengths and weaknesses. Firstly,
because there was no existing sampling frame of eligible
pharmacists we used several sources to give an indication
of those with greatest prescribing experience. We recognise
we may have missed some people with this approach.
However despite a relatively small sample size we
achieved a range of pharmacists and patients across Scot-
land. The patients were from different settings and most
Table 3 Patient responses to attitudinal statements relating to consultation satisfaction n (%) (n = 103) (some missing responses)
Statements Strongly disagree Disagree Neutral Agree Strongly agree
I am totally satisfied with my visit to this pharmacist prescriber 0 0 7 (6.8) 55 (53.4) 37 (35.9)
This pharmacist prescriber told me everything about my treatment 0 5 (4.9) 14 (13.6) 49 (47.6) 32 (31.1)
Some things about my consultation with the pharmacist prescriber
could have been better
18 (17.5) 40 (38.8) 27 (26.2) 10 (9.7) 4 (3.9)
This pharmacist prescriber examined me very thoroughly 2 (1.9) 25 (24.3) 20 (19.4) 35 (34.0) 15 (14.6)
This pharmacist prescriber was interested in me as a person, not
just my illness
1 (1.0) 6 (5.8) 17 (16.5) 53 (51.5) 22 (21.4)
I understand my illness much better after seeing this pharmacist
prescriber
1 (1.0) 10 (9.7) 41 (39.8) 30 (29.1) 16 (15.5)
I felt this pharmacist prescriber really knew what I was thinking 0 9 (8.7) 32 (31.1) 44 (42.7) 14 (13.6)
I wish it had been possible to spend a little more time with the
pharmacist prescriber
8 (7.8) 27 (26.2) 49 (47.6) 10 (9.7) 4 (3.9)
I would find it difficult to tell this pharmacist prescriber about
some private things
17 (16.5) 34 (33.0) 19 (18.4) 25 (24.3) 4 (3.9)
Cronbach’s alpha = 0.786
Table 4 Patient responses to attitudinal statements relating to experiences of pharmacist prescribing, n (%) (n = 103) (some missing responses)
Statements Strongly
disagree
Disagree Neutral Agree Strongly
agree
I trusted the pharmacist prescriber’s ability to prescribe
before I went to see him/her for the first time
1 (1.0) 8 (7.8) 15 (14.6) 49 (47.6) 24 (23.3)
I would rather see my doctor than the pharmacist
prescriber if my medical conditions were to worsen
0 5 (4.9) 22 (21.4) 42 (40.8) 31 (30.1)
It is easier to get an appointment to see the pharmacist
prescriber than the doctor
2 (1.9) 10 (9.7) 27 (26.2) 33 (32.0) 26 (25.2)
To make sure that the pharmacist prescriber is giving
me the right treatment, I would like to see my doctor
every now and then
2 (1.9) 7 (6.8) 19 (18.4) 42 (40.8) 27 (26.2)
If I had a choice between a doctor and the pharmacist
prescriber, I would consult the doctor
2 (1.9) 7 (6.8) 23 (22.3) 44 (42.7) 23 (22.3)
I get more time with the pharmacist prescriber than my
doctor(s) for discussing my health-related issues
3 (2.9) 17 (16.5) 29 (28.2) 29 (28.2) 21 (20.4)
I am more comfortable discussing medication-related
issues with the pharmacist prescriber than my doctor
3 (2.9) 27 (26.2) 41 (39.8) 14 (13.6) 12 (11.7)
I am more likely to do what my doctor advises rather
than the pharmacist prescriber
6 (5.8) 25 (24.3) 30 (29.1) 28 (27.2) 10 (9.7)
I am more interested in the quality of care than the
profession of the person who provides it
3 (2.9) 5 (4.9) 7 (6.8) 51 (49.5) 35 (34.0)
If I had to pay for the service, I would pay pharmacist
prescribers and doctors the same amount for the same care
3 (2.9) 17 (16.5) 29 (28.2) 39 (37.9) 12 (11.7)
Prescribing by pharmacists is a way for government to
save money
1 (1.0) 14 (13.6) 32 (31.1) 30 (29.1) 22 (21.4)
I would recommend seeing a pharmacist prescriber to
other people
3 (2.9) 3 (2.9) 22 (21.4) 53 (51.5) 19 (18.4)
Cronbach’s alpha = 0.596
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common therapeutic areas, potentially augmenting gener-
alisability of findings. However, we acknowledge that only
one hospital pharmacist was recruited. A strength was that
our sampling strategy focused on those pharmacists with
most experience of prescribing, recruiting only those with
over 3 months prescribing experience and managing a
prescribing case load of at least 20 patients. This meant that
we were assessing a system in ‘steady state’. The phar-
macists were responsible for patient recruitment during
their consultations which may have introduced an element
of selection bias. However, we emphasised the need to
recruit 20 consecutive patients. Participating pharmacists
may also have been more motivated and confident than
their peers about their clinical and consultation skills and
enthusiastic, potentially introducing bias. The overall
patient response rate was just under 60%; it is possible that
those patients returning the questionnaire were more
interested in and satisfied with pharmacist prescribing, and
we had no data on non-respondents for comparison. One
previously validated scale was used with minor adaptation
to alter the focus from doctor to pharmacist prescriber
consultations. In addition, our findings are based on self-
reports and perceptions rather than objective clinical
outcomes.
Most respondents were highly satisfied with the phar-
macist consultations, the approach of the pharmacists and
the extent of information given. These findings are in
parallel with recently published research in which phar-
macists cited their experience of patient care benefits [6–9].
Lloyd and Hughes have also demonstrated pharmacists’
and designated medical practitioners’ anticipation of
improved patient care [7] and Smalley reported high levels
of patient satisfaction in a study of hypertensive patients in
one medical practice [8]. Perceived benefits are also similar
to those reported for early nurse prescribers [21]. McCann
and Clark reported satisfactory relationships between nur-
ses prescribing antipsychotics for schizophrenia and
patients [10]. In our study, respondents agreed that they
trusted the pharmacist and would recommend others to see
a pharmacist prescriber. Some, however, were unsure of
the benefits of seeing a pharmacist rather than a doctor and
most agreed that given the choice they would rather see
their doctor than the pharmacist. This may reflect the long-
term, established relationship and trust most patients with
chronic conditions will have with or in their doctors rather
than any particular issues with the pharmacists. These
views may evolve over time as experience of non-medical
prescribing increases.
Our findings contrast with those of Salter et al. who used
qualitative discourse analysis of audio records of a small
number of pharmacist consultations [17]. Their results
highlighted the potential of pharmacists’ advice to under-
mine and threaten patients’ competence. There are key
differences between these two studies. The pharmacists in
our study were all registered SP and had completed an
accredited University-based course which included con-
sultation skills as a key component. Consultation skills
were also a prescribed competency in the period of learning
in practice supervised by medical practitioners [22]. We
also focused on the patients’ perspectives of the consulta-
tion process, which may be very different to the analytical
context of Salter et al. [17].
Independent prescribing by pharmacists in the UK is
now being implemented [2]. In this role, pharmacists will
assess and manage patients with undiagnosed or diagnosed
conditions without formal involvement of a doctor. They
will be authorised to prescribe, within their competence, all
licensed medicines other than controlled drugs. For this
role to be a success high levels of patient acceptance are
important and good consultation skills are essential.
Further larger scale research is required to study
patients’ views and experiences, ensuring proportional
representation of the different settings in which pharmacist
prescribers currently practice. In addition there should be
focus on evaluating objectively prescribing pharmacists’
consultation skills using validated criteria and observa-
tional methods, such as those of the Royal College of
General Practitioners [23]. This could provide robust evi-
dence of the quality of pharmacists’ consultation skills
compared to established prescribers, and permit explora-
tion of areas about which patients were less positive such
as clinical examination and privacy. Information about
clinical outcomes as well as experiences is also required.
Conclusion
Most patients were satisfied with and had positive attitudes
towards pharmacist prescribing consultations but most
would still elect to see a doctor if given the choice.
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Abstract
Aim The aim of this study was to explore the perspectives of pharmacist supplementary
prescribers, their linked independent prescribers and patients, across a range of settings, in
Scotland, towards pharmacist prescribing.
Method Telephone interviews were conducted with nine pharmacist prescribers, eight
linked independent prescribers (doctors) and 18 patients. The setting was primary and
secondary care settings in six NHS Health Board areas in Scotland.
Key findings In general, all stakeholders were supportive of pharmacists as
supplementary prescribers, identifying benefits for patients and the wider health care
team. Although patients raised no concerns, they had little idea of what to expect on their
first visit, leading initially to feelings of apprehension. Pharmacists and doctors voiced
concerns around a potential lack of continued funding, inadequate support networks and
continuing professional development. Pharmacists were keen to undertake independent
prescribing, although doctors were less supportive, citing issues around inadequate clinical
examination skills.
Conclusions Pharmacists, doctors and patients were all supportive of developments in
pharmacist supplementary prescribing, although doctors raised concerns around indepen-
dent prescribing by pharmacists. The ability of pharmacists to demonstrate competence,
to be aware of levels of competence and to identify learning needs requires further
exploration.
Keywords independent prescriber; interview; patient view; pharmacist prescribing;
stakeholder view; supplementary prescriber
Introduction
Pharmacists in the UK with at least 2 years’ post-registration professional experience can
now qualify and register as independent prescribers, allowing them to practise as
supplementary and independent prescribers. Supplementary prescribing, introduced in
2003, requires collaborative working with an independent prescriber (a doctor or dentist)
and patient to prescribe any medicine(s) for any diagnosed condition(s), within the
boundaries of a named patient’s clinical management plan.[1] Independent prescribing for
pharmacists is a more recent development and permits the management of diagnosed and
undiagnosed conditions, prescribing any licensed medicine (other than controlled drugs)
within the pharmacist’s competence, with no need for formal medical collaboration.[2] The
successful implementation of pharmacist independent prescribing services will be
enhanced by rigorous evaluation of pharmacist supplementary prescribing in terms of
structures, processes and outcomes.
The stated aims of pharmacist prescribing are to improve patient access to medicines,
making the best use of pharmacists’ clinical skills.[3,4] Supplementary prescribing has been
undertaken by pharmacists in various settings across the UK since March 2004.[5] Most of
the published literature has reported pharmacists’ perspectives of supplementary
prescribing training and/or initial practice.[5–9]
While acknowledging limitations of respondent bias and sample size, findings have
been generally positive. Any negative views reported were around service implementation,
particularly financial and organisational issues; some concerns about training were also
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identified. Similar findings were reported in a smaller study
combining questionnaire and telephone interview methods.[9]
Lloyd and Hughes used a qualitative approach to extend the
research perspective to medical mentors involved in training
for pharmacist supplementary prescribing.[10] General sup-
port for supplementary prescribing was reported, but doctors
were less supportive of an independent prescribing role for
pharmacists. Buckley et al.[11] interviewed health-related
stakeholders, finding broad support for non-medical pre-
scribing but concern that pharmacists lacked in-depth
knowledge of patient medical histories. Pharmacist prescrib-
ing is still only being practised by a minority of pharmacists
working under different funding models depending on their
home country or health-service setting. It is anticipated that,
ultimately, in the community pharmacy setting in Scotland,
core funding will be made available through the chronic
medicines service component of the community pharmacy
contract.
Only one published study has focused on the views of
patients, all of whom were attending a single hypertension
clinic; most patients viewed the standard of care as better
than before.[12] None of the research published to date has
explored concurrently the views and experiences of all three
partners of the supplementary prescribing model: patient,
independent prescriber and supplementary prescriber. It is
also fundamental to research different and diverse settings
and therapeutic areas to fully inform practice developments.
The aim of this study was to explore the perspectives of
pharmacist supplementary prescribers, their linked indepen-
dent prescribers and patients towards pharmacist prescribing
across a range of settings in Scotland.
Methods
Design
A qualitative case-study approach, including interviews,
video recording and a questionnaire, was utilised to generate
data from different professional and patient groups in various
settings. Only the findings from the interviews are reported
here.
Sampling of case-study sites
Data collected from a Great Britain-wide survey of
pharmacist supplementary prescribers[5] were used along
with Scottish prescribing data and information from the
Chief Pharmacists/Directors of Pharmacy in each Health
Board area in Scotland as a basis for purposive sampling to
identify 10 case-study sites. We aimed to provide maximum
variation in terms of therapeutic areas/patient groups,
geographical regions and care settings and to include those
with more prescribing experience. Inclusion criteria were that
the pharmacist prescribers had a current case load of at least
20 patients, had more than 3 months’ prescribing experience
and would be able to recruit one of their independent
prescribers and up to three of their current patients for a
telephone interview. No attempt was made to identify a
statistically representative sample. Eighteen pharmacists
were approached to generate the sample of 10.
Participants identified for telephone interview were sent
an information letter and participant information sheet.
Interviews were conducted by two researchers (JG and BA)
and lasted 10–30 min. Topic areas for pharmacist and doctor
interviews included perceived benefits and challenges of
supplementary prescribing, perceived changes in pharmacist
roles since becoming prescribers, relationships with the rest
of the care team, support structures for prescribers, continu-
ing professional development (CPD) and independent
prescribing. These areas were based on published research
of benefits and challenges of pharmacist supplementary
prescribing.[5,6] The topic guide for the patients focused on
patient understanding of supplementary prescribing, their
expectations of a pharmacist prescriber, issues of access to
medicines, and satisfaction. The interview guides were
reviewed by an expert panel for face and content validity
and developed further through an iterative process as the
interviews progressed and new themes or concepts emerged.
Interviews were audio-recorded and transcribed verbatim.
Data management and analysis
Data management was supported by NVivo software. Data
were analysed for recurring themes using the ‘framework’
approach.[13] After familiarisation with the data by repeated
reading of the transcripts (DS), emerging themes were
identified and the data coded, supported by NVivo. Two
researchers (BA and DS) independently verified the themes,
with any disagreement being reviewed by other members of
the research team.
Ethical approval
The research was approved by the NHS Multi-centre
Research Ethics Committee for Scotland. Research and
development approval was also obtained from each of the
NHS areas involved. All participants provided written,
informed consent.
Results
Case-study recruitment
Of the eighteen pharmacists originally approached eight felt
unable to participate due to reasons that included workload or
only recent delivery of a prescribing service. The 10
participating pharmacists were recruited from six NHS
organisational areas in the north, west, south and east of
Scotland, giving a spectrum of pharmacy settings and clinical
areas. Case-study sites have been anonymised to protect the
identity of the small number of pharmacists. The pharmacists
(see Table 1 for further details) were mostly female (n = 8)
with between four and 25 years’ experience as a pharmacist.
Of those unable to participate, four were male and four
female. One female pharmacist later withdrew for workload
reasons prior to any data collection, giving a final sample
size of nine.
Eight out of nine doctors, having between four and
20 years of clinical experience, agreed to be interviewed.
The remaining doctor, from a single-handed practice,
expressed interest in the research but was busy with practice
restructuring.
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Eighteen patients covering most geographical regions and
prescribing pharmacists agreed to be interviewed. The mean
patient age was 64 years (range 28–85 years). Patients
consulted the pharmacists at clinics for chronic diseases.
The major themes plus supporting quotes are presented
below. Interviewee type, setting and management area are
identified in parentheses below each quote.
Development of prescribing role
Pharmacists described some of the key motivating factors
which led to them undertaking supplementary prescribing.
For some, this was an opportunity to improve patient care,
complementing the functions of other members of the health
care team. ‘We have a visiting oncologist here who comes
once a fortnight . . . . As I developed more expertise in the
area it became quite apparent that having a pharmacist as a
supplementary prescriber would be really useful in our
situation.’ (Pharmacist 10, hospital, oncology)
Many others, in both primary and secondary care,
described supplementary prescribing as a natural extension
to their advisory role, almost legalising their current practice.
‘Within the [medical] practice we are almost doing a
prescribing role anyway . . . . So you are kind of doing
[prescribing] . . . going through the motions almost anyway
so this was just a natural next step to do the qualification.’
(Pharmacist 4, GP practice, cardiovascular)
Despite pharmacist motivation to improve care, patients
were somewhat confused of what to expect from their first
visit to the pharmacist prescriber. Some were apprehensive
but accepted that the pharmacist was a trained professional
and that if they were unhappy they could see the doctor.
Following the consultation they reflected positively on the
treatment they had received. ‘Well that was the thing really I
didn’t know what to expect. I just had to trust the [medical]
practice knew what they were doing and actually when I met
him it was fine and that put my mind at ease.’ (Patient 1 (of
pharmacist 9), community pharmacy, respiratory)
Patient benefits
Patient benefits of pharmacist supplementary prescribing
were acknowledged by all. Pharmacists expressed a desire to
provide good patient services and perceived that patients
were given quicker access and longer appointments, in turn
reducing doctor waiting times. ‘They were really happy that
they have got someone who they can just walk in to and talk
to instead of having to make appointments and things . . . . Oh
definitely I think that’s made a big difference to them.’
(Pharmacist 9, community pharmacy, respiratory)
These benefits were reiterated by the doctors who praised
the improvement in patient care. Pharmacists were viewed as
having expertise in all aspects of pharmacotherapy. ‘It can
simplify the process in that the pharmacist often has more
expertise and knowledge in actual drug interactions, side
effects, contra-indications; so they can provide that informa-
tion for the patient.’ (GP (of pharmacist 3), cardiovascular)
‘The main benefit for me is that it’s good for the patients.
Patients get a more detailed look at all their medication . . .
pharmacists discuss the side effects of drugs better with
patients. We should be able to as well but pharmacists have a
better knowledge of drugs and this can only benefit the
patient.’ (GP (of pharmacist 4), cardiovascular)
Patients also noted the benefits of consulting a pharmacist
prescriber. They praised the quality and extent of discussion
relating to their medicines. All were satisfied with the service
and trusted the pharmacist. ‘I’m very happy with the
pharmacist and how carefully he managed my condition
and keeps an eye on me. I would say I get better care for my
condition by the pharmacist when it comes to my prescrip-
tions and reviewing my prescriptions.’ (Patient 2 (of
pharmacist 9), community pharmacy, respiratory) ‘I have
been on my medication for a long time now and sort of know
what works with me. But I did get more information, I felt,
about how each drug worked and understand a bit more of
why some things work and some don’t.’ (Patient 1 (of
pharmacist 6), GP practice, cardiovascular/diabetes)
Health care team benefits
Pharmacists noted benefits of their enhanced job satisfaction,
responsibility and autonomy. ‘I mean taking clinical
responsibility rather than just putting referrals to doctors
saying ‘could you change this?’ or ‘could you do that?’. . .
you are actually able to do it yourself and carry it through
and see the patient.’ (Pharmacist 1, GP practice, respiratory)
In addition, many felt more integrated into the health care
team. ‘I think I work more closely with the GPs and nurses
now that I am doing the prescribing than before just because
Table 1 Settings and clinical areas of the participating prescribing pharmacists
Pharmacist Geographical region Prescribing setting Clinical area(s) Number of patients interviewed
1 1 GP practice Respiratory 3
2 1 GP practice/communitypharmacy Respiratory 3
3 1 GP practice Cardiovascular 1
4 2 GP practice Cardiovascular 3
5 3 GP practice/communitypharmacy Rheumatology/pain 3
6 4 GP practice Cardiovascular/diabetes 1
7 4 GP practice Cardiovascular 2
8* 4 GP practice Cardiovascular 0
9 5 Community pharmacy Respiratory 2
10 6 Hospital (secondary care) Oncology 0
*Pharmacist 8 was one of the first recruits but decided to withdraw from the research in the later stages. Hence the research provides case-study data
on nine pharmacists.
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you have to communicate more about what you are doing.’
(Pharmacist 1, GP practice, respiratory)
This aspect of enhanced teamwork was also noted by
many doctors. In particular some felt that having a
pharmacist prescriber allowed them more time to spend on
patients with acute conditions. ‘From our point of view it
means that we can free up doctor time to do the front-end
stuff with initial diagnosis and then we can refer them on to
clinics.’ (GP (of pharmacist 3), cardiovascular)
One doctor described a model of care where the
pharmacist managed patients in the absence of any medical
colleagues. ‘Well I think the main strength is that . . . is where
the doctor in, for example, our outreach clinics can’t always
be there as I’m only there twice a week then in between times
the pharmacy prescriber can prescribe drugs related to the
side effects of radiotherapy.’ (Hospital consultant (of
pharmacist 10), oncology)
Challenges for pharmacist supplementary
prescribing
Several challenges were raised by all parties. Funding was a
key area of discussion for pharmacists, and it was evident
that there were different funding arrangements for supple-
mentary prescribing services depending on the practice
setting. One key issue was that most pharmacists felt a
lack of any formal support networks and often relied
informally on other trained colleagues for advice. Some
sought help from line managers but felt that there was a need
for a more formal support structure. Various solutions were
offered including local, organised support, message boards,
contact lists and a directory of clinical management plans.
Some felt there were no problems at all. ‘There is not much
support structures. I mean we have a lead pharmacist if we
need support and I actually support some of the ones that are
doing their prescribing just now.’ (Pharmacist 3, GP practice,
cardiovascular)
A lack of appropriate CPD to meet pharmacist prescri-
bers’ needs also emerged as a key theme. ‘There is nothing as
far as I’m aware specific at the moment that I can sign up
to . . . I’m not aware of where I can go to get free ‘up to date’
stuff.’ (Pharmacist 2, GP practice/community pharmacy,
respiratory)
The importance of CPD, particularly with regard to
changes in clinical pharmacology, was also noted by the
doctors. ‘The challenge will be to keep up with which ones
[drugs] work better for patients on chemotherapy and
radiotherapy. With proper training and CPD this should be
manageable and experience with working with patients will
also help.’ (Hospital consultant (of pharmacist 10), oncology)
Other potential challenges for pharmacists described by
the doctors included balancing patient demand while work-
ing within their limits of competence. ‘Patients can be very
demanding and put pressure on us and other professionals to
do more. So it’s definitely a question of knowing your
limitations and not letting patients dictate what they take and
not take.’ (GP (of pharmacist 4), cardiovascular)
No major concerns were voiced by the patients. Some had
slight reservations but once they had attended their initial
consultation, they were reassured that the pharmacists were
very capable. One patient felt that she also needed to see the
doctor just in case things went wrong.
Independent prescribing
Pharmacists and doctors had strongly opposing views on
pharmacist independent prescribing. Pharmacists were eager
to undertake independent prescribing after further training.
One felt that independent prescribing would be more
beneficial within community pharmacy settings, allowing
the delivery of a stand-alone service, as well as benefiting
travel and family planning clinics. Independent prescribing
was considered by all to be the obvious next stage in their
development. ‘It’ll be of great benefit and it will be easier for
me to give out any prescription in the area that I’m
competent in and confident.’ (Pharmacist 6, GP practice,
cardiovascular/diabetes)
Overall pharmacists felt their doctors would support them
if they intended to extend their role to independent
prescribing. One pharmacist expressed reservations about
prescribing outwith her areas of competence. ‘No, well, I’ve
chatted to a few of them and they are very enthusiastic for
me to do the independent prescribing. There are certain
areas they actually wouldn’t want me to do . . . outwith my
competence . . . but no, for the areas which I am doing the
cardiac areas and some asthma things like that they
were more than happy.’ (Pharmacist 3, GP practice,
cardiovascular)
Issues relating to competence were voiced by all
pharmacists. ‘You sometimes don’t realise what you don’t
know and you can genuinely think that you are doing
something that is OK but just because your knowledge isn’t
as good as it should be, you can make maybe an error that
way and that is my main concern.’ (Pharmacist 1, GP
practice, respiratory)
Despite the perceived support from their independent
prescribers, all doctors expressed concern about the imple-
mentation of independent prescribing by pharmacists. The
major area of concern related to pharmacists’ competence in
diagnosis. ‘Well my concerns with independent prescribing
is that obviously you need to be in a position to make a
diagnosis – an appropriate diagnosis – and not to miss the
problems that may be going on which takes all of us a long
period of time to gain the kind of knowledge and then the
experience.’ (GP (of pharmacist 5), GP practice/community
pharmacy, rheumatology/pain)
One, however, did indicate support for a wider role in
secondary care. ‘No I think most doctors would welcome this
initiative and realise that this additional service can provide
more help for them.’ (Hospital consultant (of pharmacist 10),
oncology)
Discussion
This study has considered the views of pharmacists, doctors
and patients on the implementation of pharmacy prescribing.
All were supportive of pharmacists as supplementary
prescribers, identifying benefits for patients and the wider
health care team. Although patients raised no concerns, they
had little idea of what to expect on their first visit leading
initially to feelings of apprehension. Pharmacists and doctors
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voiced concerns around a potential lack of funding, support
networks and CPD. Pharmacists were keen to undertake
independent prescribing, although doctors were less suppor-
tive, citing issues around pharmacists’ inadequate clinical
examination skills. Although this study was carried out in the
UK, the findings may also be relevant to pharmacists,
doctors, patients and policy makers on a global level,
especially when other countries such as Australia, The
Netherlands and USA are also developing models for
expanding the roles of non-medical professionals such as
nurses and pharmacists in medication management.[14]
To our knowledge this is the first study conducted at a
national level which has taken this approach. Purposive
sampling resulted in a range of pharmacists, doctors and
patients across Scotland. Nevertheless, our study had some
limitations. The sampling strategy focused on experienced
pharmacist prescribers who in turn recruited the independent
prescribers and patients, introducing selection bias. Some
pharmacists would have recruited their designated medical
practitioner (mentor) during their prescribing training,
introducing a potential bias in their views expressed. Some
pharmacists approached were unable to participate despite
expressing initial interest and only one hospital pharmacist
was recruited. It is likely that those who agreed were highly
motivated, interested in pharmacist prescribing, confident
about their prescribing skills, had experience in pharmacist
prescribing and had already met and overcome many
challenges. Their views may not be representative of
pharmacist prescribers in general. However, these are the
individuals who are likely to lead developments and hence
their inclusion is justified and can provide valuable
information to the others. Due to the inclusion criteria,
purposive sampling and small sample size it is possible that
not all relevant themes emerged from the interviews so
saturation of themes may not have been achieved. Telephone
interviewing was used on the basis of logistics (mainly
geography) and convenience for participants (especially
doctors). However, this is not unusual as comprehensive
phone interviews are increasingly used in multi-stage
research and results have been found to be as reliable and
as representative as face-to-face interviews.[15–17]
Pharmacist prescribing is only evolving and hence some
of the challenges are unsurprising. Issues around funding,
support and CPD have been noted by others.[6,10] Focus on
funding is essential to any contractual discussions for
community pharmacy[18] and for strategic planning within
the managed service spanning general practice and hospital.
Similar issues of organisations and infrastructure have also
been noted in qualitative and quantitative research into
pharmacist and nurse prescribing.[19–21] Given the steady
increase in non-medical prescribers other than pharmacists,
and existing long-held concerns about the quality of medical
prescribing, interprofessional CPD might be a good oppor-
tunity to support consistent, efficient and effective prescrib-
ing practices across all proponents. The doctor–patient
relationship has been shown to be the key to positive
prescribing and thus optimal health outcomes.[22] In our
study, patients were rather anxious about their first
consultation but rapidly gained confidence thereafter. These
changes to patient perceptions are not unexpected, and are
likely to alter further with time and experience. Although
teamwork is fundamental to supplementary prescribing, there
is very little knowledge of how health care teams work in
practice.[23] Our data would suggest that the prescribing
pharmacist has made a positive contribution to the team in
terms of patient care and role clarity.
The supplementary pharmacist prescribers were keen to
undertake the independent prescribing conversion course.
They were clearly aware of the need to practice within
defined areas of competence. However, the doctors had
reservations, mostly noting issues around clinical examina-
tion skills. Such issues have also been noted by others[3,10]
and may not be resolved until robust, evidence-based data on
safe practice are available. There may also be a need to
inform the medical professionals of the scope of independent
prescribing as some respondents incorrectly assumed this to
be associated with clinical diagnosis on every occasion.
There are many parallels between our findings and those
of an overview of systematic reviews of dissemination and
implementation of interventions.[24] Many elements of
professional change observed in our study can be compared
to theoretical models of change. The social condition model
stresses the importance of environment (practice setting for
prescribing), beliefs, attitudes and intentions of those
involved (pharmacist, doctors and patients) as central
influences in successful models of change. The staged
change of behaviour suggests stages of precontemplation,
contemplation, preparation, action and maintenance.[25] The
pharmacists and independent prescribers in our study are
likely to be in the more advanced stages, which may not
necessarily be generalised to all pharmacist prescribers and
their linked independent prescribers. Rogers has classified
individuals into innovators, early adopters, early majority,
late majority and laggards depending upon how quickly they
change behaviour.[26] In terms of the pharmacists, it is likely
that this research has captured either the innovators or early
adopters. This is an important point with clear implications
for wide-scale service developments. It is likely that the
doctors were of similar classification and that the ‘best’
patients were selected for interview.
This research is part of a larger study providing detailed
contextual analysis of pharmacist supplementary prescribing
in Scotland in terms of structures and processes. There
remains an urgent need to provide evidence of patient
outcomes (economic, clinical and humanistic) of pharmacist
prescribing in large numbers of patients. The translation from
models of supplementary to independent prescribing by
pharmacists should also be researched.
Conclusions
All partners in the supplementary prescribing model
(supplementary prescribers, independent prescribers and
patients) were supportive of pharmacist supplementary
prescribing developments, particularly in relation to the
impact on patient care. Concerns around pharmacist
independent prescribing and lack of skills in diagnosis
were raised by the doctors.
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The last few years have seen develop-ments in prescribing policy and
practice in the UK, with the initial intro-
duction of supplementary prescribing
(SP) rights for pharmacists, nurses, and
other health professionals in 2003 and,
subsequently, independent prescribing
(IP) rights for pharmacists and nurses in
2006.1 SP describes “a voluntary partner-
ship between an independent prescriber
(a doctor or dentist) and a supplementary
prescriber to implement an agreed pa-
tient-specific clinical management plan
(CMP) with the patient’s agreement.”2
SP can be used to manage any diagnosed
condition and allows use of any drug
within the competence of the prescriber
and as defined by the CMP. IP is a more
recent development, described as “pre-
scribing by a practitioner responsible and
accountable for the assessment of pa-
tients with undiagnosed or diagnosed
conditions and for decisions about the
clinical management required, including
prescribing.” All licensed medicines
(other than controlled drugs) can be pre-
scribed within the independent pre-
scriber’s competence; there is no need
for a formal, written agreement with a
medical practitioner or patient.3,4 SP has
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INTERNATIONAL REPORTS
BACKGROUND: Nonmedical (ie, nonphysician) prescribing is a key development
in the UK that has brought about many changes in prescribing policy and
practice. Systematic research into the views of the general public toward such
developments is limited.
OBJECTIVE: To determine the awareness of, views on, and attitudes of members
of the Scottish general public toward nonmedical prescribing, with an emphasis
on pharmacist prescribing. 
METHODS: A questionnaire was mailed in November 2006 to a random sample of
5000 members of the general public in Scotland aged 18 and over, obtained from
the UK electoral roll. The questionnaire contained items on awareness of
nonmedical prescribing, levels of comfort with specific health professionals, and
attitudes toward pharmacist prescribing.
RESULTS: Response rate was 37.1%. More than half of the individuals who
responded were taking prescribed drugs. Nine hundred and seventy-eight
(56.6%) were aware that trained health professionals could write prescriptions for
medicines previously only prescribed by physicians. Awareness was associated
with: increasing age (p < 0.001), having a health professional in their immediate
family (p < 0.001), self-rated general health (p < 0.005), and a higher education
level (p < 0.01). In logistic regression, all factors were retained as independent
predictors of awareness (p < 0.001). Comfort levels for nonmedical prescribing
were highest for pharmacists (median 4, IQR 3–5 [1 = low, 5 = high]), closely
followed by nurses, and lowest for radiographers (median 2, IQR 1–4) (p < 0.001).
While more than half of the respondents supported pharmacists having a
prescribing role, fewer felt that pharmacists should prescribe the same range of
drugs as physicians. There were concerns about lack of privacy in a pharmacy,
despite acknowledging its enhanced convenience.
CONCLUSIONS: Our results indicate that more than half of the respondents were
aware of nonmedical prescribing. A higher proportion was more comfortable with
prescribing by pharmacists and nurses than with other healthcare professionals.
Several issues relating to aspects of clinical governance were highlighted,
specifically education and data handling. 
KEY WORDS: general public, nonmedical prescribing, Scotland, survey. 
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now been extended to cover most health professionals,
including nurses, pharmacists, physiotherapists, radiogra-
phers, and optometrists, but IP remains the preserve of only
pharmacists and nurses. These nonmedical prescribers are
regulated by their professional bodies (eg, pharmacist pre-
scribers are regulated by the Royal Pharmaceutical Society of
Great Britain). Most of their prescribing activities are con-
ducted within the National Health Service. 
Anticipated outcomes of nonmedical prescribing are pa-
tient centered and focus on providing safe, quicker, more
efficient, and easier access to medicines with overall im-
proved patient care. In addition, it promotes better use of
the skills of a wide range of health professionals, introduc-
tion of more flexible teamwork, and a reduction in physi-
cians’ workloads.3,5,6
Developments in pharmacist prescribing are not restrict-
ed to the UK. Indeed, there have been several recent, com-
prehensive international literature reviews of pharmacist pre-
scribing focusing on Great Britain, the US, Canada, and Aus-
tralia.7-9 Most primary literature focuses on aspects of
prescribing training and professional development from the
perspective of the health professional. There is a clear lack of
robust research seeking patients’ experiences and views relat-
ing to nonmedical prescribing. Smalley10 reported the views
of 127 patients attending one pharmacist-led hypertension
clinic in England and Stewart et al.11 described the perspec-
tives and experiences of 180 patients attending a pharmacist
prescriber in 9 different Scottish settings.
Almost all of the published literature on medicines in-
volving the general public relates to nonprescription drugs,
particularly analgesics and emergency hormonal contra-
ception.12-14 Obtaining the views, experiences, and issues of
concern to patients and members of the general public is
clearly important given the strategic objectives of nonmed-
ical prescribing. There is a paucity of information relating
to the views of the general public about the extension of
prescribing rights, despite the importance of this perspec-
tive. Only one study reported the general public’s attitudes
to nurse supplementary prescribing. Berry et al.15 recruited
a convenience sample of 74 members of the general public
at a London railway station. Those who had any experi-
ence of nurse prescribing were excluded. Participants ex-
pressed confidence in nurses’ abilities to prescribe the best
medication. No similar work on pharmacist prescribing
has been reported. 
The aim of the work reported here was to determine the
awareness of, views on, and attitudes of members of the
Scottish general public toward nonmedical prescribing,
with a particular emphasis on pharmacist prescribing. 
Methods 
A postal questionnaire was developed, based on the
published literature on nonmedical prescribing3,5,9 and with
demographic definitions and labels informed by Scotland’s
Census 2001.16 The questionnaire contained items on
awareness of nonmedical prescribing (3 items); levels of
comfort associated with specific health professionals un-
dertaking prescribing responsibilities, measured on 5-point
Likert scales (very uncomfortable to very comfortable; 8
items); 5-point Likert scales (strongly agree to strongly
disagree) measuring attitudes toward pharmacist prescrib-
ing (10 items); and demographics, including self-reported
general health (16 items). A final open question invited any
comments on issues or concerns related to nonmedical pre-
scribing. The questionnaire was reviewed for face and con-
tent validity by an expert panel of 8 experienced academic
pharmacy practitioners and researchers. The prepilot ques-
tionnaire was tested on a convenience sample of 10 lay indi-
viduals, which resulted in minor modifications to question
wording and formatting. The pilot questionnaire was mailed
in August 2006 to 500 members of the general public in
Scotland, aged 18 and over, obtained from the UK electoral
roll. A letter inviting participation and stating the research
background and aims was included with each questionnaire.
Piloting resulted in further minimal changes. 
The final questionnaire was mailed in November 2006
to a random sample of 5000 members of the general public
in Scotland, aged 18 and over, obtained from the UK elec-
toral roll. The same commercial company supplied contact
details for both the pilot and full study samples; individuals
in the pilot sample were excluded from the main study.
The electoral roll is a listing of individuals registered to
vote and includes the names and addresses of almost every
UK citizen over 18 years of age. There were no other ex-
clusions.
Personally addressed envelopes containing the question-
naire, cover letter, and postage-paid return envelope were
sent, with 2 reminders being sent to nonrespondents at 4-
week intervals.
This study was approved by the Ethical Review Panel
of the School of Pharmacy at The Robert Gordon Univer-
sity. The North of Scotland Research Ethics Committee
advised that this study did not require formal review by a
National Health Service Ethics Committee. 
STATISTICAL ANALYSIS
Data were coded and entered into SPSS for Windows
version 13 (SPSS Inc., Cary, NC) and analyzed using de-
scriptive statistics. The χ2 test, Student’s t-test, Wilcoxon
signed-rank test, analysis of variance (ANOVA), and
Kruskal-Wallis test were used to test for factors associated
with awareness of nonmedical prescribing and higher
comfort levels for pharmacist prescribing. Variables identi-
fied as significant in univariate analysis were further ana-
lyzed in binary logistic regression models, with comfort
levels being classified as above/equal or below the median
n The Annals of Pharmacotherapy    n 2009 June, Volume 43 www.theannals.com
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comfort level. A p value less than 0.05 was considered sta-
tistically significant a priori. Internal consistencies of the
scales were tested using Cronbach’s α, with negatively
worded statements being reverse scored. Content analysis
was performed on the responses to the open question relat-
ing to comments, issues, or concerns regarding nonmedi-
cal prescribing17 and grouped into major themes. 
Results
The response rate was 34.6% (1728/5000). A further
343 questionnaires (6.9%) were returned undelivered,
mainly due to the addressee having recently moved. The
adjusted response rate was therefore 37.1% (1728/4657). 
Respondents’ demographics are provided in Table 1 and
their utilization of health services is shown in Table 2.
More than half of the respondents were over 50 years of
age, female, working full-time or part-time, and living with
spouse or partner. The majority had seen their general
practitioner or visited a pharmacy in the previous 12
months. The median self-reported general health rating
was 4 (interquartile range [IQR], 3–5), on a scale of 1 (as
bad as it can be) to 5 (as good as it can be). More than half
(1025, 59.3%) were taking prescribed medicines (median
3, IQR 2–5). Almost a quarter of respondents (384, 22.2%)
had a health professional in their immediate family.
More than half (978, 56.6%) were aware that adequately
trained health professionals could prescribe drugs that pre-
viously were prescribed only by physicians. Of these, there
was greatest awareness of the pharmacists’ new roles, fol-
lowed closely by nurses (Table 3). The main sources of
awareness were television (322, 33%), newspapers (302,
31%), and pharmacists (201, 21%). 
Awareness of nonmedical prescribing in general was as-
sociated with increasing participant age (p < 0.001, Stu-
dent’s t-test), having a health professional in the immediate
family (p < 0.001, χ2 test), higher self-rated general health
scores (p < 0.005, Wilcoxon signed-rank test), and a higher
level of education (p < 0.01, χ2 test). In logistic regression
analysis, all of these factors were retained as independent
predictors of awareness of nonmedical prescribing: age, p
< 0.001; health professional in family, p <
0.001; general health score, p = 0.002; and ed-
ucation, p < 0.001. Whether or not the respon-
dents were prescribed regular medicines had
no significant association (p > 0.5, χ2 test) on
their awareness. 
The general public’s comfort levels associ-
ated with prescribing by different health pro-
fessional groups are given in Table 4. Ratings
were highest for pharmacists (median 4, IQR
3–5), followed closely by nurses and lowest
for radiographers and occupational therapists
(median 2, IQR 1–3) (p < 0.001, Wilcoxon
signed-rank test). A large number of respondents felt that
they did not know enough to provide an answer in relation
to several of the health professions. In terms of comfort
levels for pharmacists, higher levels were associated with
increasing participant age (p < 0.01, ANOVA), having a
health professional in their immediate family (p < 0.05, χ2
test), higher self-reported general health scores (p < 0.005,
Kruskal-Wallis test), and a higher level of education (p <
0.05, χ2 test). In logistic regression, only general health
score was retained as an independent predictor of comfort
levels for pharmacist prescribing (p < 0.001).
Attitudinal responses relating specifically to pharmacist
prescribing are given in Table 5. While well over half of
the respondents supported pharmacists having a prescrib-
ing role, just under a third felt that pharmacists were as
knowledgeable as physicians to prescribe medicines, and
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Table 2. Use of Health Services in the Past Twelve Monthsa
Had an appointment or home visit with a general practitioner 1229 (71.1)
Visited a pharmacy to get medicines and/or advice 815 (47.2)
Had an appointment or home visit with a nurse from medical practice 833 (48.2)
Had an appointment at a hospital outpatient clinic 771 (44.6)
Been admitted to a hospital 308 (17.8)
Been seen at an accident and emergency 295 (17.1)
Had an appointment or home visit with a pharmacist 98 (5.7) 
aN = 1728; all data shown as n (%). 
Table 1. Respondent Demographicsa
Age, y (mean ± SD) 54.0 ± 16.3 
Sex, n (%)
female 974 (56.4)
male 754 (43.6)
Employment status, n (%)
full-time 685 (39.6)
part-time 220 (12.7)
retired 519 (30.0)
unemployed 76 (4.4)
housewife 118 (6.8)
other 86 (5.0)
Living arrangements, n (%)
with spouse or partner 1003 (58.0)
alone 332 (19.2)
with family 322 (18.6)
with friends 20 (1.2)
other 34 (2.0)
Education level, n (%)
secondary school 889 (51.4)
college 390 (22.6)
university 389 (22.5)
aN = 1728 (some responses missing). 
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only a quarter felt that pharmacists should be able to pre-
scribe the same range of drugs as physicians. Less than one
fifth of respondents agreed that pharmacists were as knowl-
edgeable as physicians when it came to diagnosing disease or
illness. More than half of the respondents had concerns about
the lack of privacy in a pharmacy, despite acknowledging the
enhanced convenience of the pharmacy setting. 
Five hundred and five respondents (29.2%) gave open
comments. Several key themes were identified. In particu-
lar, respondents described issues relating to prescriber edu-
cation in terms of knowledge and skills, often commenting
on the difference in practice for diagnosis and prescribing.
Diagnosis was often seen as being a role solely of the med-
n The Annals of Pharmacotherapy    n 2009 June, Volume 43 www.theannals.com
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Table 5. Responses to Attitudinal Statements Relating to Pharmacists’ Prescribinga
Response, n (%)
Strongly Strongly
Statement Agree Agree Unsure Disagree Disagree Missing 
Pharmacists should have a prescribing role 321 (18.6) 883 (51.1) 318 (18.4) 118 (6.8) 57 (3.3) 31 (1.8)
A pharmacist is equally knowledgeable as a doctor 41 (2.4) 272 (15.7) 572 (33.1) 586 (33.9) 227 (13.1) 30 (1.7)
to diagnose a disease or illness
Pharmacists should be able to prescribe the same 86 (5.0) 346 (20.0) 473 (27.4) 555 (32.1) 228 (13.2) 38 (2.2)
range of medicines as doctors
It would be convenient for patients to get these 264 (15.3) 876 (50.7) 292 (16.9) 157 (9.1) 72 (4.2) 66 (3.8)
medicines prescribed in a pharmacy
A pharmacist is equally knowledgeable as a doctor 130 (7.5) 412 (23.8) 563 (32.6) 420 (24.3) 163 (9.4) 40 (2.3)
to prescribe these medicines
I feel confident in pharmacists’ abilities to prescribe 144 (8.3) 556 (32.2) 600 (34.7) 270 (15.6) 113 (6.5) 45 (2.6)
these medicines
Pharmacists would prescribe these medicines as 138 (8.0) 546 (31.6) 589 (34.1) 286 (16.6) 124 (7.2) 45 (2.6)
safely as doctors
A doctor should be involved whenever a pharmacist 341 (19.7) 632 (36.6) 400 (23.1) 278 (16.1) 34 (2.0) 43 (2.5)
prescribes these medicines
Pharmacists should have access to patients’ medical 296 (17.1) 588 (34.0) 316 (18.3) 278 (16.1) 215 (12.4) 35 (2.0)
notes before prescribing these medicines
I would be concerned about the lack of privacy in a 512 (29.6) 623 (36.1) 258 (14.9) 231 (13.4) 79 (4.6) 25 (1.4)
pharmacy for consultation
aN = 1728; all responses, Cronbach’s α = 0.784.
Table 4. Comfort Level of Respondents Regarding Receiving a Prescription for Drugs Previously 
Prescribed Only by a Physiciana
Comfort Level, n (%)
Very Very
Professional Uncomfortable Comfortable Do Not 
Group 1 2 3 4 5 Know
Pharmacists 105 (6.1) 99 (5.7) 278 (16.1) 458 (26.5) 588 (34.0) 155 (9.0)
Nurses 136 (7.9) 148 (8.6) 365 (21.1) 437 (25.3) 424 (24.5) 184 (10.6)
Optometrists 232 (13.4) 137 (7.9) 277 (16.0) 267 (15.5) 229 (13.3) 456 (26.4)
Physiotherapists 294 (17.0) 218 (12.6) 291 (16.8) 222 (12.8) 146 (8.4) 435 (25.2)
Psychologists 281 (16.3) 183 (10.6) 242 (14.0) 197 (11.4) 167 (9.7) 524 (30.3)
Occupational therapists 375 (21.7) 224 (13.0) 245 (14.2) 156 (9.0) 95 (5.5) 506 (29.3)
Radiographers 355 (20.5) 208 (12.0) 239 (13.8) 137 (7.9) 115 (6.7) 544 (31.5)
aN = 1728.
Table 3. Awareness of Specific Health Professionals’ 
Right to Prescribea
Pharmacist 727 (74.3)
Nurse 702 (71.8)
Optometrist 187 (19.1)
Psychologist 115 (11.8)
Dietician 70 (7.2)
Physiotherapist 63 (6.4)
Occupational therapist 27 (2.8)
Radiographer 23 (2.4)
Cannot remember 36 (3.7)
Other 52 (5.3)
aN = 978; all data shown as n (%). 
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ical profession; indeed, many did differentiate between the
processes of diagnosing and prescribing. Some acknowl-
edged that pharmacists may be more knowledgeable than
the physician in terms of drugs, but that physicians would
apply a more holistic approach to patient care. Many ex-
pressed trust and confidence in the prescribing role of the
medical profession, explaining this in terms of the social
standing of physicians in society, particularly when com-
pared with the standing of other health professions. Phar-
macists were also highly valued in relation to more tradi-
tional advisory roles. There were key issues relating to ac-
cess to medical records and the necessity of being able to
record prescribing actions in medical notes. Respondents
expressed concern about privacy and confidentiality of
health information and, specifically, how this could be
achieved in the community pharmacy setting.
Generally, there was little support for nonmedical pro-
fessionals to be able to prescribe the same range of drugs
as physicians. Nonmedical prescribing was seen as being
appropriate for “repeat medicines,” “minor ailments,” and
“low-risk medicines,” but that physicians would have to be
involved for “new conditions” and “rarer conditions” re-
quiring “stronger medicines.” Some commented on non-
medical prescribers operating within their competence.
Nonmedical prescribing was often seen as a way of saving
the physician’s time, reducing waiting lists, and enhancing
convenience for the patient. However, the issue of poten-
tially compromising patient safety was raised as well as the
consequential increase in workload for the nonmedical
prescriber. 
Discussion
Our research shows that more than half of the respon-
dents in this Scottish study had an awareness of nonmedi-
cal prescribing. Factors associated with awareness were in-
creasing age of the participants, level of education, self-rat-
ed general health, and having a health professional in the
immediate family. Respondents were most aware of phar-
macist and nurse prescribing and most comfortable with
these 2 groups of professionals prescribing medicines that
were previously prescribed only by physicians. It is of
paramount importance that policymakers and researchers
consider involving the general public as part of any service
development. Despite the study being conducted in Scot-
land, many of the findings may be relevant on an interna-
tional scale, given the global developments in nonmedical
prescribing.7
This research has several strengths and some weakness-
es that should be borne in mind. To our knowledge, this is
the first published study focusing on the perspectives of
the general public and aspects of prescribing by a range of
health professionals. We surveyed a large, random sample
of 5000 members of the general public over 18 years of
age residing in Scotland, with no exclusions other than
participation in the pilot study. While this may enhance the
generalizability of the findings to the whole Scottish popu-
lation (5.1 million), this is limited by the low response rate. 
In addition, there is the possibility that nonrespondents
had little interest in the topic. Also, we did not ask respon-
dents whether or not they had experienced nonmedical
prescribing. National Health Service employment figures
for Scotland as a whole are 6.2%, compared with the
22.2% of respondents in our study who reported that there
was a health professional in their immediate family; this
knowledge could have contributed to an overestimated
awareness of the developments and bias in opinions/
views.18 However, our respondents were similar in many re-
spects to the Scottish population, as per Scotland’s Census
conducted in April 2001, in terms of sex distribution, age
range, employment status, and health score.16 The Census
data did not permit comparison of numbers of regular drugs
or health professionals in immediate family, and it is possi-
ble that our data are biased regarding these 2 variables.
Although the questionnaire was developed and fully
tested in a series of stages of prepiloting and piloting, there
was no measure of test–retest reliability. We relied upon
the general public’s interpretation of the terms “adequately
trained health professional” and “medicines that only doc-
tors could prescribe in the past.” Indeed, many respondents
felt unable to answer questions relating to levels of com-
fort of a range of health professionals prescribing, possibly
because of lack of knowledge about the training for those
health professionals, as shown in Table 4 and the open
question responses. The issue of respondent recall bias
may have affected findings, as some items in the question-
naire (eg, visits to general practitioner) related to the past
12 months. There may also have been an element of social
desirability bias with the questionnaire being distributed by
a school of pharmacy.
There has been limited research in this field. Qureshi et
al.19 studied patients’ perceptions toward nurse and phar-
macist prescribing using a very specific subset of 400 pa-
tients attending an eye hospital. Berry et al.15 specifically
surveyed attitudes to nurse prescribing, and there are other
key differences compared with our research design in
terms of sampling technique, sample size, and method of
recruitment. However, both studies were positive in terms
of the general support for nonmedical prescribing. In our
study, a reasonably high proportion (56.6%) of respon-
dents claimed to be aware of nonmedical prescribing,
largely via the media and health professionals. There is a
case for public awareness in healthcare generally, but also
specifically in terms of changing prescribing roles. Sur-
veys of health professionals have, not surprisingly, shown
high levels of awareness of the concept of nonmedical pre-
scribing, but much lower awareness of the content, dura-
tion, and level of prescribing training courses.20-22
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Comfort levels with different health professionals var-
ied, demonstrating a higher rating for pharmacists and
nurses as compared with other healthcare professionals.
This is not surprising, given the likelihood of general pub-
lic contact with these 2 professional groups compared with
others such as occupational therapists and radiographers. In
terms of pharmacists, respondents were supportive of a pre-
scribing role but had concerns about complete access to all
drugs, diagnosis, and lack of any medical input. Previous
studies have reported that in general, privacy and confiden-
tiality were concerns that patients had in regard to pharma-
cist nonmedical prescribing in the community setting.23
While comfort levels may change with time as patients
and the general public experience nonmedical prescribing,
there is still a need to publicize these changing responsibili-
ties. Our research shows that reassurance for the public is
necessary in terms of clinical governance. Areas highlighted
were those of education and training and data handling.
There were also concerns relating to appropriateness of non-
medical professionals’ prescribing. A model similar to sup-
plementary prescribing, with the physician diagnosing and
the nonmedical professional prescribing or solely prescribing
chronic drug therapy would be more acceptable for some of
the respondents. Robust research measuring patients’ or ser-
vice users’ views and experiences of extended prescribing
services should be conducted to support further develop-
ments in nonmedical prescribing. The benefits of robust re-
search have been clearly demonstrated in terms of pharma-
cists’ roles in preventing drug-related problems.24
In conclusion, our results indicate that more than half of
the respondents were aware of nonmedical prescribing ini-
tiatives. The respondents also demonstrated higher levels
of comfort for pharmacist prescribing versus prescribing
by other healthcare professionals. However, several issues
relating to aspects of clinical governance were highlighted,
specifically, education and training and data handling. 
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Una Encuesta Cruzada Sobre el Conocimiento, los Puntos de Vista y
las Actitudes del Público General Escocés Hacia la Prescripción por
Profesionales no Médicos
DC Stewart, J George, HL Diack, CM Bond, DJ McCaig, ITS Cunningham,
K Munro, y D Pfleger
Ann Pharmacother 2009;43:1115-21.
EXTRACTO
TRASFONDO: La prescripción por profesionales no médicos es un desarrollo
clave en el Reino Unido (RU) que ha traído muchos cambios en la
política y la práctica de prescribir. Es limitada la investigación sistemática
sobre la visión del público general hacia dicho desarrollo.
OBJETIVO: Determinar el conocimiento, el punto de vista y las actitudes
del público general escocés hacia la prescripción por parte de profesionales
no médicos, con énfasis en la prescripción por parte del farmacéutico. 
MÉTODOS: Previo a un piloto, se envió por correo un cuestionario a una
muestra al azar de 5000 miembros del público general de Escocia de 18
años en adelante, obtenida de la lista electoral del RU en noviembre de
2006. El cuestionario contenía ítems sobre: niveles de comodidad con
específicos profesionales de la salud y las actitudes en torno a la
prescripción por parte del farmacéutico. 
RESULTADOS: La tasa de respuesta fue de un 37.1%. Más de la mitad
tomaba medicamentos recetados. Novecientos setentiocho (56.6%)
conocían que los profesionales de la salud adiestrados podían hacer recetas
de medicamentos que previamente sólo los médicos podían hacer. Conocer
sobre esta práctica estuvo relacionado con tener más edad (p < 0.001),
tener un profesional de la salud en la familia inmediata (p < 0.001),
poder auto clasificarse el estado de salud general (p < 0.005) y un nivel
educativo más alto (p < 0.01). En regresión logística, todos fueron
retenidos como factores independientes de predicción del conocimiento
(p < 0.001).
El nivel de comodidad respecto a la prescripción por profesionales no
médicos fue más alto para los farmacéuticos (mediana 4, IQR 3–5, 1
bajo a 5 alto) muy seguido por el profesional de enfermería y más bajo
para el personal de radiógrafía (mediana 2, IQR 1–4; p < 0.001). Mientras
que más de la mitad apoyaba a que el farmacéutico tuviera el rol de
prescribir, un menor número entendía que el farmacéutico debe prescribir
igual gama de medicamentos que los médicos. Existía la preocupación
en cuanto a la falta de privacidad en la farmacia a pesar de reconocer
una mayor conveniencia. 
CONCLUSIONES: Nuestros resultados indican que más de la mitad de los
que respondieron conocía sobre la prescripción por parte del profesional
no médico. Una proporción mayor se sentía más cómoda con la
prescripción por parte del farmacéutico y el profesional de enfermería
que por otros profesionales de la salud. Se resaltaron varios asuntos
relacionados a aspectos clínicos, específicamente la educación, y el manejo
de los datos. 
Traducido por Rafaela Mena
Un Sondage Transversal sur le Niveau de Connaissance, les
Opinions et les Attitudes du Grand Public Écossais face au Droit de
Prescription Accordé aux Professionnels de la Santé Non-Médecins 
DC Stewart, J George, HL Diack, CM Bond, DJ McCaig, ITS Cunningham,
K Munro, et D Pfleger
Ann Pharmacother 2009;43:1115-21.
RÉSUMÉ
OBJECTIF: Le droit de prescrire par des professionnels de la santé non-
médecins a été un tournant majeur dans le milieu de la santé au Royaume-
Uni et a nécessité plusieurs changements de politiques et de pratiques.
Peu de données quant à l’opinion du grand public face à de tels change-
ments ont été colligées. L’objectif de cette étude est d’identifier le niveau
de connaissance, les opinions et les attitudes du grand public quant au
droit de prescription accordé aux professionnels de la santé non-médecins,
en mettant une emphase particulière sur le droit de prescription des
pharmaciens. 
MÉTHODOLOGIE: Un questionnaire ayant fait l’objet d’une validation a
été posté en novembre 2006 à un échantillon aléatoire de 5000 personnes
âgées de 18 ans et plus, résidant en Écosse et faisant partie de la liste
électorale officielle du Royaume-Uni. Le questionnaire couvrait les
thèmes suivants: le niveau de connaissance quant au droit de prescription
accordé aux professionnels de la santé qui ne sont pas médecins, le
niveau de confort du public face aux différents professionnels de la santé
non-médecins détenant un tel droit, et les opinions sur le droit de
prescription accordé aux pharmaciens.
RÉSULTATS: Le taux de réponse au sondage a été de 37.1%. Plus de la moitié
des répondants (56%, n = 978) savaient que des professionnels de la santé
non-médecins avaient le droit de prescrire des médicaments. Ce niveau
de connaissance augmentait avec l’âge des répondants (p < 0.001), la
présence d’un professionnel de la santé dans la famille immédiate (p <
0.001), un niveau élevé de scolarité (p < 0.01), et une auto-évaluation
satisfaisante de l’état de santé générale (p < 0.05). Selon une analyse
logistique, tous ces facteurs ont été identifiés comme des éléments
pouvant prédire de façon indépendante, ce niveau de connaissance. Le
niveau de confort du public face au droit de prescription accordé aux
non-médecins était le plus élevé pour les pharmaciens [médiane de 4,
écart interquartile (EIQ) variant entre 3 et 5 sur une échelle où 1 est la
valeur la plus faible et 5, la plus élevée] suivi par les infirmières et
atteignant les plus faibles valeurs pour les techniciens en radiologie et
les ergothérapeutes (médiane de 2, EIQ 1–4). Bien que plus de la moitié
des répondants supportaient le concept de prescription par les pharmaciens,
bien peu étaient d’accord à ce que les pharmaciens puissent prescrire
autant de médicaments que leurs collègues médecins. Ce sondage a aussi
permis de soulever certaines inquiétudes quant à un manque possible
d’espace en pharmacie permettant un échange de données en toute
confidentialité; ces soucis étant toutefois contrebalancés par une
accessibilité accrue du pharmacien par rapport à d’autres professionnels
de la santé. 
CONCLUSIONS: Les résultats de cette étude indiquent que plus de la moitié
des répondants était au courant du droit de prescription accordé aux
professionnels de la santé qui ne sont pas médecins. Une grande propor-
tion de ces répondants était confortable avec le droit de prescription
accordé aux pharmaciens et aux infirmières. Plusieurs enjeux relatifs
aux aspects de gouvernance clinique ont toutefois été identifiés,
notamment quant à la gestion des données cliniques et quant à la
formation continue.
Traduit par Sylvie Robert
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Objective. To develop and validate an assessment tool, based on the ‘Royal College of General
Practitioners’ (RCGP) Video Assessment Tool’, for assessment of pharmacist prescribers’ con-
sultation skills.
Methods. Competency areas of the RCGP tool were left unchanged but performance criteria for
each were modified to reflect pharmacist prescribing. Each criterion and the overall consultation
were rated from 1 (poor) to 5 (excellent).
A purposive sample of 10 experienced prescribing pharmacists was selected. Each pharmacist
identified, recruited and consented two patients. Video recordings of consultations were as-
sessed independently by two randomly assigned GPs, experienced in the use of the RCGP tool,
using the newly developed scale. Inter-rater reliability was assessed. Construct validity was as-
sessed by comparing the assessor score with a patient satisfaction score. Spearman’s rho was
used to test the correlation between the two scores.
Results. The RCGP tool was modified to give the ‘Pharmacist Consultation Assessment Tool’
(PharmaCAT). The median overall PharmaCAT consultation rating was 3. There was good agree-
ment between the two assessors for total scores (intraclass correlation coefficient = 0.694).
Fourteen (78%) patient satisfaction questionnaires were returned; most (n = 13, 93%) agreed/
strongly agreed that they were entirely satisfied with the consultation. Correlations between av-
erage total scores on PharmaCAT and the patient satisfaction questionnaire were weak (Spear-
man’s rho = 0.142 and 0.242 for both assessors).
Conclusions. The PharmaCAT has been tested in the pharmacist prescriber setting. The tool had
discriminatory power across different domains and inter-rater reliability. The PharmaCAT has
potential to be used as a formative and/or summative assessment tool.
Keywords. Communication skills, consultation, pharmacy, prescribing.
Introduction
Many developments in pharmacy practice in the UK
have taken place recently. Pharmacist prescribing, ini-
tially introduced as supplementary prescribing in
2003, followed by independent prescribing in 2006,1,2
is one of the most notable developments.
The scope of independent prescribing, described as
‘prescribing by a practitioner responsible and account-
able for the assessment of patients with undiagnosed
or diagnosed conditions and for decisions about
the clinical management required, including
prescribing’, is wide ranging. All licensed medicines
(other than controlled drugs) can be prescribed within
the independent prescriber’s competence with no need
for any overarching endorsement by a medical practi-
tioner.3
Qualification as an independent pharmacist pre-
scriber requires completion of a short postgraduate
course. This comprises 26 days of university delivered
training, with an additional 12 days in practice under
the guidance of a designated medical practitioner.4 To
date, 1600 pharmacists in Great Britain have com-
pleted their prescribing training and are registered with
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the Royal Pharmaceutical Society of Great Britain as
prescribers.
Consultation skills are a key element of this train-
ing, aiming to further develop effective relationships
and communication strategies and to demonstrate
a shared approach to decision making.4
Despite the emphasis placed on consultation skills
during training, the published literature on pharmacist
prescribers’ consultation skills training or practice is
sparse. Cleland et al. used semi-structured interviews
with a purposive sample of nine prescribers to explore
views of consultation skills training and impact on
practice. While participants were positive about their
enhanced skills, some practical difficulties were high-
lighted.5 Most patient-focused research relates to
patients’ perspectives of pharmacist prescribing or
their satisfaction with prescribing services, rather than
consultation skills.6–8
Consultation skills are recognized as a central com-
ponent of the clinical encounter. A recent patient
survey reported by the General Medical Council identi-
fied communication skills as the second most influential
factor (after giving good advice and treatment) in pa-
tients’ confidence in their doctors.9 Studies involving
doctors have also demonstrated key benefits, including
enhanced working relationships, increased patient satis-
faction and improved health outcomes.10–12
Several consultation skills assessment tools are
available for medical consultations, including the ‘Se-
gue framework’,13 ‘Henbest and Stewart rating scale’14
and the ‘Royal College of General Practitioners’
(RCGP) summative assessment single route video as-
sessment.15 Of these, the latter has contributed both
formatively and summatively to the assessment pro-
cess for membership of the RCGP. Each consultation
is assessed around five broad areas of discovering the
reason for the patient’s attendance, defining the clini-
cal problem(s), explaining the problem(s) to the pa-
tient, addressing the patient’s problem(s) and making
effective use of the consultation. The application and
concurrent validity of this tool have been previously
described.16,17
As with the medical consultation, evaluation of
pharmacist prescribers’ consultation skills is critical.
However, there is no validated tool for either formative
or summative assessment of pharmacist prescribers’
consultation skills. Greenwood et al.18 reported one
study in which they used the Henbest and Stewart rat-
ing scale (assesses patient-centredness)14 and the Segue
framework (assesses content of the consultation).13
Salter et al.19 have used discourse analysis to research
pharmacist consultations. Both studies had limitations
and neither validated an evaluation tool or approach.
Thus, the aim of our study was to develop and vali-
date a tool based on the RCGP video assessment tool
for assessment of pharmacist prescribers’ consulta-
tions.
Methods
Development of the scale
The five competency areas of the RCGP video assess-
ment tool were left unchanged. Performance criteria
(PC) for each of the competency areas were modified
to reflect the pharmacist prescribing context by replac-
ing the term ‘doctor’ with ‘pharmacist prescriber’ and
placing less emphasis on physical and mental examina-
tion and clinical diagnosis. Each criterion was rated on
a scale of 1 (poor) to 5 (excellent) with the option of
scoring ‘not observed’. In addition, there was an over-
all rating for the consultation and space for free text
comments on specific strengths, weaknesses and seri-
ous concerns.
The tool was further refined by a panel of four GP
assessors with extensive training and experience in
video assessment of medical consultations and six aca-
demics with expertize in medical and pharmacy educa-
tion. The panel communicated by email apart from
one face to face meeting when face and content valid-
ity of the tool were established by consensus.
Sample of pharmacist prescribers and recruitment
A purposive sample of 10 study sites was identified.
These were selected to provide a range of geographi-
cal regions, practice settings (community pharmacy,
general practice and hospital) and therapeutic areas
of prescribing (cardiovascular, diabetes, oncology,
pain and respiratory). To participate, each pharma-
cist had to have been prescribing for at least 20 pa-
tients in the previous 3 months. Pharmacists were
approached sequentially to recruit the sample of 10.
Written informed consent was obtained from each
pharmacist. Each pharmacist identified, recruited
and consented two patients. There were no exclusion
criteria.
Data collection
One consultation between each of the recruited pa-
tients and their pharmacist prescriber was video re-
corded. The Guidance of the General Medical
Council on video recording was followed. Video re-
cording was undertaken by a researcher, except in
three cases where pharmacists undertook the record-
ing themselves, following detailed verbal and written
instructions. The pharmacists were informed that the
video recordings would be reviewed by experts but
were not given any details regarding the content of
the assessment tool.
Each recording was assessed independently by two
randomly assigned GP assessors (from the panel of
four who had contributed to tool development) using
the new scale. Data were analysed for completeness,
and inter-rater reliability (agreement between asses-
sors) was tested using intraclass correlation coefficient
(ICC).
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Construct validity was assessed by comparing asses-
sor scores with a patient satisfaction score based on
a validated scale,20 which had been adapted and used
previously for pharmacist prescriber consultations.7
Questions relating to in-depth examination and long-
term professional relationships were removed from
Baker’s scale leaving nine statements rated on a 5-
point Likert scale. The scale was completed by each
patient immediately after the consultation. Spearman’s
rho was used to test the correlations between the two
assessor scores and the patient satisfaction score.
Approval for the research was obtained from the
Multi-Centre Research Ethics Committee for Scotland
and the relevant Research and Development commit-
tees in Scotland.
Results
The RCGP tool was modified to give the Pharmacist
Consultation Assessment Tool (PharmaCAT). The
RCGP tool and PharmaCAT are compared in Table 1.
TABLE 1 Comparison between PharmaCAT and RCGP
PharmaCAT RCGP
PharmaCAT 1. The pharmacist is seen to
encourage the patient’s contribution at
appropriate points in the consultation
The doctor is seen to encourage the patient’s
contribution at appropriate points in the
consultation
The doctor is seen to respond to signals (cues)
that lead to a deeper understanding of the
problem
PharmaCAT 2. The pharmacist uses appropriate
psychological and social information to place the
patient’s health/medical conditions in context
The doctor uses appropriate psychological and
social information to place the complaint(s) in
context
PharmaCAT 3. The pharmacist explores the
patient’s health understanding
The doctor explores the patient’s health
understanding
PharmaCAT 4. The pharmacist establishes the
clinical reason leading to attendance and . . .
Grouping of 1, 2, 3 and 4
PharmaCAT 4. . . . and undertakes appropriate
assessment of the patient’s condition
systematically
6. The physical/mental examination chosen is
likely to confirm or disprove hypotheses that
could reasonably have been formed; Or is
designed to address a patient’s concern
PharmaCAT 5. The pharmacist obtains sufficient
information to be aware of other/suspected new
diagnoses beyond the scope of management, or
diagnosis, and refers to appropriate medical
professional or other health professional, if
necessary
5. The doctor obtains sufficient information to
include or exclude likely relevant significant
conditions
7. The doctor appears to make a clinically
appropriate working diagnosis
PharmaCAT 6. The pharmacist explains the
clinical condition in appropriate language
8. The doctor explains the problem or diagnosis
in appropriate language
PharmaCAT 7. The pharmacist explanation
incorporates some or all of the patient’s health
beliefs
9. The doctor specifically seeks to confirm the
patient’s understanding of the diagnosis
PharmaCAT 10. The pharmacist specifically
seeks to confirm the patient’s understanding of
any newly diagnosed conditions and
management
PharmaCAT 8. The management plan (including
any prescription) is appropriate for the clinical
reason/working diagnosis, reflecting a good
understanding of modern accepted clinical
practice
10. The management plan (including any
prescription) is appropriate for the working
diagnosis, reflecting a good understanding of
modern accepted medical practice
PharmaCAT 9. The patient is given the
opportunity to be involved in significant
management decisions to enhance concordance
11. The patient is given the opportunity to be
involved in significant management decisions
PharmaCAT 11. The pharmacist takes steps to
enhance compliance/adherence, by exploring
and responding to the patient’s understanding of
treatment
PharmaCAT 12. The pharmacist specifies the
conditions and interval for follow-up or review,
appropriately ensuring a safety net
13. The doctor specifies the conditions and
interval for follow-up or review
PharmaCAT. Overall rating Overall assessment
12. Makes effective use of resources
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Nineteen pharmacists were approached to recruit
the sample of 10. These 10 were from six National
Health Service (NHS) organizational areas in Scotland
(see Table 2). Pharmacists’ performances on each of
the 12 criteria are given in Table 3. The median over-
all rating was 3 (range 1–4) on a scale of 1 (poor) to 5
(excellent). There was good agreement between the
two assessors for the total PharmaCAT (sum of scores
of PC1–PC12) scores (ICC = 0.694).
Pharmacists performed best in PC1 (encourage the
patient’s contribution at appropriate points in the con-
sultation), PC9 (management plan is appropriate for the
clinical reason/working diagnosis) and PC12 (specifies
the conditions and interval for follow-up or review).
Lower scores were obtained for PC5 (obtains suffi-
cient information to rule out any medical condition
beyond their scope of management), PC7 (explanation
incorporates some or all of the patient’s health be-
liefs), PC8 (specifically seeks to confirm the patient’s
understanding of the clinical condition/diagnosis) and
PC10 (specifically seeks to confirm the patient’s under-
standing of the clinical condition/diagnosis). There
were 10 occurrences of ‘not observed’ for PC 7
(patient’s health beliefs).
Fourteen patient satisfaction questionnaires were
returned (see Table 4) and almost all (n = 13, 93%)
agreed or strongly agreed that they were entirely satis-
fied with the consultation.
Spearman’s rho, measuring correlation between to-
tal PharmaCAT scores for the two assessors and total
patient satisfaction scores, indicated little correlation
(rho = 0.142 and 0.242).
Discussion
In this study, we developed and tested PharmaCAT,
modified from the RCGP video assessment tool. The
tool had discriminatory power between pharmacist
prescribers and the different competency areas and
inter-rater reliability. However, there was little correla-
tion between assessors’ total PharmaCAT scores and
patients’ ratings of consultation satisfaction. Similarly,
McKinstry et al.21 showed little correlation between
the RCGP tool and patients’ scores on a consultation
satisfaction questionnaire. While patients’ views on sat-
isfaction are valuable, they may be measuring some-
thing different and additional to the skills of the
practitioner linked to other competencies. They may
also be a poor measure of discrimination.
Our research has strengths and weaknesses. To our
knowledge, this is the first study assessing pharmacist
consultations using a set of criteria covering specific
competency areas. We studied a range of settings
and specialities and importantly benchmarked phar-
macist prescribing consultations using a tool modified
from one developed for trainee GP. We used experi-
enced RCGP consultation skills assessors with many
years of experience for testing the reliability of the
PharmaCAT. Our consultations were video recorded
rather than audio taped in order to examine non-
verbal as well as verbal communication. Limitations
included the small sample numbers of pharmacists
and patients and the lack of representation from sec-
ondary care settings. There was potential for selec-
tion bias as the participating pharmacists recruited
the patients; however, this is similar to the process
used by the RCGP.
Pharmacists’ performances varied across the crite-
ria. Higher scores were obtained in relation to encour-
aging the patient’s contribution and aspects of clinical
management with lower scores for achieving concor-
dance and exploring patient health beliefs. Areas of
lower scores and omissions may reflect the pharma-
cists’ prior knowledge and management of the patient
TABLE 2 Settings and clinical areas of the participating prescribing pharmacists
Geographical
region
Prescribing setting Clinical area(s) Number of
consultations
recorded
Pharmacist 1 1 GP practice Respiratory 2
Pharmacist 2 1 GP practice/community
pharmacy
Respiratory 2
Pharmacist 3 1 GP practice Cardiovascular 2
Pharmacist 4 2 GP practice Cardiovascular 2
Pharmacist 5 3 GP practice/community
pharmacy
Rheumatology/pain 2
Pharmacist 6 4 GP practice Cardiovascular/diabetes 2
Pharmacist 7 4 GP practice Cardiovascular 2
Pharmacist 8a 4 GP practice Cardiovascular 0
Pharmacist 9b 5 Community pharmacy Respiratory 0
Pharmacist 10c 6 Hospital (secondary care) Oncology 0
aPharmacist 8 was one of the first recruits but decided to withdraw from the research in the later stages.
bPharmacist 9 had problems with the technology.
cPharmacist 10 was unable to recruit any patients (working in oncology in secondary care).
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TABLE 3 Pharmacists’ performances in each of the 12 criteria and overall scores
PC Median Score [range: 1
(poor) to 5 (excellent)]
Number of times rated
‘not observed’
1 The pharmacist prescriber is seen to encourage
the patient’s contribution at appropriate points
in the consultation
4 (1–5) 1
2 The pharmacist prescriber uses appropriate
psychological and social information to place the
patient’s health/medical conditions in context
3 (1–5) 2
3 The pharmacist prescriber explores the
patient’s health understanding
3 (1–4) 6
4 The pharmacist prescriber establishes the
clinical reason/diagnosis leading to attendance
and undertakes appropriate assessment of the
patient’s condition systematically
3 (1–5) 0
5 The pharmacist prescriber obtains sufficient
information to rule out any medical condition
beyond their scope of management, or diagnosis,
and refers to appropriate medical professional or
other health professional, if necessary
2 (1–5) 9
6 The pharmacist prescriber explains the clinical
condition/diagnosis in appropriate language
3 (1–5) 2
7 The pharmacist prescriber’s explanation
incorporates some or all of the patient’s health
beliefs
1–2 (1–4) 10
8 The pharmacist prescriber specifically seeks to
confirm the patient’s understanding of the clinical
condition/diagnosis
2 (1–3) 8
9 The management plan (including any
prescription) is appropriate for the clinical
reason/working diagnosis, reflecting a good
understanding of modern accepted clinical
practice
3.5 (1–5) 1
10 The pharmacist specifically seeks to confirm
the patient’s understanding of the clinical
condition/diagnosis
2 (1–5) 5
11 The pharmacist prescriber takes steps to enhance
concordance, by exploring and responding to the
patient’s understanding of the treatment
3 (1–5) 5
12 The pharmacist prescriber specifies the
conditions and interval for follow-up or review,
appropriately ensuring a safety net
3.5 (1–4) 1
Overall (sum of 1–12) 3 (1–4) —
TABLE 4 Patient ratings of their consultation with the pharmacist prescriber, n (%)
Statements Strongly agree Agree Neutral Disagree Strongly disagree
I am totally satisfied with my visit to this
pharmacist prescriber
12 (85.7) 1 (7.1) 0 0 1 (7.1)
This pharmacist prescriber told me everything
about my treatment
12 (85.7) 1 (7.1) 0 0 1 (7.1)
Some things about my consultation with the
pharmacist prescriber could have been better
3 (21.4) 0 2 (14.3) 5 (35.7) 4 (28.6)
This pharmacist prescriber examined me very
thoroughly
10 (71.4) 1 (7.1) 2 (14.3) 0 0
This pharmacist prescriber was interested in me
as a person, not just my illness
8 (57.1) 4 (28.6) 0 1 (7.1) 1 (7.1)
I understand my illness much better after seeing
this pharmacist prescriber
9 (64.3) 4 (28.6) 1 (7.1) 0 0
I felt this pharmacist prescriber really knew what
I was thinking
9 (64.3) 3 (21.4) 2 (14.3) 0 0
I wish it had been possible to spend a little more
time with the pharmacist prescriber
3 (21.4) 2 (14.3) 4 (28.6) 4 (28.6) 1 (7.1)
I would find it difficult to tell this pharmacist
prescriber about some private things
2 (14.3) 0 1 (7.1) 5 (35.7) 6 (42.9)
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or their lack of familiarity with the assessment tool. In
future, the assessment criteria should be embedded in
the training programme and pharmacists made aware
of the need to focus on all aspects of the consultation
assessment criteria, regardless of their familiarity with
the patient.
The development of PharmaCAT using video re-
cordings is a clear advance. Previous studies from
Greenwood et al.18 and Salter et al.19 were based on
audio recordings. Greenwood studied six pharma-
cists’ interactions with 18 congestive cardiac failure
patients. Although none of the pharmacists were reg-
istered prescribers, they were expected to explore pa-
tients’ understanding of heart failure, strategies for
self-management, undertake a medication review
and provide lifestyle advice. The authors concluded
that the Henbest and Stewart rating scale (assesses
patient-centredness)14 and the Segue framework
(assesses content of the consultation)13 were appro-
priate for assessing audio recording of pharmacist
consultations. However, they also noted the limita-
tions of audio recording including the inability to
record visual information.
Salter et al.19 used discourse analysis to explore the
advice giving role of pharmacists (non-prescribers)
during consultation for medication review with pa-
tients aged 80 years and above. One researcher
observed, taped and transcribed a total of 29 consulta-
tions with seven pharmacists. Although the pharma-
cists provided advice, this was rarely initiated by the
patients and often resisted or rejected.
The RCGP video assessment tool has recently been
modified to be used in a more formative way as part
of work-based assessment, the ‘Consultation Observa-
tion Tool’.22 This has the same competency areas as
before but each is now graded on a four-point scale of
‘insufficient evidence’, ‘needs further development’,
‘competent’ and ‘excellent’. We now note that the po-
tential of adopting this scale for PharmaCAT, subject
to confirmation of validity and reliability.
Further work is required to test PharmaCAT with
a greater number of pharmacists in more diverse ther-
apeutic areas. There may also be a role for a summa-
tive assessment tool for pharmacist prescribers based
on PharmaCAT. PharmaCAT was developed for
pharmacist prescribers but we suggest that with a simi-
lar process of modification and validation, a further
modified tool may be applicable to all non-medical
prescribers, including nurses, physiotherapists and
optometrists.
Acknowledgements
We acknowledge support from the participating phar-
macists and their patients and A Glenesk, J Repper
and R Watt (for video assessment).
Declaration
Funding: NHS Education for Scotland (Pharmacy).
Ethical approval: Multi-Centre Research Ethics Com-
mittee for Scotland and the relevant Research and
Development committees in Scotland (05/MRE00/113).
Conflict of interest: none.
References
1 Cooper R, Anderson C, Avery T et al. Nurse and pharmacist sup-
plementary prescribing in the UK—a thematic review of the lit-
erature. Health Policy 2008; 85: 277–92.
2 Tonna A, Stewart D, West B, McCaig D. Pharmacist prescribing in
the UK—a literature review of current practice and research. J
Clin Pharm Ther 2007; 32: 545–56.
3 Department of Health. Improving Patients’ Access to Medicines:
a Guide to Implementing Nurse and Pharmacist Independent
Prescribing Within the NHS in England. London: Department
of Health, 2006.
4 Royal Pharmaceutical Society of Great Britain. Indicative curricu-
lum for the education and training of Pharmacist Independent
Prescribers. http://www.rpsgb.org/pdfs/indprescfaq.pdf (accessed
on 2 March 2009).
5 Cleland J, Bailey K, McLachlan S, McVey L, Edwards RM.
Supplementary pharmacist prescribers’ views about com-
munication skills teaching and learning, and applying these
new skills in practice. Int J Pharm Pract 2007; 15: 101–4.
6 Smalley L. Patients’ experience of pharmacist-led supplemen-
tary prescribing in primary care. Pharm J 2006; 276:
567–9.
7 Stewart DC, George J, Bond CM et al. Exploring patients’ perspec-
tives of pharmacist supplementary prescribing in Scotland.
Pharm World Sci 2008; 30: 892–7.
8 Stewart DC, George J, Bond CM et al. Views of pharmacist pre-
scribers, doctors and patients on pharmacist prescribing imple-
mentation. Int J Pharm Pract 2009; 17: 89–94.
9 Coulter A. Can patients assess the quality of health care? BMJ
2006; 333: 1–2.
10 Little P, Williamson I, Warner G et al. Open randomised trial of
prescribing strategies in managing sore throat. BMJ 1997;
314: 722–7.
11 Bertakis KD, Roter D, Putman SM. The relationship of physician
medical interview style to patient satisfaction. J Fam Pract
1991; 32: 175–81.
12 Hall JA, Harrigan JA, Rosenthal R. Non-verbal behaviour in
clinician-patient interaction. Appl Prev Psychol 1995; 4:
21–35.
13 Makoil G. SEGUE: A Framework for Teaching and Evaluating
Communication in Medical Encounters. San Francisco: Divi-
sion 1 of the American Educational Research Association,
1995.
14 Henbest RJ, Stewart M. Patient centredness in the consultation:
does it make a difference? Fam Pract 1990; 7: 28–33.
15 Royal College of General Practitioners’ (RCGP) Summative As-
sessment Single Route Video Assessment. www.rcgp.org.uk/
gp_training/mrcgp/video_workbook.aspx (accessed on 2 March
2009).
16 Campion P, Foulkes J, Neighbour R, Tate P. Patient centredness in
the MRCGP video examination: analysis of a large cohort.
BMJ 2002; 325: 691–692.
17 Sirwardena AN, Edwards A, Campion P, Freeman AC, Elwyn G.
Involve the patient and pass the MRCGP: investigating shared
decision making in a consulting skills examination using a vali-
dated instrument. Br J Gen Pract 2006; 56: 857–62.
18 Greenwood K, Howe A, Holland R. The use of consultation skills
assessment tools in pharmacist-patient consultations. Int J
Pharm Pract 2006; 14: 277–82.
Family Practice—an international journalPage 6 of 7
 at The R
obert G
ordon University Library Service on June 9, 2010 
http://fam
pra.oxfordjournals.org
D
ow
nloaded from
 
63
19 Salter C, Holland R, Harvey I, Henwood K. ‘‘I haven’t even
phoned my doctor yet.’’ The advice giving role of the pharma-
cist during consultations for medication review with patients
aged 80 or more. BMJ 2007; 334: 1101–6.
20 Baker R. Development of a questionnaire to assess patients’ satis-
faction with consultations in general practice. Br J Gen Pract
1990; 40: 487–90.
21 McKinstry B, Walker J, Blaney D, Heaney D, Begg D. Do patients
and expert doctors agree on the assessment of consultation
skills. Fam Pract 2004; 21: 75–80.
22 Royal College of General Practitioners, Consultation Observation
Tool, Detailed Guide to the Performance Criteria. http://
www.rcgp.org.uk/docs/nMRCGP_COT_Guide_to_Performance
_Criteria.doc (accessed on 2 March 2009).
Page 7 of 7Assessing pharmacist prescribers’ consultations
 at The R
obert G
ordon University Library Service on June 9, 2010 
http://fam
pra.oxfordjournals.org
D
ow
nloaded from
 
64
 Paper 9 
Stewart D, MacLure K, Bond C, George J, Diack L, McCaig D, 
Cunningham S 
Pharmacist prescribing in primary care: the views of 
nominated patients across Great Britain who had 
experienced the service 
 
Abstract accepted for Royal Pharmaceutical Conference 2010 
An abstract of selected findings was also presented at the Celtic Pharmacy 
Festival 2010. 
 
One related paper is being drafted with the aim of submitting to the International 
Journal of Pharmacy Practice by Autumn 2010.  As this paper is still being written, 
we have included a copy of the accepted abstract. 
 
65
Abstract accepted for Royal Pharmaceutical Society Conference 2010
Title:
Pharmacist prescribing in primary care: the views of nominated patients across Great Britain who had experienced the
service
Abstract:
Focal points
 Views of pharmacist prescribing across Great Britain were explored in a group of nominated patients who had
experienced the service
 Pharmacist response rate was low, but patient response was higher and highlighted positive views. However, these
may not be generalisable
 Further research on patient views about pharmacist prescribing is warranted but may require novel methodological
approaches
Introduction
Seven years after the introduction of pharmacist prescribing, the views of patients who have experienced the service
remain limited. Published research has described settings, clinical conditions and patient numbers1-3. The aim was to
explore patients’ views of pharmacist prescribing in primary care settings across Great Britain.
Method
All pharmacist prescribers (n=1622, October 2008) were identified from the register of the Royal Pharmaceutical Society
of Great Britain, and sent information, consent form and two reminders. Consenting pharmacists were asked to invite
consecutive patients using standard study documentation and send the contact details of five consenting patients to the
researchers. Participating patients were mailed a questionnaire and reminder containing: Section 1 (demographics) - you
and your health; Section 2 - you and your pharmacist prescriber; Section 3 - you and your general practitioner; Section 4 -
your most recent pharmacist prescriber consultation. The research had approval from the relevant review boards. Data
were analysed using SPSS version 17.0.
Results
Of the 482 (29.7%) pharmacists who responded only 92 (19.1%) were eligible to participate. Pharmacists prescribing in
secondary care (n=194), those not prescribing (n=171), not contactable (n=13), having insufficient patients (n=11), not
able to assist (n=1) were excluded. Of those eligible, only 49 consented. By the end of March 2010, 30 log sheets had
been returned by pharmacists practicing as independent (21) or supplementary (9) prescribers recruiting 143 patients. The
patient response rate was 71.3% (n=102) with the majority (79.4%) aged 55 and over.
Examples
Strongly
agree
Agree Unsure Disagree Strongly
disagree
I get more time to discuss my health issues with a pharmacist prescriber than a GP
(n=102) 23 48 12 16 3
I am more comfortable discussing medication-related issues with a GP than with a
pharmacist prescriber (n=99) 3 25 21 39 11Se
ct
io
n
2
I am confident that a pharmacist prescriber will prescribe as safely as a GP (n=101) 32 57 11 0 1
If I thought my medical condition was getting worse, I’d rather consult a GP than a
pharmacist prescriber (n=102) 24 47 19 11 1
I do not expect a GP to review the treatment prescribed by a pharmacist prescriber
(n=98) 10 42 18 25 3Se
ct
io
n
3
Given the choice, I prefer to consult a GP rather than a pharmacist prescriber (n=100) 12 31 28 28 1
The pharmacist prescriber was interested in me as a person, not just my illness
(n=102) 44 50 5 3 0
I understand my medical condition after consulting the pharmacist prescriber (n=94) 24 58 9 2 1
I am more interested in the quality of care I receive than the profession of the person I
consult (n=100) 31 50 12 6 1S
ec
tio
n
4
I was totally satisfied with this visit to the pharmacist prescriber (n=100) 56 43 1 0 0
Table 1 – patient responses (n=102) to attitudinal statements on aspects of pharmacist prescribing
Conclusions
Pharmacist responses were low with a significant proportion of respondents not using their prescribing qualification
despite the resources invested in education and training. Although the patient response rate was high and patients valued
the pharmacist prescribing service, these findings may be heavily biased and lack generalisability. Further research on
views of patients who have experienced pharmacist prescribing is warranted but this may require novel methodological
approaches.
References
1 Smalley L. Patients' experience of pharmacist-led supplementary prescribing in primary care. Pharm J 2006;276:567-569
2 Reid F, Murray P, Storrie M. Implementation of a Pharmacist-Led Clinic for Hypertensive Patients in Primary Care – A Pilot Study. Pharm World
Sci 2005;27(3):202-207
3 Stewart DC, George J, Bond CM, Cunningham ITS, Diack LH, McCaig DJ. Exploring patients’ perspectives of pharmacist supplementary
prescribing in Scotland. Pharmacy World & Science 2008;30:892-897
66


